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 There is ample evidence that patients with psychosis are more likely to 
use illicit substances than the general population, with cannabis being the most 
popular. Research has also shown that cannabis use is associated with poor 
prognostic outcomes in patients with an established psychotic disorder. It is 
important to understand the reasons patients with psychosis endorse for their 
cannabis use and findings so far point towards an ‘alleviation of dysphoria’ model 
rather than the ‘self-medication’ hypothesis. It is not known how the level of 
motivation to change cannabis use can affect patients’ actual use. Lack of 
validated readiness to change questionnaires for use with psychotic populations 
makes it essential to develop and validate such measures. 
 The aim of this thesis was to evaluate the reasons for cannabis use and its 
effects on psychotic outcomes in a patient cohort with first-episode psychosis. 
The association between cannabis use and other illicit drug use was also 
investigated. Readiness to change was evaluated as a predictor of cannabis use 
outcomes using two questionnaires. 
 The main finding was that cannabis use was not associated with psychotic 
outcomes but was related to other illicit drug use. With regards to reasons, 
patients chose enhancement and social motives as most important for their 
cannabis use providing support for the ‘alleviation of dysphoria’ model. 
Preliminary analysis showed no clear pattern of association between readiness to 
change and cannabis use outcome. Utility of two readiness to change measures 
for use with patients with psychosis was not validated. 
 These findings add to the small evidence base that cannabis use is not 
associated with prognostic outcomes in psychosis. No evidence for the self-
medication hypothesis was observed. Readiness to change was not associated 
with cannabis use outcomes signifying the need for using validated measures to 
assess motivation in psychotic populations.  
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Chapter 1 – General Introduction 
 
1.1 Aims of the chapter 
The aims of this chapter are to provide: 
1. A brief description of the current understanding of psychosis, its aetiology 
and prognosis and a definition of the nature of first-episode psychosis for 
this thesis. 
2. A brief history and description of cannabis, its role in the aetiology of 
psychosis and its prevalence in, and effects on, psychotic disorders. 
3. The rationale for exploring reasons for cannabis use, a description of 
proposed models for co-morbid substance use and psychiatric disorders 
and a summary of the self-reported reasons for substance use in 
psychiatric patients. 
4. The rationale for investigating readiness to change cannabis use, an 
overview of the literature on readiness to change substance use in co-
morbid psychiatric populations and a description of the most commonly 
used assessment tools. 
5. A description of the thesis aims. 




Psychosis, translated from the Greek as ‘abnormality of the mind and soul’, is a 
broad concept that comprises a number of disorders (Ross, 2005). From the 
introduction of the concept of psychosis in 1841 by Canstatt (Burgy, 2008), who 
used it synonymously with ‘psychic neurosis’ to the present day of manual 
classifications and diagnostic instruments, the experience of psychosis has 
remained fairly constant. Psychosis is often associated with a loss of touch with 
reality and manifested as hallucinations, delusions and thought disorder (DSM-IV, 
American Psychiatric Association, 1994). In the current version of the 
International Classification of Diseases (ICD-10, World Health Organization 
[WHO], 1992), a number of diagnoses are grouped underneath the wider term of 
psychosis: schizophrenia, schizotypal disorder, persistent delusional disorders, 
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acute and transient psychotic disorders, induced delusional disorder, 
schizoaffective disorders, other non-organic psychotic disorders and unspecified 
non-organic psychosis.  
For the purposes of this thesis, ‘first-episode psychosis’ will be defined as 
a first experience of one or more psychotic symptoms for a minimum of 7 days 
and will include patients from all the aforementioned categories as well as those 
with bipolar and substance-use disorder with psychotic symptoms. While there 
are differences between categories, research on broad psychosis has the 
advantage of exploring characteristics of the wider diagnostic group, which 
would have been otherwise missed if one or more categories were omitted.  
Estimates of incidence and prevalence of psychosis tend to vary between 
reports. It is estimated that the prevalence of all clinically important psychotic 
disorders in the general population is around 3% (van Os, 2009). Lifetime 
prevalence rates of schizophrenia have been reported between 0.4% (Saha et al, 
2005) and 0.9% (Perälä et al, 2007) while the ratio of male to female diagnosed 
schizophrenia is about 1.4:1 (McGrath et al, 2008).  
 
1.2.2 Aetiology of schizophrenia 
Schizophrenia is subject to a major genetic influence. The risk is about 
6.5% in first-degree relatives (Kendler et al, 1993) and rises to more than 40% in 
the co-twins of monozygotic twins with schizophrenia (Cardno et al, 1999). Twin 
studies suggest that heritability is around 80% (Cardno et al, 1999) though such 
heritability measures include not only the effect of genes but also of gene-
environment interaction (van Os et al, 2008). 
A large number of studies have examined the relationship between 
various environmental events and the onset of schizophrenia. The best 
replicated include early hazards to the brain such as obstetric complications 
(Cannon et al, 2002a). In adulthood, environmental stressors including migration, 
urban life and social isolation have been shown to further increase the risk 
(Boydell et al, 2004).  
Kapur et al (2005) proposed that the excessive release of dopamine in 
acute psychosis leads to increased attention and importance (salience) being 
attributed to neutral everyday experiences and events. In turn, delusions arise 
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from an attempt by the patient to explain the unusual salience of environmental 
stimuli. 
Although the dopamine system does not appear to be implicated in the 
origins of schizophrenia, it has been proposed that the influence of the above 
genetic and environmental risk factors can leave an individual more vulnerable to 
dopamine dysregulation, which in turn acts as a final common pathway to the 
development of psychosis (Di Forti et al, 2007). 
 
1.2.3 Prognosis 
Psychosis is often viewed as a condition with fairly poor prognosis and 
outcome. A systematic review of patients in their first episode of psychosis by 
Menezes et al (2006) surprisingly observed that only 27% of the sample showed a 
poor outcome, with 42% showing a good outcome. Most patients have been 
reported to experience some level of recovery with only a small proportion 
remaining completely symptom-free (Wunderink et al, 2009). Poor outcome (e.g. 
increased symptoms, hospital readmissions, absence of remission) can be 
exacerbated by longer duration of untreated psychosis, reduced pre-morbid 
functioning, gradual onset of the disease and low insight. Schizophrenia is also 
associated with high mortality rates from increased risk of suicide (Mortensen 
and Juel, 1993), co-morbid physical health problems (Leucht et al, 2007) and 
accidents and trauma (Saha et al, 2007). In summary, psychosis and particularly 
schizophrenia are associated with adverse outcomes both in terms of mental as 
well as physical health. 
 
1.3 Cannabis 
1.3.1 Introduction  
Although historically most attention has focused on the use of 
amphetamine and methamphetamine, which can produce a schizophrenia-like 
picture (Paparelli et al, 2011), cannabis is currently the most frequently used illicit 
substance in the world (United Nations Office on Drugs and Crime, 2010). It is 
obtained from the Cannabis Sativa plant. There are over 400 natural components 
found within this plant of which around 60 have been classified as 
‘cannabinoids’. Delta-9 tetrahydrocannabinol (Δ9-THC/ THC) is the primary 
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psychoactive constituent of cannabis but another important cannabinoid is 
cannabidiol (CBD), which appears to counteract some of the psychoactive effects 
of THC (Zuardi et al, 2006). The varieties of cannabis typically available are 
marijuana or grass, resin or hash and most recently sinsemilla or skunk. Marijuana 
or grass, the herb varieties, are derived from the flowers and leaves of the plant; 
resin or hash are derived from the secretions during the flowering process and 
sinsemilla or skunk comes from the female plant at its seedless stage. 
A report by the London Metropolitan Police revealed the different levels 
of component chemicals in each of the varieties. Samples seized and analysed 
showed that marijuana and hash on average contained 2-4% of Δ9-THC compared 
to around 14% found in skunk. It was also observed that very low concentrations 
of CBD were present in the grass variety and almost completely absent in skunk – 
an alarming finding considering the increasing popularity of skunk and the lack of 
potentially protective components (Potter et al, 2008). 
 
1.3.2 Brief history of cannabis 
Although use of cannabis as either a medicinal product or recreational 
drug was fairly uncommon in the U.K. until the 1950s, it has been documented 
copiously around the world since the 16th century. At that time most information 
on cannabis (or hemp) came from observations of doctors accompanying 
empire-builders into India and, uninterested yet in its psychoactive properties, 
they were more excited about its potential as a source of rope and string. By the 
18th century, British travellers returning from Asia were eager to share their 
stories of this unique substance and by the 19th century the empire had expanded 
sufficiently to allow systematic attention to focus on cannabis by scientists and 
doctors. William Brooke O’Shaughnessy was one of the first scientists to conduct 
a range of experiments with cannabis and reportedly cure a range of conditions 
including rheumatism, rabies, tetanus and cholera. While interest was growing in 
the medical effects and potential benefits of cannabis, the British in India finding 
themselves amongst the largest market for cannabis taxed the cannabis trade. 
Producers who evaded laws and regulations were penalized and so started 
cannabis being associated with criminality (Mills, 2003).  
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Throughout the 19th century, British doctors continued to regard cannabis 
as a valuable medicine and it was evidence from India that first pointed to a 
relationship between cannabis and insanity. By the late 1800s the Indian Hemp 
Drugs Commission (IHDC) was established to investigate these claims in the 
colonies and its report comprises one of the most complete surveys on cannabis 
use to this day. They discarded any association between cannabis use and social 
problems and reported that moderate or habitual use would not cause any 
adverse health effects (Mills, 2003).  
At the dawn of the 20th century while cannabis was still widely consumed 
in India and the British were still acquiring income from ongoing taxation, the 
drug remained largely unknown in the UK besides to a small party of doctors, 
scientists and an ‘elite’ artistic group. It wasn’t until the 1920s with the 
commission of the League of Nations Advisory Council on Opium and two opium 
conferences in 1924-1925, that the Coca Leaves and Indian Hemp Regulations of 
1928 saw a set of restrictions on cannabis imposed for the first time by British law 
(Mills, 2003).  
This law was applied rather erratically until the Misuse of Drugs Act in 
1971, which introduced the drug classification system and penalty guidelines 
assigning cannabis a class B grouping. This remained until 2004 when, in 
accordance with recommendations from the Advisory Council on the Misuse of 
Drugs (ACMD), it was downgraded to class C. In 2009, against ACMD advice, it 
was upgraded and returned to class B. 
Even from the early days of hemp trade and experimentation, laws and 
policies have defended and challenged positions on cannabis continuously. As 
the most popular illicit drug around the world, which occasionally benefits from 
regulation such as in the Netherlands and more recently Portugal as well as being 
prescribed for medicinal purposes in the United States, the debate on its effects 
and safety is ongoing. 
1.3.3 Prevalence of cannabis and other drug use in schizophrenia and first episode 
psychosis 
Patients with severe mental illness have high rates of substance use 
disorder (Regier et al, 1990; Mueser et al, 1995; McCreadie, 2002). Hambrecht and 
Häfner (1996) found that, in patients with a first admission of schizophrenia, the 
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rates of substance use were twice as high as in healthy controls. Similarly high 
rates have been also documented in patients with a first episode of psychosis 
(FEP). High rates of substance misuse were also found by Addington and 
Addington (2007) in a study of admissions to an early-psychosis programme. 
Barnett et al (2007) found that substance use among people with a FEP was 
twice that of the general population with poly-drug abuse being common. 
Lifetime prevalence of substance use in patients with FEP has been reported as 
high as 74% (Lambert et al, 2005) and as low as 23% (Sevy et al 2001). Some of this 
variability will naturally be due to methodological differences but it probably also 
reflects differences in drug availability and price and the cultural acceptability of 
drug use in the different settings. 
Many studies have drawn attention to the high levels of cannabis 
consumption by patients with psychosis. For example, Green et al (2005) 
analysed 53 treatment studies and 5 epidemiological studies and reported that 
on average 42% of psychotic patients had used cannabis in their life. Lifetime use 
of cannabis in the general population is lower; for example, around 30% in the UK 
(Home Office, 2009/2010).  
In light of the high prevalence of cannabis use among young people, a lot 
of research has focused on its use in FEP (Kavanagh et al, 2004). Sevy et al (2001) 
found that cannabis was the most popular illicit substance in a sample of patients 
presenting with a first episode of schizophrenia or schizoaffective disorder. 
Barnett et al (2007) noted that cannabis abuse was reported by 51% of patients; 
use in the last month by patients was more than twice as high as in the general 
population (29% vs 12%). In another study, 63% of individuals with first-episode 
schizophrenia had at some time used cannabis and 32% were current users 
(Harrison et al, 2007). Furthermore, Linszen et al (1994) reported that 26% of 
recent-onset schizophrenic patients were abusing cannabis. 
1.3.4 Role of cannabis in aetiology of schizophrenia 
Experimental studies investigating the acute effects of cannabis 
intoxication have shown that it can induce transient psychotic symptoms in 
healthy individuals and worsen symptoms in those with an already established 
psychotic illness.  D’Souza et al (2005) administered intravenous Δ9-THC to 13 
patients with clinically stable schizophrenia or schizoaffective disorder. Δ9-THC 
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significantly increased positive, negative and general schizophrenia symptoms. 
In addition, patients were more vulnerable to the effects of Δ9-THC compared to 
healthy controls (D’Souza et al, 2004). THC impaired learning and recall in a dose-
dependent manner. Further evidence comes from Morrison et al (2009), who 
conducted a study in which 22 healthy males received intravenous THC or 
placebo in a double-blind fashion. Administration of THC induced positive 
psychotic symptoms, anxiety and dysphoria. There was also marked impairment 
on working and episodic memory and executive function.  
Although these studies demonstrate the short-term effects of cannabis 
intoxication, they cannot identify any causal relationship between cannabis and 
chronic psychosis. Evidence for an association between cannabis use and the 
development of schizophrenia has been demonstrated through longitudinal 
studies. The first such study followed up a cohort of 50,087 Swedish conscripts 
(Andreasson et al, 1987). Those who had smoked cannabis at least once by age 
18 were twice more likely to develop schizophrenia in the following 15 years than 
non-users. The risk increased in a dose-dependent fashion to 6-fold for those 
who had used cannabis more than 50 times. After controlling for 11 variables the 
risk remained significant even if somewhat lower. Similar findings were reported 
in a follow-up of this cohort after 27 years (Zammit et al, 2002).    
Another study, in the Netherlands, investigated the effects of cannabis 
use on self-reported psychotic symptoms in 4,045 psychosis-free individuals at 
baseline and then 12 and 36 months later (van Os et al, 2002). There was a dose-
response relationship between baseline cannabis use and psychotic symptoms at 
follow-up, with users being almost twice as likely to report psychotic symptoms 
and around 3 times more likely to develop a needs-based diagnosis of psychotic 
disorder than non-users after adjusting for confounders.   
In the Netherlands, Henquet et al (2005) carried out a study with 2,437 
young people. Cannabis use in adolescence and young adulthood increased the 
risk of psychotic symptoms in later life. Cannabis use at baseline was associated 
with an almost double risk of developing psychotic symptoms four years later 
even after adjusting for a number of social confounders and other drug use; this 
relationship was again dose-response dependent with increasing frequency of 
cannabis use. 
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Arseneault et al (2002), in the Dunedin Birth Cohort Study in New Zealand, 
followed up a cohort by collecting information on psychotic symptoms at age 11, 
on drug use at age 15 and 18 and on psychotic symptoms at age 26. People who 
had used cannabis by age 15 were 4 times more likely to have a diagnosis of 
schizophreniform disorder at age 26 than controls. After controlling for psychotic 
symptoms at age 11, the risk for schizophreniform disorder was not statistically 
significant but remained higher in those who used cannabis at age 15. There was 
no significant risk associated with developing schizophreniform disorder and 
cannabis use by age 18. Combined findings from age 15 and age 18 analyses 
showed an increased risk for schizophreniform disorder at age 26, which only 
slightly decreased after controlling for confounders. Also in New Zealand, the 
Christchurch study followed participants for more than 20 years and found that 
young people using cannabis by age 18 had an almost 2-fold risk of developing 
psychotic symptoms. This association again increased in a dose-response manner 
and remained significant after controlling for confounders (Fergusson et al, 
2005).  
Most recently, McGrath et al (2010) assessed cannabis use retrospectively 
in an Australian birth cohort study of 3,801 young adults at 21-year follow-up. 
Those who had smoked cannabis for 6 or more years were 4 times more likely to 
score highly on the Peters et al (1999) Delusions Inventory and twice as likely to 
develop non-affective psychosis compared to those who had never used 
cannabis. The former association was still evident when 228 sibling pairs were 
compared.  Furthermore, the authors found that a greater length of time since 
first use of cannabis and more frequent use of cannabis at follow-up were 
associated with early-onset hallucinations.  
Table 1.1 gives a summary of 11 longitudinal studies conducted in the 
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Finally, Di Forti et al (2009) found that patients presenting with a first 
episode of psychosis in south London were 6 times more likely to have smoked 
‘skunk’ than a comparative sample of the general population.  These authors 
concluded that the risk of psychosis increased with the frequency and length of 
cannabis consumption and the potency of the preparation used. Modern forms 
of cannabis could be potentially more harmful and with the relative decrease of 
cannabidiol concentrations in skunk some protective effects may have been 
removed making this a more potent form of the drug. 
 
1.3.5 Effects of cannabis use on established psychotic disorders 
Persistent substance use by those already psychotic has been associated 
with increased suicidal ideation (Hawton et al, 2005), more positive symptoms 
(Pencer and Addington, 2003) and risk of illness and injury (Dickey et al, 2000).  
‘Revolving door’ admissions occur at almost twice the frequency for users than 
non-users (Menezes et al, 1996) and admissions by substance users are also 
reported to be lengthier and more severe. Patients with psychosis who abuse 
drugs are also less likely to adhere to treatment (Janssen et al, 2006) and more 
likely to suffer from stress (Barrowclough et al, 2005) and social exclusion (Todd 
et al, 2004).  
 Cannabis use appears to play a role in causing or increasing problems 
among patients with established psychosis (Mueser et al, 2000). A follow-up 
study of psychotic patients with persistent cannabis use found that they were at 
 21 
risk of increased symptoms, hospital readmissions, and absence of remission 
(Sorbara et al, 2003). Grech et al (2005) also found that persistent cannabis use 
led to a more continuous illness at follow-up. Continuous cannabis use also made 
patients more likely to relapse (Linszen et al, 1994) and to suffer from problems 
leading to increased violence and criminal behaviour (Miles et al, 2003). A 
systematic review also showed that persistent use by patients with psychosis 
was consistently associated with increased relapse and non-adherence to 
treatment (Zammit et al, 2008). 
It is still unclear to what extent cannabis use can affect patients’ physical 
health. Based on the evidence for the appetite-enhancing effects of this drug, as 
shown in animal studies and research with cancer patients (Nelson et al, 1994; 
Hao et al, 2000), cannabis use may lead to weight gain. Isaac et al (2005) found 
that patients who reported cannabis use at admission had higher blood glucose 
levels and greater weight gain at 6 weeks than non-smokers. Further research 
needs to be conducted with larger populations, longer follow-ups and a focus on 
the interaction between cannabis use, antipsychotic properties and general 
lifestyle (i.e. diet, exercise), which can independently affect weight fluctuations. 
Finally, concerns have been expressed about the respiratory effects of cannabis, 
which is traditionally smoked mixed with tobacco and can potentially introduce 
further risks for tobacco-related illness, such as lung cancer (Hashibe et al, 2005). 
 
1.4 Reasons for cannabis use 
1.4.1 Introduction  
Studies have shown that patients with psychosis are more likely to use 
illicit drugs than the general population, with cannabis being the most popular. 
As we have seen, there exists evidence that cannabis use can contribute to the 
onset of schizophrenia and poor outcome in patients with established psychosis. 
Therefore, understanding why patients use cannabis is important. If cannabis-
using behaviour and its correlates are different for patients with psychosis, 
treatment may have to adapt in meeting these special needs. Before assessing 
the specific reasons for cannabis use, an overview of the theories of co-morbid 
substance misuse and psychotic illness as well as a summary of the existing 
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literature on reasons for general substance use in psychiatric populations will be 
presented. 
 
1.4.2. Models and theories explaining co-morbid substance misuse and psychotic 
illness 
A variety of models have been proposed to explain co-existing substance 
misuse and psychosis (Mueser et al, 1998): 
Secondary substance use disorder models: These postulate that substance-
use disorders are secondary to, and therefore are caused by, severe mental 
illness.  
a) The self-medication hypothesis: The most widely cited is the “Self 
Medication Hypothesis” (Khantzian, 1985, 1997) which theorises that patients 
take specific substances to relieve particular symptoms; substances are not 
chosen at random but have “psychopharmacological specificity.” Khantzian 
(1997) also argued that patients with schizophrenia may start taking substances 
to self-medicate prodromal symptoms, prior to the onset of the disorder, and 
that heightened rates of stimulant use in this population may be an indication of 
patients’ attempt to self-medicate negative symptoms. Self-medication of 
symptoms caused by antipsychotic medication may also be occurring (Schneier 
and Siris, 1987). Mueser et al (1998) argued that the validity of the self-
medication hypothesis depends on the existence of the following relationships: 
patients will report using certain substances to relieve particular psychiatric 
symptoms; each psychiatric diagnosis will be associated with the use of particular 
substances in epidemiological studies; observational studies will show that 
patients use specific substances to change symptoms characteristic of their 
psychiatric disorder. Mueser et al (1998) consider that the available evidence 
does not currently support any of these relationships.  
b) Alleviation of dysphoria model: A variation of the traditional self-
medication hypothesis proposes that substance misuse occurs to alleviate 
dysphoric experiences such as boredom, depression and loneliness to which 
patients with severe mental illness may be particularly susceptible. This model 
assumes that patients may engage in poly-substance misuse and do not choose 
specific substances to medicate specific undesired psychological states. 
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Secondary psychiatric illness model: This model assumes that substance-
misuse disorders can cause psychiatric disorders (e.g. drug-induced psychosis).  
Common factor model: This model proposes that psychiatric and 
substance-use disorders frequently co-occur due to underpinning shared 
biological, psychological or social factors such as genetics, family history, 
antisocial personality disorder, childhood trauma, cognitive impairment or lower 
socioeconomic status. Gregg et al (2007) argue that it is unlikely that one factor 
will be the cause of co-morbidity but rather a combination of multiple-risk 
factors.  
Bi-directional models: This model assumes that the psychiatric disorder 
and substance misuse activate and perpetuate each other with substance misuse 
acting as a stressor in biologically vulnerable individuals who are especially 
sensitive to small amounts of substances.  
Multiple risk factor models: An affect-regulation model proposed by 
Blanchard et al (2000) suggests that patients with schizophrenia use substances 
to cope with negative affect. According to the model, trait rather than state 
factors, such as neuroticism (which is associated with negative affective states) 
and impulsivity (which is associated with pleasure seeking and risk taking) 
interact with stress and make substance use more likely (Hides et al, 2004).   
According to the social learning theory (Bandura, 1977), drug use is 
viewed as a strategy adopted by people who have positive beliefs about its 
effects and limited coping skills. Furthermore, Barrowclough et al’s model of 
maintenance of substance use in psychosis (Barrowclough et al, 2007), adapted 
from Marlatt and Gordon’s model of addiction (Marlatt and Gordon, 1985), 
postulates that certain environments and cues may lead patients to use 
substances. The same environments and cues may have a connection to 
psychotic symptoms or negative experiences related to psychosis. In the context 
of poor problem-solving skills and coping strategies and lack of other sources of 
pleasure, the perceived benefits of substance use become positively reinforced.  
However, this behaviour may cause patients to feel worse leading to further 
substance use. A problematic cycle ensues whereby substance use continues and 
psychotic symptoms persist. The availability of drugs and acceptability of use 
among peers combined with the learned positive benefits of drug use also feed 
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into the cycle. “External stressors”, such as problems with family members, may 
lead to more distress and substance use causing worsening of psychotic 
symptoms.  
Finally, a cognitive-behavioural bi-directional account of substance abuse 
(Hayes et al, 1996: pp 1154) describes the abuse as a consequence of 
“experiential avoidance [which is] a.....psychological process.....that occurs when 
a person is unwilling to remain in contact with particular private experiences (e.g. 
bodily sensations, emotions, thoughts, memories, behavioural predispositions) 
and takes steps to alter the form or frequency of these events and the contexts 
that occasion them.” Thus, substance misuse acts as a short-term strategy to 
change these private emotional states (Parrott, 2008).  
Despite the multi-factorial and holistic approach these models take in 
regards to co-morbidity, there is little empirical evidence to suggest that any one 
applies to all patients. It may be that different models may be more appropriate 
for different groups of patients and on an individual level more than one model 
may be valid. 
 
1.4.3 The self-report literature on reasons for substance use among psychiatric 
patients 
A number of studies have investigated self-reported reasons for general 
illicit substance use in psychiatric patients. An analysis of interviews with 19 
patients with recent onset psychosis, who used cannabis and/or other 
substances, identified four main themes influencing their use (Lobbana et al, 
2010). One theme was the “influence of perceived drug norms on behaviour”, 
which encompassed the acceptability of drug use in patients’ communities or the 
act of purposefully not conforming to social norms. The second theme was 
“attributions for initial and ongoing drug-taking behaviour”, where some 
patients attributed taking drugs to internal reasons (e.g. it was a personal 
choice) and others attributed it to external factors (e.g. belonging to a social 
group). The third theme was “changes in life goals affecting drug use” such as 
employment, the increased importance of good health, maintaining relationships 
and income. “Beliefs about links between mental health and drug use” was the 
final theme, which yielded different views among patients. Some patients 
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reported using substances as a coping mechanism for their mental health 
problems, while others acknowledged a predisposition to mental health 
problems, which their substance use may have triggered. Some patients said that 
substance use exacerbated their symptoms and problems, whereas others did 
not acknowledge any relationship between substance use and their mental 
illness.  
Table 1.2 lists the studies, which have assessed the reasons psychiatric 
patients give for using substances in general. The reasons have been categorized 
according to Spencer et al’s (2002) modification of the Drinking Motives 
Questionnaire (Cooper, 1994).
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Spencer et al (2002) assessed motivations for cannabis and alcohol use in 
69 patients with psychotic disorders from Australian psychiatric wards and 
clinics. Patients mainly reported taking these substances for enhancement, social 
and conformity reasons and to cope with dysphoric experiences- motives similar 
to those of people who misuse substances in the general population (Cooper, 
1994). The authors also report a possible additional motive - relief of positive 
symptoms and side effects, although patients rarely rated this as their motive for 
use. These subgroups of patients were established on the basis of both cannabis 
and alcohol use and conclusions regarding subgroups cannot be drawn for 
specific substances.  
Laudet et al (2004) investigated why patients, with a variety of diagnoses, 
attending a self-help group in the USA first started using substances. Over half of 
the patients reported wanting to fit in with peers as the main reason for initiating 
use. Test et al (1989) looked at reasons for substance use among patients with 
schizophrenia or schizophrenia-related disorders. The majority said they used 
substances to relieve boredom followed by using as a social activity and to feel 
less anxious and more relaxed.  Almost half reported that they used substances 
for sleep difficulties.  
Dixon et al (1991) investigated reasons for substance abuse among 
patients diagnosed with schizophrenia and substance abuse/ dependence. Most 
reported using substances to get high and reduce feelings of depression 
followed closely by using substances to relax and to increase feelings of 
pleasure. The authors reported that reasons for use did not differ substantially 
between different drugs.  
Recently, Gregg and colleagues (2009) recruited patients with 
schizophrenia and schizoaffective disorder with co-morbid alcohol or substance 
abuse/ dependence. Almost all patients reported using substances to “chill out or 
relax.” Social reasons were also very important followed by relief of boredom. 
The following groups emerged through a factor analysis: those who use 
substances for social and enhancement reasons, those who use for self-
medication and those who take substances to change their perception of 
experiences.  
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In summary, findings from the aforementioned studies suggest that 
psychiatric patients choose substances for their mood-enhancing properties and 
social effects with a small minority endorsing self-medication motives (relief of 
positive symptoms and medication side effects) for their substance use.  
 
1.5 Readiness to change cannabis use 
1.5.1 Introduction  
Despite strong evidence for damaging effects that persistent cannabis 
use can have on psychotic patients, many fail to gain from substance use 
treatment due to lack of motivation and drop-out (Drake et al., 2004). Motivation 
is crucial in determining why and how people change problematic health 
behaviours (Miller, 1985), including those patients with dual diagnosis (Pantalon 
and Swanson, 2003).  The concept incorporates concerns about the behavior and 
need for change, willingness to take responsibility, making a commitment and 
sustaining the behaviour change (Miller and Rollnick, 2002). Readiness to Change 
(RTC) refers to the degree to which an individual is motivated to change a 
problematic behaviour and includes ‘initial attitudinal shifts reflecting 
dissatisfaction with a behaviour or lifestyle, receptivity to discussing problematic 
aspects of the behaviour, initial modifications and ongoing change efforts until a 
new behaviour or lifestyle is established’ (Carey et al, 1999a; pp 245). 
Although readiness to change in substance users has been well 
researched, this concept has only recently begun to be explored in patients with 
co-occurring severe mental illness and substance use disorders (Ziedonis and 
Trudeau, 1997; Zhang et al, 2004).  A summary of research that has examined 
readiness to change substance-using behavior in patients with co-morbid 
psychiatric and substance use disorders as well as an overview of the most 
common RTC assessment instruments will be provided. 
 
1.5.2 Readiness to change substance use in co-morbid populations 
Carey et al (2002) found that patients who were prepared for change 
reported higher problem recognition, steps taken toward change, cons of using, 
and benefits of quitting. Active change also meant less frequent substance use 
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and lower perceived costs of quitting. In another study, higher motivation on a 5-
point Likert scale at baseline or discharge was associated with increased rates of 
abstinence at 1-month follow-up (Ries and Ellingson, 1990).  
Zhang et al (2006) found that, in patients with severe and persistent 
mental health illness, taking increasing steps to reduce alcohol use led to lower 
alcohol use in that period and significant decrease in alcohol use over time. 
Moreover, Velasquez et al (1999) found that severe alcohol use in dually 
diagnosed patients at pre-treatment was related to higher readiness to change. 
Pantalon et al (2002) also found that more severe alcohol and cocaine problems 
at baseline were related to higher readiness to change.  
In contrast, the relationship between readiness to change and 
involvement in treatment has not been straightforward. Ziedonis and Trudeau 
(1997) expected that treatment seekers would have higher motivation to change 
their drug use but found that patients with high motivation were not enrolled in 
treatment. Similarly, Pantalon and Swanson (2003) found that patients with 
lower motivation to change were more treatment-adherent than patients with 
higher motivation. 
There are several possible reasons for these contradictory findings. Firstly, 
as most of the research has included patients with schizophrenia, it is possible 
that the presence of psychotic symptoms may have obscured any relationship. 
Negative symptoms in particular, such as avolition and anhedonia, can hinder the 
measurement of motivational concepts of readiness to change, as patients might 
not be able to apply the effort needed to complete such demanding measures 
(Carey et al, 2001). Secondly, a variety of instruments were used to assess 
motivation in different studies. Thirdly, patients with schizophrenia display 
deficits in a number of cognitive areas including executive function, memory, 
language and attention (Kuperberg and Heckers, 2000; Bellack et al, 1999; 
Buchanan et al, 2005). Lack of self-awareness and difficulties with abstract 
thinking could impede patients’ ability to express intention for behavioural 
change (Carey et al, 2001).  
It would not be surprising if patients suffering from both schizophrenia 
and substance use were at a cognitive disadvantage to patients with only one of 
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the two disorders (Tracy et al, 1995). However, research in the area has shown 
that patients with psychosis who use substances perform better on cognitive 
tests, such as non-verbal functioning, than those patients who have never used 
drugs (Carey et al, 2003; Potvin et al 2005: McCleery et al, 2006). This may be 
because those who became psychotic following drug abuse have less 
developmental impairment than other schizophrenic patients. 
Of course, the role of motivation and RTC in dual diagnosis populations 
can only be addressed appropriately if we implement accurate and valid 
measures and a number of instruments based on the Transtheoretical Model of 
change (TTM; Prochaska and DiClemente, 1983) have been developed to 
measure motivation to change among drug users. The TTM proposes 5 stages of 
change to signify the continuous and recurring process by which people change 
addictive behaviours: pre-contemplation, contemplation, preparation, action and 
maintenance. The TTM has, in recent years, received criticism with regards to its 
validity and applicability. Authors have argued that the TTM provides a 
descriptive rather than evaluative means of understanding addictive behaviour 
(Sutton, 2001) and it oversimplifies the process of change, since it creates 
arbitrary categories related to arbitrary definitions (Littel and Girvin, 2002). 
Taking this into account, the TTM provides a detailed characterization of 
intentional behaviour change and recommends matching the proposed 
interventions to the respective stage of change. As the stage must be identified 
(Vilela et al, 2009), a number of instruments have been designed for that purpose 
and are reviewed below. 
 
1.5.3 Instruments for assessment of readiness to change 
Staging Algorithms 
The most common instruments are the staging algorithms designed to 
assign individuals to the stages of change based on their response to 4 or 5 
questions (Carey et al, 1999a). They are quick and easy to complete and can be 
adapted for different populations and substances. Initially developed for 
smoking cessation (Prochaska et al, 1994), their effectiveness in assessing RTC 
for other substances has not yet been determined. Algorithms have also been 
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criticized for the subjective manner in which stages are defined and how 
previous behaviours are used to predict readiness to engage in a similar 
behaviour in the future (Carey et al, 1999a).  
 
Self-report questionnaires 
One of the most commonly used questionnaires is the University of 
Rhode Island Change Assessment (URICA; DiClemente & Hughes, 1990). 
Respondents utilize a 5-point Likert scale from ‘strongly agree’ to ‘strongly 
disagree’ with each of the 32 statements and then 4 scores are generated 
corresponding to pre-contemplation, contemplation, action and maintenance 
stages.  It is an internally consistent scale, which can be adapted for different 
clinical problems. The URICA can be best employed to yield a single, continuous 
score of RTC as already demonstrated by the Project MATCH Research Group 
(1997). 
The Readiness to Change Questionnaire is a 12-item scale developed to 
measure stage of change in non-treatment seeking alcohol drinkers (RCQ; 
Rollnick et al, 1992). Respondents rate each of the items on a Likert scale from 
‘strongly agree’ to ‘strongly disagree’ and the highest score among pre-
contemplation, contemplation and action scales is regarded as the current stage 
of change.  This is a reliable instrument for use in medical settings and has been 
modified to produce a version to use in treatment (Heather et al, 1999).  
The Stages of Change Readiness and Treatment Eagerness Scale 
(SOCRATES; Miller & Tonigan, 1996) is 19-item instrument developed to measure 
RTC in substance users. Once again, respondents rate each item on a Likert scale 
from ‘strongly agree’ to ‘strongly disagree’ and are then assigned to one of three 
scales: recognition, taking steps and ambivalence.  
The Cartoon Stage of Change Measure (C-SOC) is a non-verbal self-report 
instrument based on the TTM constructs developed by Wells et al (1998). The 
scale consists of a set of pictures of a gender and ethnicity- neutral character that 
participates in or abstains from illicit drug use. The participant is then invited to 
indicate how much the pictures are like or unlike them and their motivation is 
rated based on that choice. Because this measure involves limited language or 
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cognitive and abstract processing, it could potentially make a very suitable 
instrument for assessing RTC among patients with psychosis. 
 
The Readiness Ruler (RR) 
The Readiness Ruler (RR; Heather et al, 2008) is the revised version of the 
Readiness Ruler developed by LaBrie et al (2005) to assess readiness to change in 
excessive alcohol users. Heather et al (2008) rephrased the pre-contemplation 
item and deleted the maintenance stage from the initial Ruler to produce this 
single-item measure that allocates respondents to pre-contemplation (PC), 
contemplation (C), preparation (P) and action (A).  
Using the Readiness to Change Questionnaire (RCQ- Rollnick et al, 1992) 
as the gold standard, the relationship between stages of change as allocated by 
the RCQ and patients’ response on the Readiness Ruler was found to be highly 
significant (χ2=37.5, df=8, p<0.0005) in an examination of concurrent validity by 
Heather et al (2008). The contingency coefficient, measuring the degree of 
association between the two questionnaires, was 0.59 (p<0.0005). The 
correlation between the Readiness Ruler score and RCQ dimensional score was 
0.47 (n=72, p<0.0005), which although highly significant, was lower than 
expected. When calculating the correlation for the two types of administration 
(self-report or interviewer-administered) separately, the significance remained 
(self-completion, rho=0.78, n=26, p<0.0005; interviewer-led, rho=0.72, n=26, 
p<0.0005). The difference between these two correlation coefficients was not 
significant (Z=0.45, p=0.34) (Heather et al, 2008).  
This is a fairly new measure that still warrants further validation with 
regards to its power to measure change (Heather et al, 2008). As it was 
developed for excessive drinkers identified in primary care, this project will 
investigate its concurrent and predictive validity against the Readiness to Change 
Questionnaire- Treatment Version (RCQ-TV) for first-episode psychosis patients 





The Readiness To Change Questionnaire- Treatment Version (RCQ-TV) 
The Readiness To Change Questionnaire – Treatment Version (RCQ-TV) 
(Heather et al, 1999) was originally designed to assess the motivational readiness 
to change drinking behaviour among excessive alcohol consumers.  The 
questionnaire allocates participants to one of three stages outlined in the Trans-
theoretical model developed by Prochaska and DiClemente (1983): pre-
contemplation (PC), contemplation (C) and action (A).  Participants complete the 
questionnaire about one substance only - usually the substance they use the 
most or are most concerned about.  All items score from –2 (strongly disagree) 
through to +2 (strongly agree).  Therefore, the maximum score for any stage can 
either be +8 or –8.   
The stage with the highest positive score determines allocation.  Tied 
scores are allocated to the stage furthest along the cycle of change from pre-
contemplation. 
For this study, the 15 self-report items have been modified to assess 
readiness to change cannabis use.  It cannot be assumed that the instrument 
retains its psychometric properties with these modifications.  Still, it was thought 
to be more valid to have a self-report measure than other stages of change 
scales that rely solely on clinician ratings. Also, it is assumed that although this 
would be the first presentation to services for psychotic symptoms, a number of 
patients would also be receiving concurrent treatment for substance use and the 
RCQ-TV would be more appropriate than the RCQ. It is the aim of this thesis to 
explore the concurrent and predictive validity of this questionnaire against the 
RR for first-episode psychosis patients who use cannabis. 
It is evident that the above self-report measures of readiness to change 
were not developed with dual diagnosis patients in mind. In cases where they 
have been used for assessing motivation to change in patients with co-morbid 
mental health and substance use problems, evidence for their utility has been 
conflicting. Exploring to what extent motivation relates to changing cannabis use 
in patients with psychosis and developing appropriate instruments to measure 




Schizophrenia appears to be a multi-factorial disorder in which many 
susceptibility genes interact with various environmental risk factors including 
cannabis use. The experimental administration of ∆9-THC, the major 
psychoactive substance in cannabis, can produce a psychosis-like state in healthy 
individuals as well as exacerbate psychotic symptoms in patients with 
established schizophrenia. The rates of cannabis use are higher in patients with 
psychotic disorders than in the general population and longitudinal studies have 
consistently found that cannabis use in adolescence and early adult life is 
associated with later psychosis.  
Despite years of research no consensus has been reached as to the 
reasons for increased rates of substance use in patients with psychosis. With the 
increased urgency to develop effective interventions for patients with psychosis 
who also use substances, investigating the motives that sustain cannabis use in 
this population is essential and it might facilitate the tailoring of successful 
interventions to individual needs. Motivating psychotic patients who use 
substances to commit to a process of behavioural change is difficult. Readiness 
to change substance use is likely to play an important part in the recovery 
process for psychotic patients who use substances and although the construct of 
RTC has been extensively investigated in primary substance users it is still 
uncertain whether it operates similarly in patients with co-morbid psychiatric 
disorders (Kolliakou et al, 2011). 
 
1.7 Aims of the thesis 
This thesis aims to investigate: 
1. The association between cannabis use and mental health outcomes at 12 
months. 
2. The association between cannabis use and other substance use at 
baseline, 3 months and 12 months. 
3. The self-reported reasons for cannabis use at baseline, 3 months and 12 
months. 
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4. The association between readiness to change cannabis use at baseline 
and 3 months and cannabis use outcomes at 12 months. 
5. The utility of the Readiness Ruler (RR) and the Readiness to Change 
Questionnaire- Treatment Version (RCQ-TV) in assessing motivation to 
change cannabis use. 
 
1.8 Thesis outline 
 Chapter 2 will present the results from 3 systematic reviews: a) The 
effects of cannabis use on psychotic outcomes and its association with other 
drug use, b) the reasons for cannabis use in patients with psychosis and c) 
readiness to change as measure of cannabis use outcome in patients with 
psychosis. 
Chapter 3 will discuss the general methodology of the PUMP study within 
which this thesis is nested. 
 Chapter 4 will describe the baseline socio-demographic and clinical 
characteristics of the sample. It will also present preliminary findings from 
baseline comparisons between participants and non- participants and cannabis 
users and non-users. 
 Chapter 5 will present and discuss results from the study on the effects of 
cannabis use on psychotic outcomes at 12 months as well as the association of 
cannabis and other drug use at baseline, 3 months and 12 months. 
 Chapter 6 will describe and discuss findings from the study on the reasons 
for cannabis use at baseline, 3 months and 12 months. 
 Chapter 7 will present and discuss results from the study on readiness to 
change, at baseline and 3 months, as a measure of cannabis use outcomes at 12 
months. 
 Chapter 8 will comprise a summary of the findings from the experimental 
chapters and present general limitations of the PUMP study and biases in the 
thesis methods. Research and clinical implications of the findings will be 




Chapter 2 – Systematic reviews 
 
2.1 Aims of the chapter 
This chapter will describe the findings of 3 systematic reviews as follows: 
1. The effects of cannabis use on psychotic outcomes and its association 
with other drug use in patients with psychosis. 
2. The self-reported reasons for cannabis use in patients with psychosis. 
3. Readiness to change cannabis use, as a predictor of cannabis use 
outcome, in patients with psychosis. 
All reviews were completed between January and March 2010 to inform 
the development of the thesis.  
 




Criteria for selecting studies 
 Abstracts were considered eligible for full manuscript data extraction if 
they fulfilled the following criteria: (a) the design was prospective; (b) the study 
population included adolescents or adults (16-65 years old) with psychosis 
including schizophrenia or related psychotic disorders; (c) cannabis use was self-
reported and/or verified by Urinary Drug Screen (UDS); (d) psychotic outcomes 
and other drug use were reported as primary or secondary outcomes; (e) 
abstracts and full papers were in English. Studies were excluded according to 
criteria in Figure 2.1. 
 
Search Strategy 
The following electronic libraries were searched: MEDLINE (1950 to 2009); 
PsycINFO (1806 to 2009) and EMBASE (1980 to 2009). The following search 
terms were used: ‘psychosis’ and ‘cannabis’. The full search strategy is available 
in Table 2.1. The reference lists of included studies were searched for any 
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additional studies and corresponding authors and experts in the field were 
contacted for additional information on published and unpublished studies. 
 
Table 2.1 Search strategy for systematic review of the effects of cannabis use on 
psychotic outcomes and other drug use in patients with psychosis. 
 
Search words 
1 exp Cannabis/ 
 
2 cannabis.mp. [mp=title, original title, abstract, name of substance word, 
subject heading word, unique identifier] 
 
3 cannabis us*.mp. [mp=title, original title, abstract, name of substance 
word, subject heading word, unique identifier] 
 
4 cannabis smok*.mp. [mp=title, original title, abstract, name of substance 
word, subject heading word, unique identifier] 
 
5 drug us*.mp. [mp=title, original title, abstract, name of substance word, 
subject heading word, unique identifier] 
 
6 patterns of drug us*.mp. [mp=title, original title, abstract, name of 
substance word, subject heading word, unique identifier] 
 
7 patterns of substance us*.mp. [mp=title, original title, abstract, name of 
substance word, subject heading word, unique identifier] 
 
8 patterns of cannabis us*.mp. [mp=title, original title, abstract, name of 
substance word, subject heading word, unique identifier] 
 
9 6 or 3 or 7 or 2 or 8 or 1 or 4 or 5 
 
10 exp Psychotic Disorders/ 
 
11 psychosis.mp. [mp=title, original title, abstract, name of substance word, 
subject heading word, unique identifier] 
 
12 psychot*.mp. [mp=title, original title, abstract, name of substance word, 
subject heading word, unique identifier] 
 
13 11 or 10 or 12 
 




Data were extracted from papers selected for further review. A 
standardised data extraction sheet was composed to record and code the 
following information (if available) from studies: author, country of origin and 
year; study methodology; sample characteristics (size, age, diagnosis); 
assessment of outcome (psychotic outcomes and other drug use) 
 
Figure 2.1 Systematic review flow-chart of the effects of cannabis use on 

















2.2.2 Results and discussion 
The search strategy yielded 8,533 abstracts from which 24 abstracts 
satisfied the criteria and full texts of the studies were retrieved. The 10 studies 
included in the systematic review are summarized in table 2.2
8533 abstracts were screened 
22 papers fulfilled inclusion 
criteria.  
Full text was retrieved 
10 studies included in the 
review 
6 studies excluded for not 
reporting relevant results 
3 studies excluded for not 
reporting separate results for 
cannabis 
2 studies excluded for being 
retrospective 
1 study excluded for not 




Table 2.2 Studies included in the systematic review of the effects of cannabis use on psychotic outcomes and other drug use 












  Drug use 
assessment 











Prospective 3 year 
FU 
142 patients, mean 
age= 25 years, DSM-
IV 
No Yes Yes No 






101 patients, 16-50 
years old, diagnostic 
criteria not stated 
Yes No No No 









98 patients, <60 
years old, OPCRIT, 
DSM-III-R 
No Yes Yes No 
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Table 2.2 Studies included in the systematic review of the effects of cannabis use on psychotic outcomes and other drug use 












  Drug use 
assessment 





Other drug use 






262 patients, 16-40 
years old, DSM-IV 
Yes No No No 





81 patients, >16 years 
old, DSM-IV, OPCRIT  
Yes No No No 








2-month FU (on 
average) 
130 patients, 15-29 
years old, DSM-IV 
Yes Yes Yes No 
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Table 2.2 Studies included in the systematic review of the effects of cannabis use on psychotic outcomes and other drug use 












  Drug use 
assessment 





Other drug use 





1 year FU 
93 patients, 15-26 
years old, DSM-III-R 







1 year FU 
62 patients, 18-30 
years old, DSM-III 
Yes No No No 





10-12 year FU 
69 patients, 16-50 
years old, RDC and 
DSM-IV 
No Yes Yes No 




15-month FU  
103 patients, 15-30 
years old, DSM-IV  
Yes No No No 
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Psychotic outcomes 
Total symptom severity 
Martinez-Arevalo et al (1994) followed up 62 outpatients with a diagnosis 
of schizophrenia over one year and reported that 64% of patients who 
persistently smoked cannabis during the follow-up period and 37% of patients 
who smoked cannabis at baseline but subsequently stopped experienced a 
complete relapse in comparison to only 17% of non-smokers, even after adjusting 
for medication adherence and stresses. No adjustment for baseline confounders 
was undertaken as persistent use was assessed. Definition of relapse was not 
provided and cannabis exposure was not ascertained. No drug screening was 
utilised.  
In a 12-month follow-up study of 93 outpatients with recent-onset 
schizophrenia or related disorders, Linszen et al (1994) found that cannabis 
abusers had significantly more and earlier psychotic relapses than non-abusers 
with heavy users experiencing more and even earlier relapses. The relationship 
remained significant after adjusting for baseline differences in age at admission, 
gender and alcohol use. Strict criteria were applied in rating cannabis exposure 
and grouping patients according to levels of use. Drug screening was not used to 
corroborate self-reports and patients with a primary alcohol or drug dependence 
or brief drug-related psychoses were excluded from participation. 
In another follow-up (median 9 weeks and 4 days) study of 130 
outpatients with first-episode psychosis, Hinton et al (2007) compared 4 groups 
of (i) those not using cannabis at either baseline and follow up; (ii) those who 
were using cannabis at both time points; (iii) those who were using at baseline 
but not at follow-up and (iv) those who were not using at baseline but were 
using at follow-up. They observed no significant differences between groups 
over time but found that those using cannabis at follow-up scored significantly 
higher than non-users on general psychopathology, social functioning and 
functional disability measures.  No adjustment for confounders was carried out, 
as baseline comparisons between users and non-users did not reveal any 
differences. A time frame for cannabis use before admission to study was used to 
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rate exposure and all psychoses were included in the analysis. No drug screening 
was employed. 
In a study of 101 outpatients with schizophrenia and related disorders, 
Degenhardt et al (2007) reported that cannabis use was associated with a small, 
albeit significant, increase in psychopathology that persisted after adjusting for 
age, gender, psychopathology, other drug use and month of data collection. A 
time frame for use before admission to study was used to define cannabis 
exposure, no drug screening was utilised and bipolar patients were excluded 
from participation. 
Green et al (2004) found that there was no significant association 
between cannabis misuse and change in total PANSS scores from baseline to 
follow-up among 262 patients taking part in a 12-week RCT of haloperidol vs 
olanzapine for first-episode psychosis after adjusting for age of onset, duration 
of untreated psychosis and psychopathology. Current and lifetime cannabis users 
were merged to define the cannabis-using group, there were no drug screening 
procedures and patients with substance dependence were excluded from the 
study. 
 
Positive and negative symptoms 
In a prospective 15-month follow-up study of 103 in- and out-patients with 
first-episode psychosis, Wade et al (2006) found that patients who misused 
cannabis experienced higher rates of relapse of positive symptoms during follow-
up compared to patients with alcohol misuse only and the association remained 
significant after controlling for the effects of gender, age, diagnosis, duration of 
untreated psychosis and medication compliance. There is no description of 
diagnoses included in the study, drug screening was not utilised and cannabis 
exposure was not established. 
Hides et al (2006) followed up 81 inpatients with recent-onset psychosis 
over a period of 6 months and found that frequency of cannabis use (days per 
week) predicted psychotic relapse at 6 months and remained a significant 
predictor after adjusting for a number of demographic, functioning, substance 
 47 
use, stress, family and clinical variables. Cannabis exposure and diagnostic groups 
were defined and drug screening was utilized to corroborate self-reported use.  
Addington and Addington (2007), in a 3-year study of 142 in- and out-
patients presenting with early psychosis, found that cannabis users had higher 
levels of positive symptoms at 1-, 2- and 3-year follow-up points than non-users. 
This remained significant after controlling for age at onset of use, age and 
gender. All psychoses were included in the analysis and definition of cannabis 
exposure was presented. No drug screening was utilised. 
Grech et al (2005) followed up 98 inpatients with recent-onset psychosis 
over 4 years and found that there was an association between continued 
cannabis use and severity of positive symptoms at follow-up, which remained 
significant after adjusting for age at admission, ethnicity and gender. All 
psychoses were included and cannabis exposure was classified based on duration 
of use. No drug screening was applied. 
Hinton et al (2007), as described previously, also found that cannabis 
users at follow-up reported more positive symptoms than non-users. 
Stirling et al (2005), in a study of 69 inpatients with first-episode 
psychosis, reported no differences on positive symptoms between cannabis and 
non-cannabis users at 10-12 year follow-up. Adjustment for confounders was not 
undertaken as was definition of cannabis exposure not presented and urinary 
drug screen not utilised. 
No association was observed in any of the studies between cannabis use 
and negative symptoms. 
 
Other drug use 
No studies looked at the association between cannabis and other drug 
use in patients with psychosis. 
 
The effects of cannabis use on patients with an established psychotic 
disorder have been inconsistent. Three out of the four studies reported that 
persistent cannabis use was associated with increased relapse rates but one 
study failed to observe such a finding (Green et al, 2004). Similarly, five studies 
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showed that patients with ongoing cannabis use had more positive symptoms at 
follow-up than non-users but one did not report such significance (Stirling et al, 
2005). No studies reported an effect of cannabis use on negative symptoms and 
no studies examined the relationship between cannabis and other drug use. 
There are several methodological issues in the included studies. Sample 
sizes varied widely and analyses on smaller groups might have limited the power 
to detect associations otherwise significant and clinically important.  Biomedical 
screening tests to corroborate substance use were only performed in one study 
(Hides et al, 2006). The increasing evidence that self-reported cannabis use from 
a range of populations including patients with psychosis is more accurate than 
collateral reports (Martin et al, 1988; Wolford et al, 1999; Selten et al, 2002) and 
the presence of high levels of substance use in the studies (i.e. Hinton et al, 2007) 
tend to challenge the notion that urine, blood or hair analysis would have been 
necessary but some authors argued that results would have been more 
convincing if they had used alternative confirmation of substance use (Linszen et 
al, 1994). 
Studies that presented cross-sectional, rather than longitudinal, results 
were also included in the review (Linszen et al, 1994; Hinton et al, 2007; 
Addington and Addington, 2007). It would not have been possible for these 
studies to ascertain patterns of cannabis use in-between assessments so 
information on cannabis use might have lacked accuracy. Self-reported levels of 
cannabis use at follow-up don’t necessarily reflect the actual pattern of use since 
baseline and it is possible that the true impact of cannabis use has been 
misreported. Definitions of cannabis exposure might partly explain this 
discrepancy since some studies defined cannabis use based on specific criteria 
(Hinton et al, 2007) whereas others did not (Wade et al, 2006). Similarly, some 
studies grouped users based on frequency or quantity of cannabis use 
(Addington and Addington, 2007). Studies also varied in their definitions of 
psychotic diagnosis with a couple of studies excluding substance-induced 
psychosis or bipolar disorder. Early/recent/first-episode psychosis appeared to be 
used interchangeably although these terms indicated the presence of functional 
psychosis with varying durations. Adjustment for confounders was also not 
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systematically carried out. Finally, although the sample sizes reported above 
represent the number of patients whose data were available at all assessment 
points, Zammit et al (2008) point out that the high loss to follow-up and lack of 
statistical power (estimated sufficient sample size of 250) might have led to the 
underestimation of the strength of any of the associations of interest.  
  
2.3 Current reasons for cannabis use in patients with psychosis 
 
2.3.1 Methods 
Criteria for selecting studies  
Abstracts were considered eligible for full manuscript data extraction if 
they fulfilled the following criteria: (a) the design was observational and 
prospective; (b) the study population included adolescents or adults (16-65 years 
old) with psychosis including schizophrenia or related psychotic disorders; (c) 
cannabis use was self-reported and/or verified by Urinary Drug Screen (UDS); (d) 
current reasons for cannabis use as a primary or secondary outcome were 
included; and (e) abstracts and full papers were in English. Studies were excluded 
according to criteria in Figure 2.2. 
 
Search Strategy  
The following electronic libraries were searched: MEDLINE (1950 to 2009); 
PsycINFO (1806 to 2009) and EMBASE (1980 to 2009). The following search 
terms were used: ‘psychosis‘ and ‘reasons for cannabis, substance and drug use’. 
The full search strategy is available in Table 2.3. The reference lists of included 
studies were searched for any additional studies and corresponding authors and 








Table 2.3 Search strategy for systematic review of the current reasons for 
cannabis use in patients with psychosis. 
 
Search words 
1 exp Psychotic Disorders/ 
 
2 psychosis.mp. [mp=title, original title, abstract, name of substance word, 
subject heading word] 
 
3 psychot*.mp. [mp=title, original title, abstract, name of substance word, 




5 reasons for cannabis us*.mp. [mp=title, original title, abstract, name of 
substance word, subject heading word] 
 
6 reasons for drug us*.mp. [mp=title, original title, abstract, name of 
substance word, subject heading word] 
 
7 reasons for substance us*.mp. [mp=title, original title, abstract, name of 
substance word, subject heading word] 
 
8 or/ 5-7 
 
9 4 and 8 
  
 
Data extraction  
Data were extracted from papers selected for further review. A 
standardized data extraction sheet was composed to record and code the 
following information (if available) from studies: author, country of origin and 
year; assessment measures; sample characteristics (size, diagnosis); assessment 
of outcome (reasons for use). 
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2.3.2 Results and discussion 
The search strategy yielded 85 abstracts from which 13 abstracts satisfied 
the criteria and full texts of the studies were retrieved. Six studies were excluded 
for not reporting separate results for cannabis and one study was excluded for 
not reporting separate results for psychotic patients. The six studies included in 
the systematic review are summarized in Table 2.4. The reasons were 
categorized according to Spencer et al’s (Spencer et al, 2002) modification of the 
Drinking Motives Questionnaire (Cooper, 1994) to include reasons specifically 
related to psychiatric symptoms: ‘enhancement/ intoxication’, ‘social effects, 
conformity/ acceptance’, ‘coping with positive symptoms’, ‘coping with 
dysphoria and negative symptoms’ and ‘coping with medication side effects’.
85 abstracts were screened 
6 studies were excluded for not 
reporting separate results for 
cannabis 
1 study was excluded for not 
reporting separate results for 
psychotic patients 
13 papers fulfilled inclusion 
criteria. Full text was 
retrieved. 
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95%- get high 
48%- talkative 
48%- feel more emotions 
62%- more interests 
57%- more thoughts 
33%- concentrate better 
29%- energy levels 
24%- sexual interest 
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41%- intoxication effects 58%- social 
reasons 
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80%- get high 
100%- to increase 
pleasure 
40%- to increase 
energy 
40%- to increase 
emotions 
40%- to talk more 
40%- to be more 
creative 
40%- to increase 
concentration 
40%- to work and 
study better 
40%- to increase 
confidence 
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83.3%- get high 
72.2%- pleasure - 
talkative 
58.3%- increase 
emotions and feelings 
55.6%- more creative 
33.3%- arrange 
thoughts 
33.3%- work better 














88.9%- to relax 
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Addington and Duchak (1997) investigated reasons for cannabis use 
among patients with a diagnosis of schizophrenia. The most frequent reasons 
were to increase pleasure and to get high, to relax and reduce depression and to 
be more sociable. In 2004, Green and colleagues compared male cannabis users 
with psychosis to a cannabis-using control group without psychosis. Patients 
with psychosis most commonly reported using cannabis for positive mood 
alteration, coping with negative affect and for social activity reasons. Relaxation 
was the least popular reason for cannabis use together with general coping with 
negative mood and cognitive enhancement. Availability of cannabis seemed to 
be a very important reason for its use. Schofield et al (2006) had the benefit of a 
larger sample diagnosed with a schizophrenia spectrum disorder. Patients again 
reported using cannabis to relax, to have as an activity with friends and to relieve 
boredom. Less than a quarter of patients used cannabis to reduce the side 
effects of antipsychotic medication, or to reduce positive symptoms. Fowler et al 
(1998) explored reasons for cannabis use amongst the largest sample of patients 
i.e. 58. Using cannabis to reduce dysphoria was the most common reason, 
succeeded by social reasons and intoxication effects. However, they argued that 
their sample was unrepresentative as the patients were from outpatient clinics 
only and there were more males than females. In Switzerland, Schaub et al 
(2008) used a case-control design and investigated reasons for cannabis use 
among outpatients with schizophrenia and matched controls. Using a 
questionnaire, they found that the majority of patients used cannabis to relax, 
get high and increase pleasure. The only significantly different reason between 
the two groups was that more patients than controls reported taking cannabis to 
relieve boredom. Goswami et al (2004) were only able to examine reasons for 
cannabis use in 5 dually diagnosed patients. All 5 patients stated they used 
cannabis to increase pleasure and 4 out of the 5 patients stated they used 
cannabis to get high, relax and satisfy curiosity. 
Methodological problems are quite evident in the above studies. Not all 
employed standardized criteria for diagnosis (Schofield et al, 2006; Schaub et al, 
2008) and sample sizes varied, with a tendency towards smaller groups 
(Goswami et al, 2004). Some studies focused on co-morbid groups where 
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patients had an established, and possibly primary, substance use disorder 
(Addington and Duchak, 1997; Fowler et al, 1998) while others included patients 
who were just cannabis users (Schofield et al, 2006; Green et al, 2004; Schaub et 
al, 2008). In addition, a variety of techniques and instruments were used to 
assess reasons for use. Both interviews and questionnaires were utilized, and 
reasons were identified through free response, open-ended questions or fixed 
lists.  
Dekker et al (2009) point out that older studies may have taken place 
when concentrations of THC in cannabis were lower than they are nowadays, 
which may have affected patients’ experiences of the drug. Schaub et al (2008) 
argue that most studies did not investigate the medications patients were taking, 
and therefore some patients may have been taking cannabis to reduce the side 
effects of older typical antipsychotics. 
Despite these inconsistencies, it does appear that patients with psychosis 
use cannabis for the same reasons as the general population (Green et al, 2004). 
Patients smoke cannabis mostly because of its ‘enhancing’ effects, and ‘to get 
high’ or to reduce negative states such as depression and dysphoria. Social 
reasons follow closely, with ‘relief from voices and other positive symptoms’ 
being less important. ‘Coping with medication side effects’ was the least popular 
motive, and thus there was little support for the self-medication hypothesis. 
Although this hypothesis cannot be altogether dismissed due to the 
aforementioned methodological flaws in the studies, the results point more 
towards an alleviation of dysphoria. 
Further research in this area requires adequate sample size and structured 
criteria for diagnosis of psychiatric illness and substance use. There should be 
emphasis on the use of validated instruments for assessing reasons for cannabis 
use, rather than individualistic interviews that are difficult to replicate or apply to 
future studies. Urine drug screens should be used to compliment self-reported 
use. It would also be useful to investigate the relationship between reasons for 
use and symptomatology and explore this over a follow-up period. This would 
shed light on whether cannabis use does actually alleviate dysphoric experiences 
and reduce social withdrawal and boredom. 
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2.4 Readiness to change as a predictor of cannabis use outcome 
 
2.4.1 Methods 
Criteria for selecting studies 
Abstracts were considered eligible for full manuscript data extraction if 
they fulfilled the following criteria: (a) The design was observational and 
prospective; (b) The study population included adolescents or adults (16-65 years 
old) with psychosis including schizophrenia or related psychotic disorders; (c) 
Cannabis use was either self-reported and/or verified by positive urinalysis or hair 
analysis; (d) Measurement of readiness to change as a primary or secondary 
outcome was included; (e) Abstracts and full papers were in English. Studies 
were excluded according to criteria in Figure 2.3. 
 
Search strategy 
The following electronic libraries were searched: MEDLINE (1950 to 2009); 
PsycINFO (1806 to 2009) and EMBASE (1980 to 2009). The following search 
terms were used: ‘psychosis’ and ‘readiness/motivation to change’. The full 
search strategy is available in Table 2.5. The reference lists of included studies 
were searched for any additional studies and corresponding authors and experts 






Table 2.5 Search strategy for systematic review of readiness to change cannabis 
use, as a predictor of outcome, in patients with psychosis. 
 
Search words 
1 exp Psychotic Disorders/ 
 
2 psychosis.mp. [mp=title, original title, abstract, name of substance word, 
subject heading word] 
 
3 psychot*.mp. [mp=title, original title, abstract, name of substance word, 




5 Readiness to change.mp. [mp=title, original title, abstract, name of 
substance word, subject heading word] 
 
6 Motivation to change.mp. [mp=title, original title, abstract, name of 
substance word, subject heading word] 
 
7 Motivation to quit.mp. [mp=title, original title, abstract, name of substance 
word, subject heading word] 
 
8 Behaviour* change mp. [mp=title, original title, abstract, name of 









Data were extracted from papers selected for further review. A 
standardized data extraction sheet was composed to record and code the 
following information (if available) from studies: author, country of origin and 
year; assessment of readiness to change; sample characteristics (size, age, 
diagnosis); assessment and classification of outcome (reduction or cessation of 
cannabis use); follow-up period. 
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2.4.2 Results and discussion 
The search strategy yielded 215 abstracts, from which 6 abstracts satisfied 
the criteria and full text of the study was retrieved. Of these six studies, five did 
not report separate results for cannabis use and one did not have a follow-up 
period. No studies were eligible for inclusion. 
 
 
Figure 2.3 Systematic review flowchart of readiness to change, as a predictor of 



















2.5 Strengths and limitations of systematic reviews 
One of the main strengths of these reviews is that they are based on 
principles derived from the Cochrane Collaboration methods, such as an a priori 
protocol. Experts in the field were contacted for further papers to ensure results 
were as comprehensive as possible. The same quality can be attributed to the 
search strategies, which were very extensive and detailed and included psychosis 
rather than schizophrenia as it was judged to be broader. Lastly, it was decided 
215 abstracts were screened 
5 studies were excluded for not 
reporting separate results for 
cannabis 
1 study was excluded for not 
having a follow-up 
6 papers fulfilled inclusion 
criteria 
No studies included in the 
review 
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not to limit the searches to cannabis but include substance use in general to 
ensure they were as inclusive as possible in obtaining relevant papers. 
A possible limitation of the reviews is the exclusion of studies that 
reported substance use in general and the inclusion of only those focused on 
cannabis use. Two reasons led to this decision. Firstly, use of individual 
substances may have different prognostic effects in patients with psychosis, be 
sustained for different reasons and motivate behaviour change to varying 
degrees. Although cannabis is one of the most popular substances among 
psychotic patients and research has been extensively carried out to look at the 
effects of persistent use in this population, results have not always been 
conclusive. Similarly, research has not been extensively carried out on the 
reasons for such high rates of use in this population and the limited results have 
been largely uncertain. Including general drug use in our review would not have 
yielded sufficient detail on why patients use cannabis in particular. 
Also retrospective studies were excluded to minimise recall bias. Although 
establishing cause and effect in studies with so many possible confounders (i.e. 
baseline symptom severity and functioning, other drug use) is an already difficult 
task, including prospective studies only provided a more accurate account of 
patterns of cannabis use, readiness to change and effect on prognosis and actual 
behaviour change. 
Finally, the search was limited to studies of patients diagnosed with 
psychosis and related disorders only. It was important to consider psychosis as 
an independent risk factor for cannabis use, which would not have been as 
accurately investigated if we had included other psychiatric illnesses. 
 
2.6 Summary 
 The systematic reviews performed on the effects of cannabis use on 
psychotic outcomes and reasons for cannabis use have generated conflicting 
findings. Literature so far has shown negative effects of cannabis use on 
psychotic prognosis but some research has not observed such results. Mood 
enhancing and social reasons for cannabis use have been largely endorsed but a 
small number of patients still reported using cannabis motivated by self-
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medication. We were unable to find relevant literature reporting on the 
association between cannabis use and other drug use or readiness to change and 
cannabis use outcomes. In the next chapter, the general methodology of the 










Chapter 3 – General methodology 
 
3.1 Aims of the chapter 
The data presented within this thesis are nested within the Physical 
health and substance Use Measures in first-onset Psychosis (PUMP) study and 
thus general methodological procedures for this project are identical to the 
main study. This chapter will: 
1. Outline the aims and hypotheses of the PUMP study. 
2. Provide an overview of the PUMP study (design, setting, sample selection 
and recruitment procedure) and summarize the study data collection 
schedule. 
 
3.2 The PUMP study 
3.2.1 Main aims and hypotheses of the PUMP study 
1. Patients with their first episode of psychosis who have unhealthy lifestyle 
habits are more likely to develop the features of the metabolic syndrome 
(central obesity plus one of the following: raised triglycerides, reduced 
HDL cholesterol, raised blood pressure, raised fasting plasma glucose) 
(Alberti et al, 2006) over a one-year follow-up period than those with 
healthier lifestyles allowing for relevant confounding factors such as age, 
ethnicity and family history of metabolic diseases.  
2. Patients with their first episode of psychosis who use cannabis and other 
substances will have more psychotic symptoms at 12-month follow-up 
compared to non-substance users. 
3. The rate of progression of metabolic (glucose and lipids) dysregulation 
over a 12-month period will be greater in those taking clozapine and 
olanzapine compared to other antipsychotics. 
 
3.2.2 The PUMP study methodology 
Design 
The PUMP study is a prospective observational cohort of patients, with a 
first episode of psychosis, who were followed up for a minimum of 12 months to 
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test the association between lifestyle (diet, exercise, and substance use) and 
antipsychotic medication factors with a) psychotic symptoms and b) components 
of the metabolic syndrome.  
Setting 
 Patients were recruited from the boroughs of the South London and 
Maudsley (SLaM) NHS Trust: Southwark, Lambeth, Croydon and Lewisham. 
Participants were also recruited from the Bromley and Greenwich boroughs 
under the Oxleas NHS Trust, as well as from West Sussex and Brighton under the 
Sussex NHS Trust. Both inpatient and outpatient services were targeted.  Ethics 
approval was granted by the Ethics Committee at the Institute of Psychiatry (REC 
Ref No. 08/H0807/53). The PUMP study was funded by the National Institute for 
Health Research (NIHR) Programme Grants for Applied Research in the 
Department of Health [RP-PG-0606-1049]. 
 
Sample selection 
Patients presenting with a first-episode psychosis were consecutively 
approached for participation in the study if they were: 
1. aged 16-65 years. 
2. presenting to services within the last 6 months with a first-onset 
psychotic disorder (ICD 10 definition of functional psychosis). 
3. experiencing positive psychotic symptoms of at least 7 days duration. 
 Patients were excluded from the study if they met any of the following 
criteria: 
1. evidence of psychotic symptoms precipitated by an organic cause. 
2. moderate or severe learning disabilities. 
3. major medical or neurological illness. 
4. insufficient command of English to complete assessments. 
5. contact with health services (GP or psychiatric) for psychosis longer than 






Baseline data for the PUMP study were gathered between May 2008 and 
July 2011. 
Inpatients 
Researchers screened for potential participants at the beginning of each 
week through a variety of means to ensure the maximum level of recruitment 
and minimise selection bias. They took a list of all new admissions to SLaM and 
Oxleas wards (including intra-hospital transfers), which may treat psychotic 
patients, and screened clinical notes to assess for eligibility. This was 
supplemented with regular communication with doctors, nurses and healthcare 
assistants on the wards.  
Outpatients 
In the Sussex NHS Trust recruitment was carried out solely from 
community and home treatment teams. This method also complemented ward 
recruitment in SLaM and Oxleas where resources were available to cover these. 
Researchers attended weekly team meetings where the caselog was discussed.  
New referrals were identified and screening followed an identical procedure to 
that of the inpatients above. There were a number of teams that did not produce 
a caselog to screen. In this case, care coordinators and teams leaders were 
approached and invited to suggest patients they thought might be suitable for 
the study. It is therefore possible that in these teams some eligible patients may 
have not been identified. 
 When a patient was deemed suitable and after checking with the ward or 
community team that it was safe to proceed, patients would be approached and 
invited to participate in the study. The specifics of the project would be fully 
described and patients would be given the information and consent sheets. If 
patients were willing to participate and able to give informed consent, they were 
requested to read through the information sheet, invited to ask any questions 
and confirm that they fully understood the study. Afterwards, they would be 
reassured that they could withdraw from the study at any time without having to 
give a reason and asked to sign the consent form. On occasions, patients would 
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ask researchers to visit them in the future to discuss participation or leave the 
information for them to consider at a separate time. Consequently, some 
patients would have been approached on several occasions as requested. If 
patients asked not to be approached again, this of course was respected. 
3- and 12-month follow-ups 
Three-month follow-ups were completed by December 2010 and 12-month 
follow-ups by July 2012.  
At 3 and 12 months post-consent, researchers re-contacted all patients 
who had consented to the study regardless of completion status at baseline and 
invited them to take part in the follow-ups. Patients who were excluded or had 
withdrawn from the study post-consent were not re-contacted. 
Once again a variety of procedures was employed to maximise retention 
rates and follow-up completion. The patients’ clinical notes were checked to 
establish whether they were in hospital or in the community. If the patient was 
still in hospital, the ward team would be contacted and an appointment to visit 
would be arranged. The follow-up process would be explained and the patient 
would be invited to complete the assessments.  
If the patient had been discharged, researchers would utilize the contact 
details (phone, email, address, nominated friend/relative) provided by the 
patient at consent to get in touch. Firstly, all patients were sent a letter 3 months 
before due follow-up date to remind them of the study and ask them to return a 
pre-paid reply slip to indicate whether they would be interested in participating 
and provide their preferred method of contact. If a patient replied they did not 
wish to complete follow-up assessments, this would be honoured and no further 
contact would be pursued. In cases where no reply was received and other 
means proved ineffective, the following professionals (if permission had been 
granted by patient at consent) would be contacted to help establish contact: (i) 
care coordinator and/or (ii) other assigned health-care worker. It was quite often 
the case that clinical notes were not informative enough to help researchers 
identify whether patients were still in contact with services. In this instance, and 
only if consent had been given by patient at baseline, researchers would contact 
the last known GP the patient was registered with. If the GP was not able to 
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provide researchers with up-to-date contact details, the patient would be 
classified as non-contactable and no attempt for further contact would ensue. In 
the case where the patient had not provided consent to contact their assigned 
health-care professional or GP, no further action would be taken and the patient 
would be classified as non-contactable. 
A summary of the recruitment and completion rates of the PUMP study at 



















Figure 3.1 PUMP study recruitment and completion rates 
 Screened for eligibility (n= 11507) 
Eligible (n= 1149) Not eligible (n= 10556) Unable to determine (n= 138) 
Refused (n= 263) 
Other reasons (n= 427)   
 178 excluded  
 199 not contactable  
 50 transferred 
Consented (n= 321) Excluded after consent  
(n= 27) 
Consented and eligible 
(n= 294) 
Drop-out at baseline (n= 42) 
Reasons: 
Withdrawn (n= 16) 
Missed (n=6) 
Missing person (n= 1) 
Refused (n= 19) 
Completed baseline  
(n= 252) 
Drop-out at 3 months 
(n= 104) 
Reasons: 
Not contactable (n= 37) 
Declined (n= 47) 
Withdrew (n= 9) 
In prison (n= 2) 
Deceased (n= 1) 
Missing person (n= 1) 
Missed (n= 7) 
Due for 3- month f-up 
(n= 278) 
Not followed-up (n= 65) 
Followed-up (n= 213) 
Completed 3-month  
f-up 
(n= 118) 
Due for 12-month f-up 
(n= 268) 
Drop-out at 12 months 
(n = 141) 
Reasons:  
Not contactable (n= 51) 
Declined (n= 73) 
Withdrew (n= 1) 
Missed (n= 11) 
In prison (n=5) Completed 12-month 
 f-up (n= 127) 
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Measures  
 The full data collection schedule took 4 hours to complete and comprised a number of assessments collected at baseline, 3 
months and 12 months. Table 3.1 summarizes the thesis hypotheses, assessment instruments and plan for analysis. 
Table 3.1 Thesis hypotheses, assessment instruments and analysis plan 
Hypotheses Instruments Analysis plan 
CHAPTER 5 
1. Patients who use cannabis at 12 months will 
have higher total symptom severity than 
those who are not current users or have 
never used cannabis. 
2. Patients who use cannabis at 12 months will 
have more positive symptoms than those 
who are not current users or have never used 
cannabis. 
3. At each time point, patients who use 
cannabis will be more likely to use other 
drugs than those who are not current users 
or have never used cannabis. 
 
• Positive and Negative 
Syndrome Scale (PANSS) 
• Cannabis Experience 
Questionnaire (CEQ) 
• Hypotheses 1 and 2 
a) Chi-square tests, independent sample t-tests 
and Mann-Whitney tests 
b)  Univariate and multivariate linear regressions 
•  Hypothesis 3: 
a) Chi-square tests, independent sample t-tests, 
Mann Whitney tests and Fisher’s exact tests 
b) Univariate and multivariate logistic regressions 
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Table 3.1 Thesis hypotheses, assessment instruments and analysis plan (cont.) 
Hypotheses Instruments Analysis plan 
CHAPTER 6   
1. At each time point, patients who use 
cannabis will be more likely to do so because 
of its enhancing effects and for social 
reasons rather than to ‘self-medicate’. 
2. The changes in reasons for cannabis use 
across the 3 time points will be examined in a 
post-hoc analysis. 
• Reasons for Use Scale 
(RFUS) 
• Hypothesis 1 
a)   Paired-sample t-tests 
• Hypothesis 2 
         b)   Random intercept model 
 
 
CHAPTER 7   
1. Readiness to change at baseline according to 
the Readiness Ruler will be associated with 
cannabis non-use at 12 months. 
2. Readiness to change at 3 months according 
to the Readiness Ruler rather than the 
Readiness to Change Questionnaire- 
Treatment Version will be associated with 
cannabis non-use at 12 months. 
• Readiness Ruler (RR) 




• Hypotheses 1 and 2  
a) Chi-square tests, independent sample t-tests, 
Mann Whitney tests and Fisher’s exact tests 
b) Univariate and multivariate logistic regressions 
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3.3 Thesis rationale 
  Numerous studies have shown that patients with psychosis are 
more likely to use illicit drugs than the general population with cannabis 
being the most popular. There is evidence that cannabis use can contribute 
to the onset of schizophrenia and poor outcome in patients with established 
psychosis.  Therefore, understanding why patients use cannabis and 
whether they are motivated to change their habits is important. To date, 
there has been little support for the ‘self-medication’ hypothesis, while the 
literature points more towards an ‘alleviation of dysphoria’ model. There is a 
lack of research as to whether psychotic patients are ready to change their 
use of cannabis, which has implications for identifying which treatment 
strategies are likely to be effective. The purpose of this thesis is to examine 
the reasons for cannabis use in first-episode psychosis as well as report a 
preliminary investigation of motivational processes in cannabis-using 
behaviour in patients with psychosis and its effects on cannabis use 
outcomes. The thesis design, measures and analysis plan are presented in 
table 3.2.  
  In the next chapter, the baseline characteristics as well as 
comparisons between participants and non-participants and cannabis users 
and non-users by socio-demographic and clinical variables will be examined.
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3.4 Candidate’s contribution 
 This thesis was an extension of one of the main PUMP hypothesis, namely 
that patients who use cannabis and other substances will have more psychotic 
symptoms at 12 months than non-users. Anna developed this into a full PhD 
proposal by proposing two further research ideas to investigate reasons for 
cannabis use and readiness to change in first-episode psychosis. Anna was solely 
responsible for identifying the appropriate instruments to examine reasons for 
use and readiness to change, training researchers in their application and 
developing the hypotheses to test the research questions. 
 Anna was one of the first researchers to join the PUMP team in 2008 and 
continued as a Research Worker and PhD student until the end of the study in 
July 2012. Anna’s main responsibilities comprised the identification of potentially 
eligible participants, recruitment and assessment of these at baseline, 3 months 
and 12 months in SLaM as well as Oxleas and providing supervision and training 
to new researchers. Anna was also responsible for blood and saliva collections 
from consented participants. Data were entered by the Abacus company and 
Anna was solely responsible for all aspects of data management i.e. liaising with 
the company, cleaning and maintaining the PUMP data set and preparing it for 
analysis.  
 Anna conducted all of the analysis presented in this thesis following 
supervision from Professor Khalida Ismail, Dr Zerrin Atakan, Dr Daniel Stahl 
(senior statistician) and Ms Hannah Sallis (junior statistician). Anna wrote this 
thesis in its entirety under the supervision of Professor Khalida Ismail and Dr 
Zerrin Atakan. 
 
3.5 Limitations of the PUMP study and methodological decisions for thesis 
 The PUMP study collaborated with the Genetics and Psychosis study 
(GAP) for the duration of the 4-year project. This offered the advantage of a large 
number of researchers working in recruitment and assessment for both studies 
but unfortunately meant that the joint data collection schedules took almost 12 
hours to complete at baseline and 8 hours at 3- and 12-month follow-ups. 
 Considering the burden on potential participants and after careful 
supervision, Anna was able to include the RFU scale and the RR at baseline but 
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the RTCQ-TV was only used at 3 months as it was considered lengthy by the 
team. Thus, the utility of the RR and the RCQ-TV in assessing changes in cannabis 
use at the 12-month follow-up was only tested at 3 months. Due to the length of 
the assessments and the fact that both studies’ protocols had already been 
approved, it was also not possible to replace the CEQ with an instrument more 
suitable to record patterns of cannabis use or complement this questionnaire 
with a severity of dependence scale and/or a diagnostic instrument for cannabis 
use disorder. One item from the CEQ was used to categorise participants into 
current cannabis users or non-users at each time point. 
 Although the PUMP study continued collecting data until July 2012, the 
thesis had to be completed before the end of the study according to the PhD 
submission timetable. Analysis based on diagnosis was not possible as data, 
which might have been available later on, were incomplete at the time of 
submission. Similarly, 12-month follow assessments continued for the PUMP 
study so Anna was not able to make full use of data collected for the duration of 
the study. 
 Due to the limitations with regards to available data at the time of thesis 
preparation and submission as well as the high drop-out rate, it was not 
appropriate to validly perform a repeated-measures analysis as it was initially 
planned. The sample size was not large enough to allow for changes in cannabis 
use and psychopathology to be repeatedly examined at the 3 time points in a 
prospective manner. Instead, to test the effects of cannabis use on 
psychopathology, in chapter 5, a series of univariate and multivariate regressions 
were performed at 12 months while controlling for confounders as identified 
from differences between cannabis users and non-users at baseline. At 12-month 
follow-up issues arose with missing psychopathology data from the PANSS 
subscales. Percentages of these missing data and the reasons for not inputting 




Chapter 4 – Basic characteristics and preliminary analysis 
 
4.1 Synopsis 
This chapter examines the baseline characteristics of the sample. The 
measures used to collect these data will be briefly described. Socio-demographic 
characteristics of the sample will be presented together with information on 
diagnosis, lifetime and current tobacco, alcohol, cannabis and other drug use. 
Data on psychopathology and stressful events as well as medication compliance 
will be reported. Differences between participants and non-participants (drop-
outs) based on age, gender and ethnicity will be examined. Lastly, current 
cannabis users and non-users will be compared based on the aforementioned 
measures. These comparisons are important for identifying potential systematic 
biases and confounders that will need to be controlled for in later analyses. 
 
4.2 Sample selection 
A final sample of 321 patients was recruited in the PUMP study between 
May 2008 and July 2011. A sample of 286 patients recruited and followed up 
between May 2008 and December 2011 was included in this thesis. Of the 286 
patients, 27 were subsequently excluded for not satisfying the criteria for a first 
episode of psychosis or needing a translator and a further 40 patients dropped 
out at baseline leaving a final sample of 219 patients available for assessments.  A 
summary of baseline recruitment and retention rates is shown in Figure 4.1.  
Due to the long battery of assessments included in the PUMP study and 
the relatively unstable nature of a first-episode psychosis population, there was a 
significant variation in the completion rates of assessments. For each chapter, a 
sample summary will be included with the number of patients that were available 












Data on ethnicity were collected using the Office of National Statistics 
Classification of Ethnicity (2001). Ethnic groups were merged into 3 categories: 
black, white and other. The Medical Research Council Socio-demographic 
Schedule (Mallett, 1997) was used to collect information on current living status 
(accommodation), relationship and employment status and level of educational 
achievement. These variables were grouped as following: 
1. Living status: living alone or with others 
2. Relationship status: single or not single 
3. Employment status: employed, unemployed or student  
4.        Educational level: no qualifications, GCSE/ A and O’ Levels and 
vocational or professional qualifications.  
Consented (n= 286) 
 
Excluded after consent (n= 27) 
 
Consented and 
eligible (n= 259) 
 
Drop outs at baseline (n= 40) 
Reasons: 
Withdrawn (n= 15) 
Missed (n= 6) 
Missing person (n= 1) 
Refused (n= 18) 
 




Operational Criteria (OPCRIT 4) 
Diagnoses were made according to DSM-IV criteria (American Psychiatric 
Association, 2000) using the Operational Criteria (OPCRIT; McGuffin et al., 1991). 
This was done based on the clinical notes for the month after a patient’s first 
contact with psychiatric services. The first month was used in order to increase 
reliability of diagnoses across patients who had been in contact with services for 
various time periods.  
Psychiatrists trained in OPCRIT carried out all diagnoses. They scored 10 
test diagnoses to ensure inter-rater reliability (Cronbach’s Alpha=.95). DSM-IV 
diagnoses were then pooled to increase simplicity of analysis. These groups were 
non-affective psychosis (schizophrenia; schizophreniform disorder; delusional 
disorder; atypical psychosis; psychosis not otherwise specified) and affective 
psychosis (schizoaffective disorder - depressed type; major depressive episode 
with psychotic features; schizoaffective disorder – manic type; manic episode 
with psychotic features). 
 
Psychopathology 
Positive and Negative Syndrome Scale (PANSS) 
The PANSS (Kay et al, 1987) was used as a measure of current 
psychopathology. It is a 30-item questionnaire that consists of 3 subscales: 
positive (7 items), negative (7 items) and general psychopathology (16 items). 
Each item is scored on a scale of 1 to 7: absent, minimal, mild, moderate, 
moderate severe, severe and extreme. A score of 4 (moderate) or higher 
indicates the presence of clinical psychopathology. Each item has specific criteria 
for each point on the scale to assist with administration and scoring. The 
measure was completed through interview and collateral information from 
health-care workers based on the 7 days prior to assessment. PANSS is 
interpreted as either a total score (range 30-210) or grouped into severity 
categories of mildly ill (<58), moderately ill (58-74), markedly ill (75-95) and 




The Brief Life Events Questionnaire (BLEQ) 
The BLEQ (Brugha and Cragg, 1990) was used to collect data on significant 
life events occurring in the six months prior to interview. The questionnaire 
examines 12 events and patients were asked to indicate whether any of the 
events had happened to them or not. If yes, then the participant indicated the 
level of distress caused by that event: very bad, moderately bad or not too bad. 
The measure yields two scores: a total number of stressful events out of a 
maximum 12 and a score incorporating the number of stressful events plus the 
level of distress for each event.  
As with other measures, the BLEQ was administered by researchers who 




Tobacco and alcohol 
 Data were collected on lifetime and current tobacco and alcohol use. Two 
questions assessed lifetime and current tobacco use, respectively. For 
information on alcohol use, patients were asked if they had every used alcohol 
and then to investigate current alcohol use the Alcohol Use Disorders 
Identification Test (AUDIT; Babor et al, 2001) was used. This measure yields a 
total score corresponding to levels of alcohol dependency. For parsimonious 
reasons and to reduce risk of multiple testing, information on tobacco, alcohol 
and other drug use was limited to current or lifetime use only. As these variables 
were not primary or secondary outcomes but were used as confounders in later 
analysis, it was not the objective of this thesis to focus on consumption levels for 
any of the aforementioned substances. Therefore, the first item of the AUDIT 
was used to assess current alcohol use. This item indicates how often alcohol has 
been consumed in the last 12 months (never to 4 or more times per week) and 
responses were grouped into having used or not having used alcohol in the last 
year. 
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Cannabis and other drug use 
The Cannabis Experience Questionnaire - Modified Version (CEQ mv) 
 The CEQmv (DiForti et al, 2009) was used to collect information on 
cannabis and other drug use (non-prescribed opiates, stimulants, hallucinogens 
and sedatives). This measure was derived from the original Cannabis Experience 
Questionnaire (CEQ; Barkus et al 2006), which was developed to assess 
psychological experiences while under the influence of cannabis as well as 
immediately after the effects had worn off. 
 The modified version was expanded to include questions on current 
and/or past cannabis use, age of first use, frequency of use, type of cannabis 
preferentially used and context and cost of use. The CEQmv also includes 
questions on other non-prescribed drugs both on current and past use including 
age of first use and frequency of use. 
 The questionnaire was administered by researchers who read out the 
questions and invited participants to choose or provide the most suitable 
response according to lifetime, current use or non-use. 
 For the description of the sample, patients were classified into the groups 
summarized in Table 4.1.  
 
Table 4.1 Groups of lifetime and current users and non-users of tobacco, alcohol, 
cannabis and other drugs  
 Tobacco Alcohol Cannabis Other drugs 
Lifetime 
user 
Used in the 
past but not 
using currently 
Used in the 
past but not in 
the last year 
Used in the 
past but not in 
the last year 
Used in the 





Current use Used at least 
once in the last 
year 
Used at least 




Non-user Never used Never used Never used Never used 




Self-reported medication compliance was assessed using the Composite 
Measure of Compliance (Kemp et al, 1996). This scale is scored based on 
assignment to one of the 7 rating points: complete refusal (1), partial refusal (2), 
reluctant acceptance (3), occasional reluctance (4), passive acceptance (5), 
moderate participation (6) and active participation (7). Each rating point has 
specific criteria to assist with administration and scoring, which was carried out 
by interview from researchers.  
Urinary Drug Screen 
The Concateno Drug Screen Test Cup (Urine) was used to corroborate 
self-reported cannabis use. The test is a lateral flow chromatographic 
immunoassay for the qualitative detection of drugs and drug metabolites in urine 
for in vitro diagnostic use (Tietz, 1986). 
A side-by-side comparison conducted using the Concateno Drug Screen 
Test Cup (Urine) and commercially available rapid drug tests have yielded high 
accuracy after presumptive positives were confirmed by gas chromatography/ 
mass spectrometry (GC/MS) (>99% for positive specimens and 99% for negative 
specimens) (Concateno, 2012). 
To test sensitivity a drug-free urine pool was spiked with THC to the 
concentrations of +/- 50% cut-off. At cut-off (50ng/Ml) the test was able to detect 
53% of true positives. This rate was 100% when concentrations reached +50% cut-
off. In terms of specificity the test is able to detect 50ng/Ml of positive 
compounds in urine at 5 minutes (Concateno, 2012). 
 
4.4 Analyses 
All analyses were conducted using the Statistical Package for the Social 
Sciences Version 15 (SPSS 15, 2006). All continuous independent variables were 
checked for normal distribution using the Kolmogorov-Smirnov test, frequency 
histograms, Q-Q plots, values of skew and kurtosis. If a variable did not meet the 
assumptions of parametric tests, non-parametric statistics were used. Where 
appropriate, variables were split into categorical groupings.  
 82 
Percentages are presented for all categorical variables and mean scores 
are presented for all continuous variables except for age, BLEQ, medication 
compliance, PANSS positive symptoms and PANSS negative symptoms as these 
had non-normal distributions as follows: The Kolmogorov-Smirnov test showed 
age, D(259)=0.136, p<.001, BLEQ, D(174)=0.174, p<.001, medication compliance, 
D(151)=.274, p<.001, PANSS positive symptoms,  D(166)=0.118, p<.001 and PANSS 
negative symptoms, D(162)=0.115, p<.001 to have a significant non-normal 
distribution. Visual investigation of histograms, values of skew and kurtosis, 
stem-and-leaf plots and Q-Q plots confirmed this observation and so for these 
variables median scores will be described.  Table 4.2 shows the socio-
demographic characteristics and table 4.3 the basic clinical characteristics of the 
baseline sample. 
Independent sample t-tests (t) and chi-square tests (χ2) were used to 
investigate baseline differences between participants and non-participants as 
well as current cannabis users and non-users. Based on the observation from the 
Kolmogorov-Smirnov test above, the Mann-Whitney test (U) was used to 
describe differences based on age, BLEQ, medication compliance, positive and 
negative PANSS symptoms. Table 4.4 shows the differences between 
participants and non-participants based on age, gender and ethnicity and tables 
4.5 and 4.6 show the differences between current cannabis users and non- users 
based on socio-demographic and clinical characteristics, respectively. 
 
4.5 Results 
Socio-demographic characteristics of sample 
The following observations were made: median age at first presentation 
to services is late twenties and two-thirds of the sample is male. Half of the 
patients are of white origin and over a third of black origin and half of the sample 
holds vocational or professional qualifications. Two-thirds are currently 





Table 4.2 Socio-demographic characteristics of baseline sample 
Age (n=259)  
Median (IQR) 27 (22-35) 
Gender (n=259) (%)  
Male 63.7 
Female 36.3 




Education level (n=205) (%)  
No qualifications 19.5 
GCSE/ A and O’ Levels 32.2 
Vocational/ professional qualification 48.3 




Living status (n=207) (%)  
Alone 33.8 
With others 66.2 
Relationship status (n=206) (%)  
Single 74.8 




 Almost two-thirds of the patients are diagnosed with non-affective 
psychosis. The mean total PANSS score falls in the lower end of the moderately ill 
category and there were no patients in the severely ill group. The median scores 
on the BLEQ and medication compliance scale indicate a low rate of stressful 
events and high medication adherence, respectively. There are very high rates of 
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self-reported alcohol, tobacco and cannabis use with over half the patients 
reporting current cannabis use (Table 4.3). 
 
Table 4.3 Basic clinical information of baseline sample 
Diagnoses (n= 142) (%)  
Non-affective  59.9 
Affective 40.1 
Total PANSS Scores (n= 154)  
Mean Total (SD) 58.9 (14.6) 
PANSS Severity Groups (n= 154) (%)  
Mildly ill  49.4 
Moderately ill  35.7 
Markedly ill  14.9 
Positive PANSS scores (n= 166)  
Median (IQR) 14 (10-18.5) 
Negative PANSS scores (n= 162)  
Median (IQR) 14 (10-19) 
BLEQ (n= 174)  
Median (IQR) 2 (1-3) 
Medication compliance (n= 151)  
Median (IQR) 6 (5-7) 
Lifetime cannabis use (n= 201) (%)  
Users 78.1 
Non-users 29.1 









Table 4.3 Basic clinical information of baseline sample (cont.) 
Lifetime Tobacco use (n= 200) (%)  
Users 85.5 
Non-users 14.5 
Current Tobacco use (n= 167) (%)  
Users 77.8 
Non-users 22.2 
Lifetime Alcohol use (n= 200) (%)  
Users 89.5 
Non-users 10.5 
Current Alcohol use (n= 166) (%)  
Users 90.4 
Non-users 9.6 
Other Lifetime Drug use (n= 178) (%)  
Users 53.4 
Non-users 46.6 






Participants vs non-participants 
No significant differences were found between participating patients and 














Age   U 0.064 
Median (IQR) 26 (22-34) 30.5 (24.25-39.75)   
Gender (%)   χ2 0.596 
Male  64.4 60   
Female  35.6 40   
Ethnicity (%)   χ2 0.751 
White  50.2 47.5   
Non-white  49.8 52.5   
     
 
 
Current self-report cannabis vs non-cannabis users 
The following observations were made based on the comparison 
between current cannabis users and non- users across socio-demographic and 
clinical data: there were no differences between the two groups on ethnicity, 
education level and employment or relationship status but cannabis users were 
more likely to be younger, male and living alone (Table 4.5). 
 
Table 4.5 Differences between current self-reported cannabis and non-cannabis 
users based on socio-demographic characteristics 
 Cannabis users Non-users Test Sig. 
Age  (n= 84) (n= 114) U 0.007 
Median (IQR) 24 (21-31) 28 (22-35)   
Gender (%) (n= 84) (n= 114) χ2 0.001 





21.4 43.9   
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Table 4.5 Differences between current self-reported cannabis and non-cannabis 
users based on socio-demographic characteristics (cont.) 
 Cannabis users Non-users Test Sig. 
Ethnicity (%) (n= 84) (n= 114) χ2 0.268 
White  56 44.7   
Black  33.3 39.5   
Other  10.7 15.8   
Education level (%) (n= 81) (n= 108) χ2 0.166 
No qualifications  24.7 13.9   
GCSE/ A and O’ Levels  29.6 33.3   
Vocational/ professional 
qualification  
45.7 52.8   
Employment status (%) (n= 79) (n= 107) χ2 0.240 
Unemployed  70.9 58.9   
Employed  7.6 10.3   
Student  21.5 30.8   
Living status (%) (n= 81) (n= 109) χ2 0.004 
Alone  44.4 24.8   
With others  55.6 75.2   
Relationship status (%) (n= 80) (n= 109) χ2 0.357 
Single 77.5 71.6   
Not single 22.5 28.4   
     
 
 
There were no differences between the two groups on diagnoses, 
assignment to PANSS severity group or medication compliance. Cannabis users 
had a higher total PANSS score than non-users as well as a higher score on the 
positive PANSS subscale and reported more stressful life events in the 6 months 
prior to interview. Cannabis users were also more likely to report lifetime and 
current tobacco, alcohol and other drug use than non- users (Table 4.6). 
A total of 88 baseline urine drug screens were performed to corroborate 
current cannabis use (Table 4.6). There was a fair agreement (Cohen’s 
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kappa=0.37) (Landis and Koch, 1977) between participants’ reports and 
urinalysis. Based on findings by Martin et al (1988), it was expected that the 
agreement would be higher but this is very likely due to the high number of 
cannabis users who produced negative screens. As the aim at baseline was to 
capture occasional as well as regular and recent cannabis use (at least once in the 
last year), it is expected that self-reported use will not always correspond to 
positive samples. It is anticipated that this agreement will be higher at 3- and 12-
month follow-ups as criteria for cannabis use are not dependent on a strict time 
frame. Two of the 42 self-reported non-users produced UDS results positive for 
cannabis. It is most likely that these present false negative results based on 
Colcateno sensitivity levels at 97%. Therefore, these two patients will continue to 
be treated as non-users for the purposes of analysis. 
 
Table 4.6 Differences between self-reported current cannabis users and non-
users based on clinical characteristics 
 Cannabis users Non-users Test Sig. 
Diagnosis (%) (n= 57) (n= 74) χ2 0.893 
Non-affective  59.6 60.8   
Affective  40.4 39.2   
Total PANSS scores  (n= 62) (n= 86) t 0.017 
Mean Total (SD) 62.56 (15) 56.77 (14.1)   
PANSS Severity Groups (%) (n= 62) (n= 86) χ2 0.065 
Mildly ill  38.7 54.7   
Moderately ill  38.7 34.9   
Markedly ill  22.6 10.4   
Positive PANSS scores (n= 71) (n= 88) U 0.004 
Median (IQR) 15(11-21) 13(8-16.75)   




15 (10-20) 13(9.25-17)   
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Table 4.6 Differences between current self-reported cannabis users and non-
users based on clinical characteristics (cont.) 
 Cannabis users Non-users Test Sig. 
BLEQ (n=72) (n= 97) U 0.001 
Median (IQR) 3 (1-4) 2 (1-3)   
Medication Compliance (n=61) (n=89) U 0.068 
Median (IQR) 6 (5-7) 7 (5-7)   
Lifetime Tobacco use (%) (n= 82) (n= 112) χ2 <0.001 
User 98.8 75   
Non-user  1.2 25   
Current Tobacco use (%) (n= 81) (n= 81) χ2 <0.001 
User  92.6 64.2   
Non-user  7.4 35.8   
Lifetime Alcohol use (%) (n= 81) (n= 112) χ2 0.021 
User 96.3 86.6   
Non-user  3.7 13.4   
Current Alcohol use (%) (n= 79) (n= 104) χ2 0.010 
User  89.9 75   
Non-user  10.1 25   
Other Lifetime Drug use (%) (n= 82) (n= 97) χ2 <0.001 
User  72 37.1   
Non-user  28 62.9   
Other Current Drug use (%) (n= 82) (n= 97) χ2 0.004 
User 17.1 4.1   
Non-user  82.9 95.9   
Urinary Drug Screen (%) (n= 46) (n=42) Kappa <0.001 
Positive 40.5 4.3   
Negative 59.5 95.7   
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Current cannabis vs non-cannabis users based on UDS results 
 There were no differences between current cannabis users and non-users 
according to UDS results in baseline positive and total PANSS scores (table 4.7). 
 
Table 4.7 Differences between current cannabis users and non-users based on 
UDS results (cont.) 
 Cannabis users Non-users Test Sig. 
Total PANSS scores  (n= 14) (n= 57) t 0.210 
Mean Total (SD) 56.75 (12) 61.29 (12)   
Positive PANSS scores (n= 16) (n= 58) U 0.536 
Median (IQR) 15.5 (11-19.5) 15 (10-18)   
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4.6 Discussion 
This chapter reported the basic socio-demographic and clinical 
characteristics of the baseline sample and a comparison of participants and non-
participants as well current cannabis users and non-users on variables of interest. 
All participants 
Age at first presentation to services, employment, living and relationship 
status are consistent with data from other first-episode studies in London and 
the rest of the U.K. (Morgan et al, 2005; Hutton et al, 1998; Morrison et al, 2012) 
although in our sample a larger percentage of patients were of white ethnicity 
compared to black. Also, in our study half of the patients held vocational or 
professional qualifications, which is not consistent with the findings of the 
AESOP study (Morgan et al, 2005), but this might be due to grouping of 
educational levels into different categories between the AESOP and present 
study. The ratio of male to female participants in this study was consistent with 
data in the aforementioned first-episode studies in London and the U.K. Similarly 
in a study by Kirkbride et al (2006) the risk for all psychotic disorders, with the 
exception of affective psychosis, after controlling for age, study centre and 
ethnicity, was greater for men than women. In the general population, cannabis 
users who come in contact with treatment services tend to be younger, male and 
in mainstream education but living with family or other relatives rather than 
alone (National Treatment Agency for Substance Misuse, 2012). 
There were very high rates of self-reported alcohol, tobacco and cannabis 
use with over half the patients reporting current cannabis use. Previous studies 
on recent-onset psychosis and related disorders have reported similarly high 
rates (Addington and Addington, 2007; Hinton et al, 2007; Degenhardt et al, 
2007). 
Psychopathology levels were low with complete absence of patients 
scoring on the severe end of the PANSS spectrum and this might appear 
surprising considering the nature of a first-episode population. For ethical 
reasons patients were only approached for consent after consulting with 
assigned health-care staff. If they didn’t judge the patient to be well enough to 
be provided with information about the study, this was postponed until 
permission was given. It is only natural that within this time patients’ mental 
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health improved. Also, the high levels of self-reported medication adherence 
might partly explain the moderate levels of psychopathology in this sample. 
 
Cannabis vs non-cannabis users 
As previously observed (Addington and Addington, 2007; Linszen et al, 
1994), cannabis users were more likely to be younger and male than non-users.  
Cannabis users also showed higher rates of lifetime and current tobacco, 
alcohol and other drug use than non-users. Degenhardt et al (2007) reported that 
over two-thirds of the cannabis users in their study had used tobacco and alcohol 
in the last month but no research has compared cannabis users and non-users on 
other drug use and it is the aim of this thesis to examine differences between the 
two groups at each time point. 
Previous comparisons between cannabis users and non-users on clinical 
measures have revealed mixed findings, which are apparent in the current study 
as well. Some studies have found differences in baseline psychopathology with 
cannabis users rating higher (Addington and Addington, 2007) but others have 
reported similar scores in the two groups (e.g. Stirling et al, 2005). In this study, 
cannabis users had a higher total and positive, but not negative, PANSS score 
and reported more stressful life events than non-users. These will be statistically 
controlled for in later analyses, as will alcohol, tobacco and other drug use since 
there were significant differences between the two groups on these measures. 
Self-reported cannabis use has been shown to be more accurate than 
collateral reports (Martin et al, 1988; Wolford et al, 1999; Selten et al, 2002) and 
therefore we did not expect a significant difference on psychopathology 
outcomes between users with positive and negative UDS. However, it is most 
likely that in a sample of largely hospitalised patients access to cannabis was 
limited at the time of assessments and self-reported use in the last year was 
more accurately associated with symptomatology. This is consistent with 
findings from longitudinal studies that have found that improvement in 
symptoms after cannabis use cessation can be seen more clearly in the long 
rather than short term (Gonzáles-Pinto et al, 2011). 
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4.7 Summary 
 The sample characteristics observed at baseline were similar to other 
studies on recent-onset psychosis with regards to the ratio of male to female 
participants, relationship, employment and living status. A larger percentage of 
patients from white rather than black ethnicity participated in this study and half 
of the patients held vocational or professional qualifications. No differences 
were found between those who were available for baseline assessments and 
those who dropped out shortly after consent. Cannabis users were more likely to 
be younger and male and reported higher rates of lifetime and current tobacco, 
alcohol and other drug use. They also scored higher on the total and positive 
PANSS scales and reported more stressful events than non-users. In the next 
chapter the effects of cannabis use at 12 months on total and positive symptom 









Chapter 5 – Association of cannabis use with symptom severity at 12 
months and other drug use at baseline, 3 months and 12 months 
 
5.1 Synopsis 
The systematic review on the consequences of cannabis use on the 
course of psychosis showed that the effects of persistent use have been 
inconclusive (Chapter 2; section 2.2). Some studies have found that continuous 
cannabis use is associated with higher relapse rates and more positive symptoms 
but not negative symptoms. Variations in diagnostic criteria for psychosis, small 
sample sizes and lack of adequate adjustment for confounders are some of the 
methodological limitations. No research has examined the relationship between 
cannabis use and other drug use in patients with psychosis.  
This chapter aims to first assess the effects of 12-month cannabis use on 
symptom severity (total and positive PANSS scores) while controlling for 
potential baseline confounders and second to examine the association between 
cannabis and other drug use at 3 time points; baseline, 3 months and 12 months. 
No significant association was observed between cannabis use and total PANSS 
scores at 12 months and total PANSS scores at baseline were the only predictors 
of total PANSS scores at 12 months. Cannabis use at 12 months, total PANSS 
scores and current tobacco use at baseline were associated with 12-month 
positive PANSS symptoms but in a multivariate analysis only the association 
between baseline total PANSS scores and 12-month positive PANSS scores 
remained significant. Cannabis users were more likely than non-users to use 
other drugs at baseline and 3 months but this difference was not detected at 12 
months. 
These findings contribute to the evidence base that cannabis use does not 
appear to worsen prognosis following the onset of psychosis.  Reasons for these 
negative findings are examined in this chapter. The relationship of cannabis with 
other drug use will be discussed within the context of this project as well as 
findings from general population studies as previous psychiatric research has not 




1. Patients who use cannabis at 12 months will have higher total symptom 
severity than those who are not current users or have never used 
cannabis. 
2. Patients who use cannabis at 12 months will have more positive symptoms 
than those who are not current users or have never used cannabis. 
3. At each time point, patients who use cannabis will be more likely to use 
other drugs than those who are not current users or have never used 
cannabis. 
 
5.3 Sample selection 
Cannabis use and psychotic symptoms at 12 months 
Of the 259 patients available for assessment at baseline, 151 dropped out 
at 12-month follow-up time leaving a sample of 108 patients available for 
assessments. A summary of the retention rates and reasons for drop out at 12 
months are summarized in Figure 5.1.  
 








Cannabis and other drug use at baseline, 3 months and 12months 
Due to the high rate of attrition at follow-up points, in October 2010 3-
month follow-up assessments were stopped to focus resources on 12-month 
follow-up assessments. Thirty-two patients were therefore not assessed at 3 
months. At 3 months, 109 of the 259 patients were available for assessments. A 
Baseline - 
Eligible and available for 
assessments (n= 259) 
Drop outs at 12 months (n= 151) 
Reasons: 
Withdrawn at 3 time points (n= 25) 
Refused (n= 68) 
Not contactable (n= 42) 
Missed (n= 11) 
In prison (n= 4) 
Deceased at 3 months (n=1) 
 
12-months- 
Eligible and available for assessments (n= 108) 
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summary of retention rates at 3 months is presented in Figure 5.2. At baseline 219 
patients were available for assessments (Chapter 4; Figure 4.1) and 108 patients 
were available at 12 months (Figure 5.1). Completion rates of measures used in 
the analyses vary from these figures and are indicated in the respective results 
sections. 
 
















Symptom severity was assessed using the PANSS. Cannabis and other 
drug use were established through the CEQmv and stressful events were assessed 
by the BLEQ. Questions on lifetime and current tobacco, alcohol and other drug 
use were used to group patients into users and non-users. Urinalysis was also 
performed at 3 and 12 months. Details of these measures as well as instruments 




Comparison between completers and non-completers 
Chi-square tests, independent sample t-tests and Mann-Whitney tests 
were used to assess differences on gender, age, baseline cannabis use and 
baseline total and positive PANSS scores between completers and non-
completers of 12-month total PANSS scale.  These tests were also used to 
Baseline- 
Eligible and available for 
assessments (n= 259) 
Drop outs at 3 months (n= 150) 
Reasons: 
Withdrawn at baseline and 3 months 
(n= 24) 
Refused (n= 47) 
Not contactable (n= 36) 
Missed (n= 7) 
In prison (n= 3) 
Deceased (n= 1) 
Not followed up (n= 32)  
3 months- 
Eligible and available for assessments (n= 109) 
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examine differences between patients who had completed the 12-month positive 
PANSS scales and to investigate differences between patients with information 
on other drug use and those with missing data.  
 
Cannabis use and total PANSS scores at 12 months 
A univariate and multivariate linear regression approach was used to 
address the relationship between cannabis use and total PANSS scores at 12 
months. The potential confounders were age, gender and baseline total PANSS 
scores, positive PANSS scores, BLEQ scores, lifetime and current tobacco use, 
lifetime and current alcohol use and other lifetime and current drug use.  
First, unadjusted analyses were conducted to describe the data. Using 
visual inspection of the data and formal statistical tests, the normality of the total 
PANSS scores distribution in cannabis users and non-users at 12 months was 
investigated. The Mann-Whitney test and Spearman’s correlation (rs) were used 
to assess each potential covariate and differences in or associations with total 
PANSS scores at 12 months respectively. 
Variables were entered into the regression model starting with the main 
explanatory variable, cannabis use at 12 months. Each variable was then entered 
in sequence of importance based on significance levels and effect size from 
baseline comparisons between cannabis users and non-users. If a variable 
significantly contributed to the model, it was retained and this process was 
applied to all subsequent variables to assess whether they contributed to the 
model. If a variable showed no significant association with 12-month total PANSS 
scores, after controlling for variables already in the model, it was removed. In the 
final model cannabis use was retained regardless of significant contribution, as it 
was the main explanatory variable of interest. 
 
Cannabis use and positive PANSS scores at 12 months 
A univariate and multivariate regression approach was used to address 
the relationship between cannabis use and positive PANSS scores at 12 months. 
The potential confounders were age, gender, baseline total PANSS scores, 
positive PANSS scores, BLEQ scores, lifetime and current tobacco use, lifetime 
and current alcohol use and other lifetime and current drug use.  
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First, unadjusted analyses were conducted to describe the data. Using 
visual inspection of the data and formal statistical tests, the normality of the 
positive PANSS scores distribution in cannabis users and non-users at 12 months 
was investigated. The Mann-Whitney test and Spearman’s correlation (rs) were 
used to assess each potential covariate and differences in or associations with 
positive PANSS scores at 12 months respectively. 
Variables were entered into the regression model starting with the main 
explanatory variable, cannabis use at 12 months. The aforementioned method of 
building the regression model was followed. In the final model cannabis use was 
retained regardless of significant contribution, as it was the main explanatory 
variable of interest. 
 
Association between cannabis use and other drug use at baseline, 3 months and 12 
months 
 A logistic regression approach was used to test whether cannabis use at 
each time point was associated with other drug use. Potential confounders were 
age, gender, baseline total PANSS scores, positive PANSS scores and BLEQ 
scores. As with the linear regression model, variables were entered based on 
significance level and effect size from baseline comparisons between cannabis 
users and non-users. If a variable significantly contributed to the model, it was 
retained and this was repeated for every subsequent variable. Cannabis use was 
retained in the model regardless of significant contribution, as it was the main 
predictor of interest. 
 Unadjusted analysis was carried out to provide an overall description of 
the data. The Mann-Whitney test, independent samples t-test, chi-square test 
and Fisher’s exact test were used to assess each potential covariate and 




Completers vs non-completers of 12-month total and positive PANSS scale 
 Comparisons between completers and non-completers of 12-month total 
PANSS found no differences in age or gender but showed that patients who did 
not complete the 12-month total PANSS reported significantly higher baseline 
total PANSS scores (M=61.2, SE=1.8) than those who completed total PANSS 
assessment at 12 months (M=56.2, SE=1.4; t(152)=2.11, p=0.037). Results also 
showed that patients who did not complete the 12-month total PANSS reported 
significantly higher baseline positive PANSS symptoms than those who 
completed the assessment (U=2748.5, p=0.040) (Table 5.1).  
 





Gender (%) (n=99) (n =160) χ2 0.060 
Male  56.6 68.1   
Female 43.4 31.9   
Age (n=99) (n=160) U 0.969 
Median (IQR) 27(23-35) 27.5 
(21.25-36.75) 
  
Baseline Cannabis use (%) (n=79) (n=119) χ2 0.656 
Users 40.5 43.7   
Non-users 59.5 56.3   
Baseline PANSS scores (n=71) (n=83) t 0.037 
Mean (SD) 56.2(12) 61.2(16)   
Baseline PANSS positive scores (n=75) (n=90) U 0.040 
Median (IQR) 12(9-16) 15(10-20)   
 
Comparisons between completers and non-completers of 12-month 
positive PANSS scale revealed no differences in age, baseline total or positive 
PANSS scores but male participants were more likely to complete the 12-month 
positive PANSS scale (χ2(1)=4.5, p=0.034) than female participants (Table 5.2).  
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Table 5.2 Differences between completers and non-completers of 12-month 




Gender (%) (n=94) (n=165) χ2 0.034 
Male  55.3 68.5   
Female 44.7 31.5   
Age (n=94) (n=165) U 0.851 
Median (IQR) 26.5(23-34.25) 28(22-37)   
Baseline Cannabis use (%) (n=80) (n=118) χ2 0.783 
Users 41.3 43.2   
Non-users 58.7 56.8   
Baseline PANSS scores (n=74) (n=91) t 0.237 
Mean (SD) 57.4 60.2   
Baseline PANSS positive scores (n=74) (n=91) U 0.206 
Median (IQR) 13(10-16.25) 14(10-20)   
     
 
Completers vs non-completers of other drug use at baseline, 3 months and 12 
months 
With regards to other drug use, comparisons between completers and 
non-completers showed one significant difference. At baseline, patients without 
available data on other drug use reported higher positive PANSS scores than 
those whose data were available (U=728.5, p=0.024). No other differences were 










Table 5.3 Comparison between completers and non-completers of information 
on other drug use at 3 time points 
 Completers Non-completers Test Sig 
BASELINE     
Gender (%) (n=181) (n=78) χ2 0.448 
Male  65.2 60.3   
Female 34.8 39.7   
Age (n=181) (n=78) U 0.368 
Median (IQR) 26(22-35) 29(23-36.25)   
Baseline total PANSS scores (n=140) (n=14) t 0.159 
Mean (SD) 59.4(14.8) 53.6(12.4)   







Median (IQR) 14(10-19) 19(7-13)   
3- MONTH FOLLOW-UP     
Gender (%) (n=83) (n=176) χ2 0.756 
Male  65.1 63.1   
Female 34.9 36.9   
Age (n=83) (n=176) U 0.779 
Median (IQR) 27(22-35) 27.5(22-36.75)   
Baseline total PANSS scores (N=64) (N=90) t 0.066 
Mean (SD) 56.3(13.9) 60.7(15)   
Baseline positive PANSS 
scores 
(N=70) (N=95) U 0.287 
Median (IQR) 14(9-17) 14(10-19)   
12-MONTH FOLLOW-UP     
Gender (%) (n=76) (n=183) χ2 0.493 
Male  60.5 65   
Female 39.5 35   
Age (n=76) (n=183) U 0.694 
Median (IQR) 
 
28(23-34) 27(22-36)   
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Table 5.3 Comparison between completers and non-completers of information 
on other drug use at 3 time points (cont.) 
 Completers Non-completers Test Sig 
Baseline total PANSS 
scores 
(n=53) (n=101) t 0.389 
Mean (SD) 57.5(12.8) 59.6(15.5)   
Baseline positive PANSS 
scores 
(n=59) (n=106) U 0.336 
Median (IQR) 13(10-18) 14.5(10-19)   
     
 
Cannabis use and total PANSS scores at 12 months 
The Kolmogorov-Smirnov test showed total PANSS scores in the cannabis 
users to be normally distributed, D(29)=.092, p=.20 and total PANSS scores in the 
non-users to have a non-normal distribution, D(61)=.116, p=.04. Visual 
investigation of the data confirmed this observation and so unadjusted results 
were attained through non-parametric procedures. 
The Mann-Whitney test was used to examine the differences in 12-month 
total PANSS scores between cannabis and non-cannabis users, male and female 
participants, baseline current and lifetime tobacco users and non-users, lifetime 
and current alcohol users and non-users and other lifetime and current drug 
users and non-users. Significant gender differences were observed. Male patients 
reported higher symptom severity (Mdn=51.5) at 12 months than female patients 
(Mdn=42), U=882, p=.023. No other comparisons yielded significant findings 
(Table 5.4). 
Spearman’s correlations were used to assess the association between 
age, baseline total PANSS scores, positive PANSS scores, BLEQ scores and 12-
month total PANSS scores at two-tailed significance. A positive relationship was 
found between baseline total PANSS scores and 12-month total PANSS scores 





Table 5.4 Unadjusted effects on 12-month total PANSS scores by main 
explanatory variable and potential confounders 
 12-month PANSS scores 
Median (IQR) 
Test Sig 
Cannabis use at 12 months  U 0.086 
Users (n=25) 54(43-62)   
Non-users (n=61) 46(36-60)   
Gender   U 0.023 
Male  (n=56) 51.5(38.25-61.75)   
Female (n=43) 42(32-50)   
Baseline Lifetime Tobacco use  U 0.592 
Users (n=66) 46(35-62.5)   
Non-users (n=15) 44(32-60)   
Baseline Current Tobacco use  U 0.118 
Users (n=44) 48(37.5-64)   
Non-users (n=35) 42(32-60)   
Baseline Lifetime Alcohol use  U 0.922 
Users (n=72) 45.5(35-63.5)   
Non-users (n=9) 47(42.5-56)   
Baseline Current Alcohol use  U 0.174 
Users (n=60) 43.5(35-58.75)   
Non-users (n=17) 52(42.5-63.5)   
Baseline Other Lifetime Drug use  U 0.908 
Users (n=37) 45(35-60)   
Non-users (n=36) 56.5(35.25-63.75)   
Baseline Other Current Drug use  U 0.600 
Users (n=5) 36(33.5-61)   
Non-users (n=68) 46(35-62.25)   






Table 5.5 Spearman’s correlation coefficients between potential confounders 
and 12-month total PANSS scores 
 12-month PANSS scores Sig 
Baseline total PANSS scores  0.28 0.019 
Baseline positive PANSS scores 0.04 0.735 
Baseline BLEQ 0.08 0.471 
Age -0.53 0.601 
   
 
A univariate linear regression was used to assess the association between 
cannabis use (dependent variable) and total PANSS scores (independent 
variable) at 12 months. Although results from the unadjusted tests showed 
significant findings only for gender and baseline total PANSS scores, it was 
decided to further test all dependent variables (baseline total and positive PANSS 
scores, age, gender, baseline BLEQ, baseline lifetime and current alcohol use, 
baseline other lifetime and current drug use and baseline lifetime and current 
tobacco use) in separate regressions as previous research has shown these 
covariates attenuate the level to which cannabis use is associated with symptom 
severity. The only variable that was significantly associated with total symptom 
severity at 12 months was baseline total PANSS scores (F(1,69)= 5.09, p=0.027). 
This variable predicted 6.9% of the variance in 12-month total PANSS scores. The 
main dependent variable, cannabis use at 12 months, was not significantly 
associated with 12-month total PANSS scores at the 5% level, but was retained in 
the model anyway. In the final model, baseline total PANSS scores were entered 
together with cannabis use at 12 months and remained a significant predictor of 
12-month total PANSS scores. Although cannabis use was not associated with 12-
month total PANSS scores on its own (p=0.081), adjusting for baseline total 
PANSS scores improved the significance level (p=0.071).  The final model (n=67) 
accounted for 11.7% of the variance in 12-month total PANSS scores (F(2, 64)= 4.2, 
p=0.035) (Table 5.6). For an average one-point increase in baseline total PANSS 
scores, 12-month total PANSS scores increased by 0.38 points when baseline total 
PANSS scores were the only predictor. When added to the final model together 
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with 12-month cannabis use, the increase was attenuated to 0.32 but remained 
significant.  
The distribution of the residuals versus predicted value was examined for 
linearity and homoscedasticity; the autocorrelation plot was examined for 
independence and the normal probability plot was examined for normality. No 
violations of the above assumptions of linear regression were found.  
 
Table 5.6 Linear regression model assessing predictors of 12-month total PANSS 
scores 
 B 95% CI Sig 
Univariate analysis 
   
Cannabis use at 12 months 5.60 -0.70 – 11.90 0.081 
Baseline total PANSS scores 0.38 0.04 – 0.72 0.027 
Baseline positive PANSS scores 0.30 -0.71 – 0.77 0.935 
Age -0.05 35 – 60 0.787 
Gender -7.14 -14.80 – 0.51 0.067 
Baseline BLEQ 0.64 -1.56 – 2.84 0.565 
Baseline Lifetime Alcohol use 3.14 -8.79 – 16.06 0.602 
Baseline Current Alcohol use -4.08 -13.31 – 5.14 0.381 
Baseline Other Lifetime Drug use 1.16 -6.53 – 8.85 0.764 
Baseline Other Current Drug use -2.84 -18.06 – 12.38 0.711 
Baseline Lifetime Tobacco use 3.59 -6.04 – 13.22 0.461 
Baseline Current Tobacco use 5.86 -1.76 – 13.48 0.130 
Multivariate analysis (final model)    
Cannabis use at 12 months 7.07 -0.62 - 14.75 0.071 
Baseline total PANSS scores 0.32 0.02 - 0.61 0.035 
    
 
Cannabis use and positive PANSS scores at 12 months 
The Kolmogorov-Smirnov test showed positive PANSS scores in the 
cannabis users to be normally distributed, D(29)=.145, p=0.123 and positive 
PANSS scores in the non-users to have a non-normal distribution, D(64)=.210, 
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p<0.001. Visual investigation of the data confirmed this observation and so 
unadjusted results were attained through non-parametric procedures. 
The Mann-Whitney test was used to examine the differences in 12-month 
positive PANSS scores between cannabis and non-cannabis users, male and 
female participants, baseline current and lifetime tobacco users and non-users, 
lifetime and current alcohol users and non-users and other lifetime and current 
drug users and non-users. Cannabis users reported higher positive PANSS scores 
(Mdn=11) than non-users (Mdn=9; U=682, p=0.039). No other significant 
differences were observed (Table 5.7). 
Spearman’s correlations were used to assess the association between 
age, baseline total PANSS scores, positive PANSS scores, BLEQ scores and 12-
month positive PANSS scores at two-tailed significance. No significant 
relationships were observed (Table 5.8). 
 
Table 5.7 Unadjusted effects on 12-month positive PANSS scores by main 
explanatory variable and potential confounders 




Cannabis use at 12 months  U 0.039 
Users (n=29) 11(8-15)   
Non-users (n=64) 9(7-13)   
Gender   U 0.833 
Male  (n=52) 10(7.25-14)   
Female (n=42) 9.5(7-15)   
Baseline Lifetime Tobacco use  U 0.172 
Users (n=68) 10(7.25-15)   
Non-users (n=15) 9(7-10)   
Baseline Current Tobacco use  U 0.052 




9(7-11.5)   
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Table 5.7 Unadjusted effects on 12-month positive PANSS scores by main 
explanatory variable and potential confounders (cont.) 




Baseline Lifetime Alcohol use  U 0.719 
Users (n=73) 10(7-14.5)   
Non-users (n=8) 9.5(9-10)   
Baseline Current Alcohol use  U 0.862 
Users (n=60) 9(7-14.75)   
Non-users (n=17) 10(8.5-11)   
Baseline Other Lifetime Drug use  U 0.529 
Users (n=38) 9.5(7-13.25)   
Non-users (n=36) 10(7.25-15)   
Baseline Other Current Drug use  U 0.527 
Users (n=5) 7(7-16.5)   
Non-users (n=69) 10(8-14)   
    
 
 
Table 5.8 Spearman’s correlation coefficients between potential confounders 
and 12-month positive PANSS scores 
 12-month positive PANSS scores Sig 
Baseline total PANSS scores  0.19 0.112 
Baseline positive PANSS scores 0.23 0.052 
Baseline BLEQ  0.08 0.471 
Age -0.10 0.351 
   
 
A univariate linear regression was used to assess the relationship between 
cannabis use (dependent variable) and positive PANSS scores (independent 
variable) at 12 months. Although results from the unadjusted tests showed 
significant findings only for cannabis use, it was decided to further test all 
dependent variables (baseline total and positive PANSS scores, age, gender, 
baseline BLEQ, baseline lifetime and current alcohol use, baseline other lifetime 
and current drug use and baseline lifetime and current tobacco use) in separate 
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regressions as previous research has shown these covariates attenuate the level 
to which cannabis use predicts positive symptom severity. The variables that 
were significantly associated with 12-month positive PANSS score were cannabis 
use at 12 months (F(1,91)= 5.34, p=0.023), baseline total PANSS scores (F(1,67)= 
4.74, p=0.033) and baseline current tobacco use (F(1,77)= 4.48, p=0.038). These 
variables predicted 5.5%, 6.6% and 5.5% of the variance in 12-month positive 
PANSS scores, respectively. In the final model, baseline total PANSS scores and 
baseline current tobacco use were added to cannabis use at 12 months. The only 
variable that remained a significant predictor of 12-month positive PANSS 
symptoms was baseline total PANSS scores. The final model (N=66) accounted 
for 14% of the variance in 12-month positive PANSS scores (F(3, 62)= 3.35, 
p=0.025) (Table 5.9). For an average one-point increase in baseline total PANSS 
scores, 12-month positive PANSS scores increased by 0.10 points when 
controlling for cannabis use at 12 months and baseline current tobacco use. 
The distribution of the residuals versus predicted value was examined for 
linearity and homoscedasticity; the autocorrelation plot was examined for 
independence and the normal probability plot was examined for normality. No 





Table 5.9 Linear regression model assessing predictors of 12-month positive 
PANSS scores 
 B 95% CI Sig 
Univariate analysis    
Cannabis use at 12 months 2.20 0.31 – 4.10 0.023 
Baseline total PANSS scores 0.89 0.01 – 0.17 0.033 
Baseline positive PANSS scores 0.16 -0.02 – 0.33  0.085 
Age -0.02 -0.11 – 0.08 0.734 
Gender -034 -2.14 – 1.45 0.707 
Baseline BLEQ 0.21 -0.34 – 0.76 0.444 
Baseline Lifetime Alcohol use 1.71 -1.47 – 4.88 0.288 
Baseline Current Alcohol use 1.37 -0.98 – 3.72 0.250 
Baseline Other Lifetime Drug use -0.82 -2.86 – 1.22 0.426 
Baseline Other Current Drug use -0.36 -4.44 – 3.72 0.861 
Baseline Lifetime Tobacco use 2.34 -0.21 – 4.88 0.071 
Baseline Current Tobacco use 2.03 0.12 – 3.95 0.038 
Multivariate analysis (final model)    
Cannabis use at 12 months 1.86 -0.63 – 4.36 0.140 
Baseline total PANSS scores 0.10 0.01 – 0.17 0.041 
Baseline Current Tobacco use 1.23 -1.05 – 3.52 0.285 
    
 
Repeated-measures analysis 
 A repeated measures analysis was not feasible because the sample size of 
patients with total PANNS scores at both time points would have been small in 
one of the cells (n=3 for non-cannabis users at baseline who reported cannabis 
use at 12 months), which does not provide adequate power to detect an 
interaction or the minimum sample size to obtain a stable model. As an 
alternative a univariate regression was used to test the differences between the 
4 cannabis groups (baseline and 12-month use/ baseline use and 12-month non-
use/ baseline and 12-month non-use/ baseline non-use and 12-month use). Results 
confirmed the findings from the existing regression: cannabis use was not a 
predictor of total PANSS scores at 12 months (F (3,62=1.34, p=0.269) and only 
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baseline total PANSS scores remained a significant predictor of 12-month total 
PANSS scores (B=0.322, p=0.035). It is apparent that additional analysis within 
the limitations of the sample size does not produce different results and is 
therefore not necessary. 
 
Cannabis use and other drug use at baseline, 3 months and 12 months 
At baseline, the chi-square test was used to investigate gender and 
cannabis use differences between other drug users and non-users and the 
Fisher’s exact test was used at 3 and 12 months. The Mann-Whitney test was used 
to explore differences in age, baseline positive PANSS scores and BLEQ scores 
between other drug users and non-users at the three time-points and an 
independent-samples t-test was performed to examine differences in baseline 
total PANSS scores between the two groups at each time point.  
At baseline, there was a significant association between cannabis use and 
other drug use (χ2(1)=8.24, p=0.004). Patients who used cannabis were 5 times 
more likely to also use other drugs than non-users. No other significant findings 
were observed (Table 5.10).  
At 3 months there was still a significant association between cannabis and 
other drug use (Fisher’s exact, p=0.003) (Table 5.11) but this significant 
relationship was not observed at 12 months (Table 5.12). No other significant 
relationships were found.  
A logistic regression model was performed only for baseline data, as there 
were less than 10 other drug users at 3 and 12 months, which violated the 
assumptions for a logistic regression. 
 
Table 5.10 Unadjusted effects on other drug use at baseline by main explanatory 
variable and potential confounders 
 Other drug 
users 
Non-users Test Sig 
Gender (%) (n=18) (n=163) χ2 0.089 
Male  83.3 63.2   
Female 16.7 36.8   
Age (n=18) (n=163) U 0.368 
Median (IQR) 29(23-38.8) 26(21-35)   
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Table 5.10 Unadjusted effects on other drug use at baseline by main explanatory 
variable and potential confounders (cont.) 
 Other drug 
users 
Non-users Test Sig 
Cannabis use at baseline (%) (n=18) (n=168) χ2 0.004 
Users 77.8 42.2   
Non-users 22.2 57.8   
Baseline BLEQ (n=15) (n=141) U 0.147 
Median (IQR) 3(1-4) 2(1-3)   
Baseline total PANSS scores (n=15) (n=125) t 0.835 
Mean (SD) 58.7(14) 59.9(14.9)   







     
 
Table 5.11 Unadjusted effects on other drug use at 3 months by main 
explanatory variable and potential confounders 
 Other drug 
users 
Non-users Test Sig 
Gender (%) (n=9) (n=74) Fisher’s 0.484 
Male  77.8 63.5   








Cannabis use at 3 months (%) (n=9) (n=74) Fisher’s 0.003 
Users 77.8 25.7   
Non-users 22.2 74.3   
Baseline BLEQ (n=9) (n=62) U 0.354 
Median (IQR) 3(1-4.5) 2(1-3)   








Table 5.11 Unadjusted effects on other drug use at 3 months by main 
explanatory variable and potential confounders (cont.) 
 Other drug 
users 
Non-users Test Sig 
Baseline positive PANSS scores (n=8) (n=62) U 0.270 
Median (IQR) 14(10.25-23) 13.5(8-16.25)   
     
 
Table 5.12 Unadjusted effects on other drug use at 12 months by main 
explanatory variable and potential confounders 
 Other drug 
users 
Non-users Test Sig 
Gender (%) (n=7) (n=69) Fisher’s 1.000 
Male  57.1 60.9   
Female 42.9 39.1   
Age (n=7) (n=69) U 0.155 
Median (IQR) 29(24-48) 27(22.5-34)   
Cannabis use at 12 months (%) (n=7) (n=68) Fisher’s 0.419 
Users 57.1 36.8   
Non-users 42.9 63.2   
Baseline BLEQ (n=5) (n=57) U 0.527 
Median (IQR) 2(1.5-4) 2(1-3)   














     
 
 
 Although results from the unadjusted tests showed only a significant 
relationship between cannabis and other drug use, all variables were tested in 
the model. Only cannabis use was a significant predictor of other drug use at 
baseline (χ2(1)= 8.5, p=0.004) so no other variables were retained in the model. 
Confirming the results from the unadjusted analysis, in the final model (n=179), 
cannabis users were almost 5 times more likely to use other drugs than non-
 113 
cannabis users (exp(B)=4.79, CI 95% (1.51 – 15.18), p=0.008) (Table 5.13). Although 
this is an exploratory analysis, it should be mentioned that only 18 of the 179 
patients whose data were included in the model were using other drugs at 
baseline. While this is not a violation of the assumptions for a logistic regression, 
such differences might not have been observed if more cannabis users had been 
included in the model. 
 
Table 5.13 Logistic regression model assessing predictors of other drug use at 
baseline 
 Odds ratio 95% CI Sig 
Univariate analysis    
Baseline total PANSS scores 1.00 1.00 – 1.03 0.833 
Baseline positive PANSS scores 1.00 0.92 – 1.09 0.981 
Age 1.02 0.98 – 1.07 0.383 
Gender 0.34 0.09 – 1.24 0.102 
Baseline BLEQ 1.21 0.91 – 1.60 0.192 
Multivariate analysis (final model)    
Cannabis use at baseline 4.79 1.51 – 15.18 0.008 
    
 
Urinary Drug Screen 
 Seventy-seven drug screens were performed at 3 months and 60 samples 
were available at 12 months. As anticipated there was better (substantial) (Landis 
and Koch, 1977) agreement between patients’ self-reported cannabis use and 
urinalysis than at baseline with Cohen’s kappa=0.683 and 0.692 respectively 
(Table 5.14).  Three of the 53 self-reported non-users at 3 months and 4 of 41 at 12 
months produced UDS results positive for cannabis. It is most likely that these 
present false negative results based on Colcateno sensitivity levels at 97%. 
Therefore, these patients will continue to be treated as non-users for the 
purposes of analysis. 
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Table 5.14 Level of agreement between self-reported cannabis use and 
urinalysis at 3 and 12 months 
 Positive (%) Negative (%) Sig 
3 months    <0.001 
Cannabis users (n=24) 70.8  29.2  
Non-users (n=53) 5.7 94.3  
12 months   <0.001 
Cannabis users (n=19) 78.9 21.1  
Non-users (n=41) 9.8 90.2  
    
 
Current cannabis vs non-cannabis users based on UDS results 
 There were no differences between current cannabis users and non-users 
according to UDS results rather than self report across 12-month positive and 
total PANSS scores (table 5.15). 
 
Table 5.15 Differences between current cannabis users and non-users based on 
UDS results  
 Cannabis users Non-users Test Sig. 
Total PANSS scores  (n= 18) (n= 37) U 0.187 
Median (IQR) 49 (43.5-62)  43 (35-61.5)   
Positive PANSS scores (n= 17) (n= 39) U 0.100 
Median (IQR) 11 (8-14.5) 9 (7-12)   
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Levels of cannabis use 
Data on frequency of cannabis use at 12 months were available for 30 of the 32 
users. Eleven reported using cannabis every day; 8 using more than once per 
week; 5 using a few times each month; 5 using a few times each year and 1 having 
used only once or twice. Two-thirds of the cannabis users at 12 months reported 
using cannabis at least once per week. The available data on the levels of 
cannabis use at 12 months were not sufficient to test differences on PANSS 












 Missing item data can be prorated; that is replacing the missing item score 
by the mean of the observed items if less than 20% of the items scores are 
missing as simulation studies have shown that pro-rating (or case mean 
substitution) is a robust method when data are missing on less than 20% of items 
in both random and systematic patterns (Roth et al, 1999). We, therefore, 
excluded 5% of the 12-month positive PANSS subscales and 12% of the 12-month 
total PANSS scales from analysis because more than 20% of the subscale items 
were missing.  
 
5.7 Summary of findings 
The main findings of this chapter were: 
1. Cannabis use at 12 months was not independently associated with 12-
month total PANSS scores. Baseline total PANSS scores were the only 
independent predictor of 12-month total PANSS scores. In the final model, 
where both variables were included, the association of cannabis use and 
12-month total PANSS scores improved but remained non-significant. 
2. Cannabis use at 12 months, baseline total PANSS scores and baseline 
current tobacco use were independently associated with 12-month 
positive PANSS scores. When all variables were tested together, only 
baseline total PANSS scores remained a significant predictor of 12-month 
positive PANSS scores. 
3. Cannabis use at baseline was associated with other drug use and this 
remained significant after adjusting for potential confounders. 
Unadjusted analysis showed a significant relationship at 3 months but this 
was not observed at 12 months. Adjusted analysis was not possible at 3 
and 12 months due to insufficient power. No other variables were 




Cannabis use and symptom severity 
 Using a series of cross-sectional assessments this chapter described a) the 
association between cannabis use and total symptom severity at 12 months, b) 
the association between cannabis use and positive symptom severity at 12 
months and c) the relationship between cannabis and other drug use at baseline, 
3 months and 12 months. 
Contrary to the hypothesis that patients who use cannabis at 12 months 
will score higher on the total PANSS scale, no significant effect of cannabis use 
on total PANSS scores was observed in this study. This finding is consistent with 
Green et al (2004) who reported a lack of association between cannabis misuse 
and changes in total PANSS scores between baseline and follow-up in an RCT of 
haloperidol vs olanzapine among patients with psychosis. In contrast, a number 
of other studies have found cannabis use to be associated with total symptom 
severity (Martinez-Arevalo et al, 1994; Degenhardt et al, 2007; Linszen et al, 1994; 
Hinton et al, 2007).  
 Although cannabis use independently predicted 12-month positive PANSS 
scores, this relationship did not remain significant when adjusting for potential 
confounders. This is consistent with the findings by Stirling et al (2005) who 
observed a similar pattern of positive symptomatic outcome between cannabis 
users and non-users in a study of psychosis and neurocognition but inconsistent 
with the results of five studies (Hinton et al, 2007; Wade et al, 2006; Hides et al, 
2006; Addington and Addington 2007; Grech et al, 2005), which found cannabis 
use to significantly affect positive symptoms even after controlling for potential 
confounders. 
Although no consensus has been reached on the relationship between 
cannabis use and psychotic outcomes, this study observed results that do not 
confirm the hypotheses. A number of issues might help explain these findings, 
which although not altogether surprising are not strongly supported by previous 
research. Cannabis users at baseline rated higher in total and positive PANSS 
scores than non-users and were more likely to be younger, male and report 
lifetime and current use of tobacco, alcohol and other drugs; factors that could 
have affected follow-up psychopathology. The strength of the association 
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between cannabis use and total PANSS scores could have been further 
underestimated by the higher non-completion rates of 12-month total PANSS 
scores by patients with more severe baseline symptomatology (total and positive 
PANSS scores). Baseline symptom severity across the sample was low which 
could have also masked a significant relationship if patients with more mental 
health problems were lost to follow-up. Cannabis users were not less likely than 
non-users to complete 12-month symptom severity assessments and so the 
association would not have been biased by the lack of a sufficient number of 
cannabis users. Although these observations could have accounted for the loss 
of a significant effect by cannabis use on positive symptoms in the multivariate 
analysis, this finding seems to be consistent with suggestions from previous 
studies that adjusting for psychotic symptoms at some earlier point will 
substantially reduce the size of the relationship between cannabis use and 
psychotic symptoms at follow-up (Arseneault et al, 2002). The lack of a 
significant relationship between cannabis use and positive symptoms at 12 
months, when adjusting for potential confounders, could have also been 
affected by the higher rate of male patients that failed to complete the 
assessment. As cannabis users tended to be male, it is possible that the lower 
completion rate of positive PANSS subscale by men could have underpowered 
the adjusted regression. 
It is important to address the finding that baseline tobacco use was 
associated with more positive symptoms at 12 months. This observation has not 
been previously reported most likely because adequate adjustment for potential 
substance use confounders has not been systematically adopted. Prevalence of 
tobacco use in patients with schizophrenia has been reported around 85%, much 
higher than in the general population (~30%) (De Leon, 1996). Kelly and 
McCreadie (2000) found that 68% of patients with schizophrenia were also heavy 
smokers (25 cigarettes or more per day) compared to only 11% of the general 
population who smoke (Olincy et al, 1997).  
The fact that tobacco use might be an indication for poorer outcome in 
schizophrenia is one theory that has received most attention among a number of 
suggestions that aim to explain the high rates of smoking in this population.  
Smokers are often younger and male and score higher on positive symptom 
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scales (Ziedonis et al, 1994). This commonly describes the characteristics of the 
present sample and observing an independent effect of tobacco use on 
psychotic outcomes is justified. Even so, the strongest predictor of 12-month 
positive psychotic symptoms was still baseline total symptom severity as the 
significant relationship between tobacco use and psychotic outcomes was lost 
when adjustment for confounders was made. 
 
Strengths and limitations 
The main strength of this study is that it investigated and consistently 
controlled for potential confounders identified from baseline comparisons 
between cannabis users and non-users. These adjustments included measures of 
baseline psychopathology and substance use, which can independently affect 
psychotic outcomes. Even studies that reported similar results (Green et al, 2004; 
Stirling et al, 2005) did not adequately control for potential confounders and this 
is widely lacking in research that supported a relationship between cannabis use 
and psychotic outcomes. An additional advantage to this rigorous method was 
the use of a univariate regression model, which allowed the separate 
investigation of potential confounders and only retained those with significant 
effects. A traditional method of simultaneously entering variables into the model 
is not likely to have produced different results but would not have allowed for an 
assessment of individual associations to be examined. 
 A further advantage of this study is the strict criteria for definition of first-
episode psychosis and cannabis use at baseline and the inclusion of patients from 
all psychosis groups. First episode was identified as first contact, rather than 
admission, with services so that recruitment included both inpatients and 
outpatients but only those who had experienced their first episode in the 
preceding six months were included in the study. This way cannabis reduction or 
cessation due to continuous contact with services as well as improvement in 
mental health state from treatment involvement was prevented. Cannabis use at 
baseline was defined as any use within the preceding 12 months to ensure that 
occasional users and patients who had stopped using just before presentation or 
admission were not improperly classified as non-users. This criterion was not 
applied to the 3- and 12-month follow-up to allow for a clear distinction between 
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persistent and non-persistent users. Patients with any diagnosis of a psychotic 
disorder were included in the analyses. Zammit et al (2008) have highlighted a 
trend whereby effects of cannabis use on symptom severity are observed in 
mainly schizophrenic populations but such an association is not always present 
when all psychotic diagnoses are included. Although this might be worthy of 
further investigation, it is unlikely that it caused the lack of association in this 
study as previous research that reported significant results had included all 
psychotic diagnoses (Grech et al, 2005). Patients with a diagnosis of substance-
induced psychosis were included in the study and it might be possible that the 
effects of cannabis are different between those with and those without such 
diagnosis although Hides et al (2006) found that their results did not change 
when the substance-induced psychotic patients were excluded from the analysis.  
A further strength of this study is the use of urinalysis to validate self-
reported cannabis use and is only the second study to employ drug screens at all 
assessment points (van Dijk et al, 2012). Although agreement was not as high as 
found in the only previous study that investigated reliability statistically (Cohen’s 
kappa=0.90; Hides et al, 2006), it was still satisfactory and as anticipated higher 
in the 3- and 12-month follow-ups than at baseline. About a third of users still 
produced negative samples at 3 and 12 months, which is likely to have 
contributed to an underestimation of the level of agreement. 
The sample size of this study is at the lower end of a very wide range of 
sample sizes in previous research (56 to 262) but even so it is not likely to have 
affected the results. Although a large sample size would ensure adequate power 
to detect significant associations, some studies with small sample sizes have 
reported positive findings (Martinez-Arevalo et al, 1994; Stirling et al, 2005; Hides 
et al, 2006). However, the relatively small sample size prevented any further 
classification of cannabis exposure based on frequency, quantity or duration 
before presentation.  Some research that has reported significant results 
(Addington and Addington, 2007) as well as those studies that did not observe 
associations (Stirling et al, 2005) also failed to examine cannabis exposure in 
more detail.  
The study design whereby data were collected in a cross-sectional manner 
did not allow for cannabis use information between the follow-up points to be 
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utilised. Absence of a significant association between cannabis use and symptom 
severity might be attributed to changes in levels of substance use immediately 
after baseline and between follow-ups. If patients reduced their cannabis use 
following contact with services, they would still be classified as users at the 
various follow-ups although their mental health would have invariably improved. 
For the same reason it was not feasible to investigate changes in cannabis use in 
such way as to identify persistent users and non-users as well as baseline users 
who stopped and baseline non-users who initiated use at some future point. It 
would need vigorous longitudinal assessments to ascertain continuity, 
discontinuity and initiation of cannabis use although time-group interactions 
were not observed in the study by Hinton et al (2007), indicating that patterns of 
change did not differ between cannabis groups. Measuring compliance to 
medication is similarly challenging but unlikely to have influenced the results. 
Although it is unclear how adherent patients are with treatment in between 
follow-ups, the high rates of medication compliance are consistent with the low 
symptomatology.  
Two thirds of the sample was male and male patients were also more 
likely to be cannabis users. Gender differences have been shown to exist in the 
course of schizophrenia (Morgan et al, 2008) but have presented women as 
having a less continuous course of illness and better functioning. This is unlikely 
to have influenced the results of this study, as findings already show a low 
symptomatology even with the high male to female ratio. Similar to these 
findings, van Diijk et al (2012) included a number of reliable measures and a wide 
range of possible confounders but still observed a lack of association between 
cannabis use and psychotic outcomes in a first-episode, male-only psychotic 
population.  
 Finally, this study did not investigate the relationship between cannabis 
use and negative symptoms. Paucity of research reporting significant effects of 
cannabis use on negative symptoms and the fact that none of the studies 
included in the systematic review observed such a relationship suggest that 
cannabis research should focus on clarifying the possible of effects of use on 
total and positive symptom severity. In addition, no significant differences on 
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negative symptoms were found from comparisons between cannabis users and 
non-users at baseline.  
 
Cannabis and other drug use at baseline, 3 months and 12 months 
 In keeping with the results from the unadjusted analysis, cannabis use 
was the only predictor of other drug use at baseline when controlling for 
potential confounders. A similar pattern of unadjusted association was observed 
at 3 months although numbers were not sufficient to test this finding in a 
regression model. Unadjusted analysis at 12 months did not show a significant 
effect of cannabis use on other drug use and a regression model was not utilised 
due to the lack of sufficient numbers. 
 Insufficient power is most likely to have led to the lack of association 
between cannabis and other drug use at 12 months. The low rates of current, 
illicit drug use at baseline (20%, see Chapter 4; section 4.5) are consistent with the 
findings from previous research reporting on illicit drug use in psychotic 
populations (Lammertink et al, 2001) but this rate further decreased at 
subsequent follow-ups due to drop-out. The number of patients who used 
cannabis and any of the other illicit substances at baseline and 3 months is similar 
(77.8%) but decreases by almost a third at 12 months (57.1%). Even if numbers 
were sufficient, a lack of association at 12 months could have still been observed 
since a significant naturalistic reduction of substance use occurs over time in 
psychotic populations (Addington and Addington , 2007). This might already 
partly explain the differences in association between cannabis and other drug 
use over the follow-up period although the lack of power makes any 
interpretation difficult. 
 The rates of concurrent cannabis and other illicit substance use at 
baseline are consistent with those reported by Hinton et al (2007). Most research 
tends to report rates of poly-substance use, including alcohol, when considering 
the characteristics of cannabis users so whether these findings are widely 
representative is uncertain. The association of cannabis and other drug use while 
controlling for potential confounders was assessed and this, to our knowledge, is 
the first investigation of its kind in patients with psychosis. A strong trend 
emerged from unadjusted and adjusted analyses with cannabis use being the 
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only predictor of concurrent illicit drug use. No other variables were 
independently associated with illicit drug use. 
 Due to the lack of psychosis research reporting on such an association, 
present results can only be discussed in comparison to general population 
studies, which have mainly focused on the extent to which cannabis acts as a 
‘gateway drug’ that leads to the use of other illicit substances. The gateway 
theory (Kandel, 2003) proposes a causal, sequential association where cannabis 
use (a) precedes 0ther illicit substance use and (b) increases the likelihood of 
future illicit substance use. The present findings are not suitable to provide 
evidence in favour or against this theory, as only concurrent use was examined 
and, where this was established, temporal sequence of cannabis and other drug 
use was not ascertained. Results are similar to reports by Fergusson et al (2006) 
who found, during a 25-year study, that increasing cannabis use in any year was 
associated with increasing rates of other illicit substance use as well as findings 
from a 12-year study which showed that regular cannabis use predicted the 
maintenance of other illicit drug use (Swift et al, 2012). These similarities should 
be interpreted with caution as both studies strictly defined cannabis exposure 
and concentrated on the effects of varying frequencies of use, a distinction that 
was not applied in the current study.  
 Any meaningful inferences directly from the present results or through 
comparisons with general population studies are bound to be problematic at 
least due to the relatively small sample size and differences in sample 
characteristics, definition of cannabis exposure and measurement of outcomes. 
Persistent cannabis use in the general population has been associated with 
psychosocial harm (Macleod et al, 2004) and in patients with psychosis it has 
demonstrated some poorer prognostic outcomes (Zammit et al, 2008) but the 
association between persistent concurrent cannabis and other illicit substance 
use in the general or psychiatric populations has not been examined. What our 
findings suggest is that there is a strong, albeit unconfirmed, association 
between current cannabis and other illicit drug use in a psychotic population at 





 This chapter described the findings from a series of cross-sectional 
assessments investigating the effects of cannabis use on total and positive 
symptom severity at 12 months and its association with other drug use at 3 time 
points. Cannabis use was not associated with either total or positive PANSS 
scores at 12 months. Baseline cannabis use was associated with other drug use 
but this finding could not be replicated at 3 and 12 months due to insufficient 
numbers. In the next chapter, the reasons for cannabis use at baseline, 3 months 



















Chapter 6 – Reasons for cannabis use at baseline, 3 months and 12 months 
6.1 Synopsis 
Despite some inconsistent findings for the reasons for cannabis use in 
patients with psychosis (Chapter 2; section 2.3), the evidence to date points 
towards an ‘alleviation of dysphoria’ model. The self-medication hypothesis 
(Khantzian, 1985) has received little support over the years with research 
showing that patients with psychosis use cannabis mostly because of its 
enhancing effects, to ‘get high’ or reduce unpleasant states such as depression 
or boredom. There has been no research so far examining the changes in reasons 
for cannabis use over time. In this chapter, reasons for cannabis use in first-
episode psychosis will be assessed and compared at 3 time points.  
It was observed, at all 3 time points, that enhancement was much more 
important to patients than any other reason for cannabis use. A post-hoc analysis 
also showed that patients had stronger reasons for their cannabis use at baseline 
than at 12 months. These findings support the emergent ‘alleviation of dysphoria’ 
model and show that reasons for use may change over time and be amenable 
targets for intervention. 
 
6.2 Hypotheses  
1. At each time point, patients who use cannabis will be more likely to do so 
because of its enhancing effects and for social reasons rather than to ‘self-
medicate’. 
2. As the literature in the field of changes in reasons for cannabis use over time 
is absent, it was decided not to form a hypothesis, as there was no evidence 
base for justification. Rather, the changes in reasons for cannabis use across 




6.3 Sample selection 
At baseline, 219 patients were assessed but information on cannabis use 
was available for 198 patients (84 users and 114 non-users). At 3 months, data on 
cannabis use were available for 108 of the 109 patients who were assessed (29 
users and 79 non-users) and at 12 months, 108 patients were assessed but 
information on cannabis use was available for 101 patients (32 users and 69 non-
users). Sixty-six of the 84 cannabis users completed the Reasons for Use Scale 
(RFUS) at baseline, all 29 at 3 months and all 32 at 12 months (Table 6.1). 
 
Table 6.1 Number of participants with data on cannabis use and RFUS at 
baseline, 3 months and 12 months 
 Cannabis users/ 
Completers 
Non-users 
Baseline 84/66 114 
3 months 29/29 79 
12 months 32/32 69 
   
 
6.4 Measures 
The Reasons for Use Scale (RFUS) 
The Reasons for Use Scale (Spencer et al, 2002) was used to assess 
reasons for cannabis use. This is a 26-item self-report instrument that includes 
items from the Drinking Motives Questionnaire (DMQ; Cooper, 1994) and 
additional motives specific to symptoms of mental illness. Internal reliability of 
the scale has been demonstrated in patients with psychotic disorders (Spencer et 
al., 2002).  It is administered to better understand participants' reasons for 
substance use and thus tailor any intervention to meet an individual’s needs.  The 
26 items relate to the 5 subscales that are believed to reflect a participant’s 
reasons for drug use (Table 6.2): 
1. Enhancement  
2. Social motive  
3. Coping with unpleasant affect  
4. Conformity and acceptance  
5. Relief of positive symptoms and side effects  
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Table 6.2 Subscales and subscale items of the RFUS 
Subscales Subscale items 
Enhancement - Because it makes you feel good 
- Because it's fun 
- To get high 
Social motive - Because it's what most of your friends do when 
you get together 
- Because it makes a social gathering more 
enjoyable 
- As a way to celebrate  
- To be sociable 
Coping with 
unpleasant affect 
- Because it helps when you are feeling nervous 
- Because it helps when you are feeling depressed 
- To forget your worries 
- To feel more motivated 
- To make it easier to sleep 
- To help me concentrate 
- Because you feel more self-confident or sure of 
yourself 
- To relieve boredom 
- To decrease restlessness 
- To slow down racing thoughts 
- To relax 
Conformity and 
acceptance 
- So you won't feel left out 
- To be liked 
- To help you talk to others 
- To be part of a group 
- Because your friends pressure you to do it 
Relief of positive 
symptoms and side 
effects 
- To get away from the voices 
- To reduce side effects of medication 
- To feel less suspicious/paranoid 
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Participants complete the questionnaire about one substance only and in 
this case, cannabis.  The questionnaire utilises a 5-point scale that reflects how 
often they use the substance for each specific reason: never/almost never (0), 
some of the time (1), half of the time (2), often (3), and almost always/always (4). 
The scale is rated by the mean score on each subscale. 
 
6.5 Analyses 
Participants rated 5 reasons for their cannabis use at the 3 time points and 
the analysis examined the differences between reasons for use at each time 
point and the differences in these ratings between baseline, 3 months and 12 
months. 
A series of paired-sample t-tests were carried out to test differences 
between mean scores on each subscale of the RFUS at baseline, 3 months and 12 
months. Ten pairs were created from the 5 subscales: enhancement, social 
motive, coping with unpleasant affect, conformity and acceptance and relief of 
positive symptoms and side effects. The Bonferroni correction at 0.05 was used 
to correct for multiple testing of the paired-sample t-tests. 
In order to assess differences in mean scores on the RFU subscales as well 
as test whether these differences change over time, a random intercept model 
was used. Fixed effects of reason (5 subscales) and time (baseline, 3 months and 
12 months) were included in the model, in addition to a random effect of 
participant. This model allows subjects who had data at any of the time points to 
contribute to the analysis - unlike a repeated-measures ANOVA test, which 
excludes subjects with any missing values. 
 
6.6 Results 
Ten paired sample t-tests were performed for baseline, 3 months and 12 
months to assess any differences between mean scores on the RFU subscales. 





Table 6.3 Differences in reasons for cannabis use at baseline 
Pairs Reasons M SE t(df) Sig 
 1 Enhancement 3.2 0.14 6.26(65) <0.001 
 Social motive 2.3 0.13   
2 Enhancement 3.2 0.14 6.36(64) <0.001 
 Coping with unpleasant 
affect 
2.3 0.11   
3 Enhancement 3.2 0.14 11.04(64) <0.001 
 Conformity and 
acceptance 
1.5 0.10   
4 Enhancement 3.2 0.14 10.51(64) <0.001 
 Relief of positive 
symptoms and side 
effects 
1.4 0.10   
5 Social motive 2.3 0.13 -0.15(64) ns 
 Coping with unpleasant 
affect 
2.3 0.11   
6 Social motive 2.3 0.13 7.50(64) <0.001 
 Conformity and 
acceptance 
1.5 0.10   
7 Social motive 2.3 0.13 5.49(64) <0.001 
 Relief of positive 
symptoms and side 
effects 
1.4 0.10   
8 Coping with unpleasant 
affect 
2.3 0.11 7.15(64) <0.001 
 Conformity and 
acceptance 
1.5 0.10   
9 Coping with unpleasant 
affect 
2.3 0.11 8.62(64) <0.001 
 Relief of positive 
symptoms and side 
effects 
1.4 0.10   
10 Conformity and 
acceptance 
1.5 0.10 0.91(64) ns 
 Relief of positive 
symptoms and side 
effects 
1.4 0.10   





Table 6.4 Differences in reasons for cannabis use at 3 months 
Pairs Reasons M SE t(df) Sig 
 1 Enhancement 3.1 0.26 4.6(28) <0.001 
 Social motive 2.0 0.18   
2 Enhancement 3.1 0.26 2.63(28) 0.014 
 Coping with unpleasant 
affect 
2.4 0.16   
3 Enhancement 3.1 0.26 7.03(28) <0.001 
 Conformity and 
acceptance 
1.3 0.08   
4 Enhancement 3.1 0.26 5.11(28) <0.001 
 Relief of positive 
symptoms and side 
effects 
1.6 0.15   
5 Social motive 2.0 0.18 -
2.03(28) 
ns 
 Coping with unpleasant 
affect 
2.4 0.16   
6 Social motive 2.0 0.18 4.90(28) <0.001 
 Conformity and 
acceptance 
1.3 0.08   
7 Social motive 2.0 0.18 1.78(28) ns 
 Relief of positive 
symptoms and side 
effects 
1.6 0.15   
8 Coping with unpleasant 
affect 
2.4 0.16 7.50(28) <0.oo1 
 Conformity and 
acceptance 
1.3 0.08   
9 Coping with unpleasant 
affect 
2.4 0.16 6.60(28) <0.oo1 
 Relief of positive 
symptoms and side 
effects 
1.6 0.15   
10 Conformity and 
acceptance 
1.3 0.08 -1.79(28) ns 
 Relief of positive 
symptoms and side 
effects 
1.6 0.15   





Table 6.5 Differences in reasons for cannabis use at 12 months 
Pairs Reasons M SE t(df) Sig 
 1 Enhancement 3.3 0.19 6.75(31) <0.001 
 Social motive 1.8 0.14   
2 Enhancement 3.3 0.19 5.54(31) <0.001 
 Coping with unpleasant 
affect 
2.1 0.11   
3 Enhancement 3.3 0.19 10.84(31) <0.001 
 Conformity and 
acceptance 
1.2 0.05   
4 Enhancement 3.3 0.19 7.83(31) <0.001 
 Relief of positive 
symptoms and side 
effects 
1.4 0.12   
5 Social motive 1.8 0.14 -1.82(31) ns 
 Coping with unpleasant 
affect 
2.1 0.11   
6 Social motive 1.8 0.14 4.91(31) <0.001 
 Conformity and 
acceptance 
1.2 0.05   
7 Social motive 1.8 0.14 2.50(31) 0.018 
 Relief of positive 
symptoms and side 
effects 
1.4 0.12   
8 Coping with unpleasant 
affect 
2.1 0.11 8.32(31) <0.001 
 Conformity and 
acceptance 
1.2 0.05   
9 Coping with unpleasant 
affect 
2.1 0.11 5.34(31) <0.001 
 Relief of positive 
symptoms and side 
effects 
1.4 0.12   
10 Conformity and 
acceptance 
1.2 0.05 -1.59(31) ns 
 Relief of positive 
symptoms and side 
effects 
    






Enhancement was rated by participants as much more important than 
social use (t(64)=6.26, p<0.001), coping with unpleasant affect (t(64)=6.36, 
p<0.001), conformity and acceptance (t(64)=11.04, p<0.001) and relief of positive 
symptoms and side effects (t(64)=10.51, p<0.001).  
Social motive was given higher value by cannabis users than conformity 
and acceptance (t(64)=7.50, p<0.001) and relief of positive symptoms and side 
effects (t(64)= 5.49, p<0.001) but not coping with unpleasant affect.  
Coping with unpleasant affect was given a higher rating than conformity 
and acceptance (t(64)=7.15,p<0.001) and relief of positive symptoms and side 
effects (t(64)=8.62, p<0.001).  
 
3 months 
Enhancement was again rated as more important than social use 
(t(28)=4.6, p<0.001), coping with unpleasant affect (t(28)=2.63, p=0.014), 
conformity and acceptance (t(28)=7.03, p<0.001) and relief of positive symptoms 
and side effects (t(28)=5.11, p<0.001). 
Social motive was more important to cannabis users than 
conformity/acceptance (t(28)= 4.90, p<0.001) but not rated higher than relief of 
positive symptoms and side effects or coping with unpleasant affect. 
Coping with unpleasant affect was rated as more important than 
conformity and acceptance (t(28)=7.50,p<0.001) and relief of positive symptoms 
and side effects (t(28)=6.60, p<0.001). 
 
12 months 
Enhancement was still rated as more important than social use 
(t(31)=6.75, p<0.001), coping with unpleasant affect (t(31)=5.54, p<0.001), 
conformity and acceptance (t(31)=10.84, p<0.001) and relief of positive 
symptoms and side effects (t(31)=7.83, p<0.001). 
Social motive was more important to cannabis users than conformity and 
acceptance (t(31)= 4.91, p<0.001) and relief of positive symptoms and side effects 
(t(31)= 2.50, p=0.018)  but not rated higher than coping with unpleasant affect. 
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Coping with unpleasant affect was rated as more important than 
conformity and acceptance (t(31)=8.32,p<0.001) and relief of positive symptoms 
and side effects (t(31)=5.34, p<0.001). 
 Conformity and acceptance was not rated as more important than relief 
of positive symptoms and side effects at baseline, 3 months or 12months. 
In summary, at each time-point patients rated enhancement as much 
more important for their cannabis use than any other reason.  
 Social motive was more important than conformity and acceptance and 
relief of positive symptoms and side effects but patients appeared to give it 
equal weight when compared to coping with unpleasant affect at baseline, 3 and 
12 months. At 3 months patients didn’t rate social motive as more important than 
relief of positive symptoms and side effects.  
 Coping with unpleasant affect was found to be much more important to 
patients than conformity and acceptance and relief of positive symptoms and 
side effects at all 3 time points.   
 Conformity and acceptance failed to rate higher than relief of positive 
symptoms and side effects at baseline, 3 months or 12 months (Table 6.3). 
 The Bonferroni correction at 0.05 (0.05/30= 0.0017) showed that 21 out of 
23 t-tests remained significant. Enhancement/coping with unpleasant affect at 3 
months and social motive/relief of positive symptoms and side effects at 12 
months lost their significance at 0.05. The large number of significant results that 
were consistent across baseline, 3 and 12 months makes it unlikely that findings 
reflect false positive observations and differences cannot be attributed to 









Table 6.6 Comparisons between mean RFU subscale scores at each time point  
 Baseline 3 months 12 months 
Subscales    
Enhancement (E) SM / C- / CA / R+ SM / C- / CA / R+ SM / C- / CA / R+ 
 
Social motive (SM) CA / R+ / C-2 CA / R+2 / C-2 CA / R+1 / C-2 
 
Coping with unpleasant 
affect (C-) 
 




R+2 R+2 R+2 
 
Relief of positive 
symptoms and side 
effects (R+) 
 
- - - 
All significance levels at p<0.001 besides 
1 p<0.05 
2 non-significant 
- comparison already performed in previous cells 
 
A random intercept model analysis was performed to explore differences 
between mean scores on the RFU subscales while controlling for time with ‘relief 
of positive symptoms and side effects’ and ‘baseline’ entered as the constant 
variables. Both time (F(2,567)=108.1, p<0.001) and reason (F(4, 532)=4.5, p<0.001) 
were found to significantly contribute to the model. Enhancement reasons for 
cannabis use (M=3.01) were more important than relief of positive symptoms and 
side effects (M=1.26; t=17.48, p<0.001). Social motive was chosen as more 
significant in sustaining cannabis use (M= 1.93) than relief of positive symptoms 
and side effects (M=1.26; t=6.65, p<0.001). Similarly, coping with unpleasant 
affect was rated higher as a reason for cannabis use (M=2.1) than relief of 
positive symptoms and side effects (M=1.26), (t=8.35, p<0.001). Patients did not 
rate conformity and acceptance as a significantly more important reason for 
cannabis use than relief of positive symptoms and side effects (Table 6.4, Figure 
6.1). These results confirm earlier baseline observations from the paired-sample t-
tests.  
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Time appeared to have a significant effect on scores when controlling for 
reason. On average, scores on any subscale were .28 points higher at baseline 
than 12 months (t=2.97, p<0.05) but no significant differences were observed in 
mean subscale scores between 3 months and 12 months. This means that 
patients felt more strongly about each reason sustaining their cannabis use at 
baseline than they did at 12 months but did not rate reasons for use at 3 months 
higher than at 12 months (Table 6.4, Figure 6.1).  
The distribution of the residuals was examined graphically following this 
analysis and no violations of the assumptions of the random intercept model 
were found. 
 
Table 6.7 Random intercept model testing the differences in reasons for 
cannabis use while controlling for time 
 t 95% CI Sig 
Reason    
Relief of positive symptoms and side effects    
Enhancement  17.48 1.56 – 1.95 <0.001 
Social motive 6.65 0.47 – 0.86 <0.001 
Coping with unpleasant affect 8.35 0.64 – 1.04 <0.001 
Conformity and acceptance -0.56 -0.25 - 0.14 0.572 
Time    
12 months     
Baseline 2.97 0.09 - 0.47 0.003 
3 months 1.4 -0.06 - 0.36 0.161 
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6.7 Summary of findings 
The main findings of this chapter were: 
1. Enhancement followed by social motive was the most important 
motivator for cannabis use at all 3 time-points. 
2. Reasons for cannabis use endorsed by patients with psychosis do not 
provide support for the traditional self-medication hypothesis. 
3. Patients felt much more strongly about their reasons for use at baseline 





 Using a series of cross-sectional assessments this chapter described the 
reasons for cannabis use among patients with psychosis at baseline, 3 months 
and 12 months. In a post-hoc analysis changes in the reasons endorsed between 
the 3 time points were examined. 
 Consistent with the hypothesis that enhancing and social effects would 
be more important reasons for use than attempts to self-medicate, as in the 
general population (Cooper, 1994), patients who used cannabis at each time 
point were more likely to do so because of its enhancing effects rather than any 
other motive. Social use followed closely but was not rated higher than coping 
with unpleasant affect at any follow-up point and was as important as relief of 
positive symptoms and side effects at 3 months. These data support previous 
studies that investigated reasons for cannabis use in patients with psychosis as 
no evidence for the self-medication hypothesis was observed (Schaub et al, 
2008; Addington and Duchak, 1997; Green et al, 2004; Schofield et al 2006; 
Goswami et al, 2004; Fowler et al, 1998). However, only two studies (Goswami et 
al, 2004; Green et al, 2004) found that enhancing effects were the most 
important reason for cannabis use among patients with psychosis. The rest of 
the studies reported that coping with unpleasant affect- mainly relief of boredom 
and anxiety- were rated much higher than any other reason followed by 
enhancement and social use. This is similar to findings reported by Henquet et al 
(2010) who found that patients were more sensitive to the mood-enhancing 
effects of cannabis (i.e. large and significant decreases in negative affect were 
observed after cannabis use).  
 The diversity of instruments used to assess reasons for use might explain 
this slight variability. Misclassification of the social motives is likely to have 
occurred as most of the previous studies utilized lists, which only included one or 
two reasons related to social motive (Addington and Duchak, 1997). These 
appear to resemble the items on the conformity and acceptance rather than the 
social motive subscale of the present instrument, which distinguishes between 
social enhancement reasons and reasons related to social pressure. This has 
possibly led to underestimation of the significance of social motives for cannabis 
use in previous research. On the contrary, the two studies that found 
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enhancement followed by social motives to be the most important motivators 
for cannabis use had clearly described social motives as ‘social activity’ and ‘to 
increase socialization’ (Goswami et al, 2004; Green et al, 2004).  
A post-hoc analysis showed that patients felt much more strongly about 
their reasons for use at baseline than at 12 months although no difference was 
observed between 3 and 12 months. It is likely that contact with services and 
treatment for psychosis incorporates some intervention targeting cannabis use. 
Over time patients might have had the opportunity to explore the reasons for 
their cannabis use and possible effects it has on their illness trajectory, which 
may have reduced the level of certainty they feel over what sustains their use. It 
has also been previously suggested that the reasons patients endorse for their 
cannabis use do not always appear to be justified by the subsequent perceived 
effects of the actual use. For instance, patients reported using cannabis to relieve 
anxiety or depression or to relax but appeared not to gain relief from these 
symptoms or achieve relaxation after use (Addington and Duchak, 1997; Green et 
al; 2004). Similarly with encouraging patients to explore their reasons, 
supporting them in recognizing the perceived and actual effects of cannabis use 
and emphasizing any discrepancies is likely to have lessened the confidence in 
the reasons they had considered to be previously sustaining their use. It is also 
possible that the lower rate of completion of the RFUS at 3 and 12 months might 
have overestimated how strongly patients feel about their reasons at baseline 
and/or underestimated this effect at 3 and 12 months. The lack of significant 
differences between 3 and 12 months, where similarly low completion rates were 
achieved, further supports this likelihood. 
 
Strengths and limitations 
 The main strength of this study is that it utilised a validated and reliable 
measure for assessing reasons for cannabis use in patients with psychosis. This is 
a comprehensive instrument, which comprises a Likert scale to measure how 
much of the time each reason has played an important role in using cannabis. 
Research so far has been mostly conducted using lists of proposed reasons that 
patients complete based on a YES/NO response (Schaub et al, 2008). Patients 
with schizophrenia have been known to appear more suggestible (Kot and 
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Serper, 2002) so the use of a Likert scale rather than an invitation to simply 
accept or reject an already proposed reason is more likely to prevent frequent 
positive responses while increasing variability and strengthening the significant 
differences observed between reasons.  
 Another advantage of this study is the sample size at baseline, which is 
the largest among studies that have investigated reasons for cannabis use in 
psychosis. The lower sample sizes at 3 and 12 months are still relatively large 
compared to previous research (Goswami et al, 2004). The consistency between 
findings from this study and previous research with smaller groups suggests that 
results are unlikely to be due chance and are further validated by the benefit of a 
larger sample. 
 A further strength of this study was the inclusion of both inpatients and 
outpatients. Research so far has only investigated reasons for cannabis use in 
stable, outpatient populations. This has occasionally been intentional to avoid 
bias from severely ill patients who might have already failed in self-medication 
attempts and would be less likely to choose this reason for their cannabis use 
(Goswami et al, 2004). The inclusion of hospitalised and community patients’ 
reasons for use validates previous research so excluding inpatient groups is not 
likely to have affected the results. The low psychopathology rates in this sample 
also indicate a relative remission and further avoid potential bias from severely ill 
patients. However, it might be argued that low symptom severity might prevent 
patients from choosing self-medication reasons as the stability of their illness 
might allow them to enjoy cannabis for other reasons, which they are more likely 
to endorse as important. It is not possible to assess this likelihood as no research 
has investigated reasons for cannabis use in patients with varying degrees of 
symptom severity. 
 The inclusion of patients with psychosis has been another advantage of 
this study. Most previous research has examined reasons for cannabis use in 
patients with schizophrenia and only two had included patients with wider 
psychotic disorders (Green et al, 2004; Schofield et al, 2006). Present findings 
contribute to the evidence base by showing that reasons for cannabis use remain 
fairly stable in psychotic populations and are consistent with results from 
research in schizophrenia-only patients. 
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 This study did not take into account the different classes of medication by 
which patients were treated. Typical antipsychotics have been shown to have 
particularly unfavourable effects for patients with schizophrenia who use 
cannabis (Marchese et al, 2003). Atypical neuroleptics are related to a different 
group of side effects, such as weight gain and other metabolic irregulations 
(Rummel-Kluge et al, 2010). The only study that considered this difference found 
that fewer patients treated with atypical rather than typical antipsychotics were 
likely to report that cannabis improved the feeling of being ‘slowed down’ 
caused by the medication (Addington and Duchak, 1997). However, Schaub et al 
(2008) showed that patients treated with atypical antipsychotics chose only one 
reason more often than healthy controls and that was using cannabis to ‘reduce 
boredom’.  There is a possibility that different classes of antipsychotics as well as 
treatment with antidepressant or anxiolytic medication or a combination of both 
might lead to over- or understating the importance that certain reasons have in 
sustaining cannabis use. This would also obscure findings when investigating 
reasons for cannabis use in treated and medication-free patients, although no 
research has examined this distinction so far. 
 Although the sample size was adequately large for this investigation, the 
number of patients completing the RFUS was not sufficient to allow for further 
analysis based on classification of cannabis exposure in terms of frequency or 
quantity. Cannabis abusers have been shown to endorse illness and medication-
related reasons for use more often than cannabis users (Fowler et al, 1998). 
Similarly, in the study by Schofield et al (2006) greater amount and frequency of 
cannabis use was observed when side effects were motivators. On the contrary, 
daily cannabis users were more likely to state they used cannabis to increase 
pleasure and go along with the group (Schaub et al, 2008). None of the studies 
observed an increased report of self-medication reasons for use across the 
different cannabis groups. Lack of endorsement of self-medication motivators in 
this study might have been due to infrequent cannabis use. This was not possible 
to consider although studies that examined different patterns of use have not 
consistently reported a greater incentive to relief positive symptoms or 




 This chapter described the results from a cross-sectional design used to 
assess the reasons for cannabis use in patients with psychosis at 3 time points 
and reported the findings from a post-hoc analysis on the changes in these 
reasons between baseline, 3 months and 12 months. Enhancement was the most 
commonly endorsed reason for use across the 3 times points followed by social 
motives. The post-hoc analysis demonstrated that patients’ ratings for any 
reason at baseline were significantly higher than at 12 months. In the next 
chapter readiness to change cannabis use at baseline and 3 months is examined 






Chapter 7 – Readiness to change as a predictor of cannabis use outcome 
 
7.1 Synopsis 
 Motivation to change drug use has been extensively researched in 
primary substance users but it is just emerging as an area of interest in 
populations with co-morbid psychiatric and substance use disorders (Chapter 1; 
section 1.5.2). The limited literature on readiness to change drug use in 
psychiatric populations has presented mixed findings. Although higher readiness 
to change has been associated with lower rates of drug use, lower readiness to 
change has shown better treatment involvement and adherence (Chapter 2; 
section 2.4). No research so far has examined readiness to change as a measure 
of cannabis use outcome in patients with psychosis and RTC instruments have 
not been validated for use in psychotic populations. As many cannabis users with 
psychosis drop out of treatment due to lack of motivation, readiness to change is 
an important aspect of clinical intervention as it is a malleable construct that 
might affect prognosis. In this chapter, readiness to change cannabis use at 
baseline and 3 months will be examined as a measure of cannabis use outcome at 
12 months using the Readiness Ruler and the Readiness to Change Questionnaire- 
Treatment Version.  
Assessment of readiness to change as a predictor of cannabis use and 
comparison of the utility of the questionnaires to address this was not 
statistically possible, due to the low number of cannabis users who completed 
the instruments, and results are summarized descriptively. 
  
7.2 Hypotheses 
1. Readiness to change at baseline according to the Readiness Ruler will be 
associated with cannabis non-use at 12 months. 
2. Readiness to change at 3 months according to the Readiness Ruler rather 
than the Readiness to Change Questionnaire- Treatment Version will be 
associated with cannabis non-use at 12 months. 
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7.3 Sample selection 
Two hundred and nineteen patients were assessed at baseline, 108 at 3 
months and 109 at 12 months (Chapter 5; section 5.4). Of these, information on 
cannabis use was available for 84 users at baseline and at 3 months data on 
cannabis use were available for 29 users. Data on readiness to change at baseline 
and cannabis use at 12 months were available for 27 of the 84 baseline users. 
Information on readiness to change at 3 months and cannabis use at 12 months 
was available for 14 of the 29 cannabis users (Table 7.1). 
 
Table 7.1 Number of participants with data on cannabis use at 12 months and 
readiness to change at baseline and 3 months 
 Cannabis 
users 
Completers of RR/ 
Cannabis use  
at 12 months 
Completers of RCQ-TV/ 
Cannabis use  
at 12 months 
Baseline 84 27 - 
3 months 29 14 14 
    
 
7.4 Measures 
Cannabis use at baseline, 3 months and 12 months was assessed by the 
CEQmv (Chapter 4; section 4.2). Cannabis use at baseline was defined as use at 
least once in the last year. At 3 and 12 months cannabis use was not strictly 
defined within a particular time frame but participants were invited to report use 
or non-use around the point of follow-up assessments. Non-use was defined as 
not having used cannabis in the last year for baseline assessments and not using 
cannabis around the time of each follow-up assessment. Readiness to change at 
baseline was measured by the Readiness Ruler (RR) and at 3 months by the RR 
and the Readiness to Change Questionnaire- Treatment Version (RCQ-TV). Due to 
the length of the baseline data collection schedule, it was decided to use the 





7.5 Analyses and results 
Due the small sample size it was not possible to statistically test the a 
priori hypotheses. 
According to the RR, of the 19 patients at the action stage at baseline, 12 
were using cannabis at 12 months and 7 were not. Of the 2 patients who were 
assigned to the contemplation stage, 1 was still using cannabis at 12 months and 1 
had stopped. Five patients chose the pre-contemplation stage at baseline, of 
which 3 were cannabis users at 12 months and 2 were non-users. One patient at 
the preparation stage was not using cannabis at 12 months (Figure 7.1). 
 Figure 7.1 Stage of change allocation at baseline according to RR and cannabis   








At 3 months the RR and RCQ-TV were used to assess readiness to change 
cannabis use in 14 cannabis users. Only one was a non-user at 12 months (Figure 
7.2).  
Eleven patients were assigned to the same stage of change by both 
questionnaires. Seven patients were assigned to the action stage, 2 patients to 
the pre-contemplation stage and 2 patients to the contemplation stage.  
Assignment to stage of change was not consistent for 3 patients. One 
patient chose preparation with the RR and contemplation with the RCQ-TV, 
another patient was assigned to contemplation with the RR and action with the 
RCQ-TV (non-user) and one patient chose preparation with the RR and pre-
contemplation with the RCQ-TV. 
 
Figure 7.2 Stage of change allocation at 3 months according to RR and RCQ-TV 
























Cannabis users at 12 months              Cannabis non-user at 12 months 
Preparation (RR) and Contemplation (RCQ-TV) - 1 patient           Contemplation (RR) and Action (RCQ-TV) - 1 patient 
Preparation (RR) and Pre-contemplation (RCQ-TV) - 1 patient 
Contemplation (RR and RCQ-TV) - 2 patients 
Pre-contemplation (RR and RCQ-TV) - 3 patients 
Action (RR and RCQ-TV) - 6 patients 
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7.6 Summary of findings 
 It appears that the majority of users (19/27) were assigned to the action 
stage at baseline but more than half of them (12/19) were using cannabis at 12 
months. The pre-contemplation, contemplation and preparation stages seemed 
to be much more associated with cannabis non-use. At 3 months a similar pattern 
was observed; all patients in the action stage by the RR were cannabis users at 12 
months. The only patient to report non-use at 12 months had been assigned to 
the action stage by the RCQ-TV and the contemplation stage by the RR indicating 
some inconsistency in stage allocation by the two measures and showing small 
evidence for the RCQ-TV in predicting behaviour change more accurately than 
the RR. The lack of sufficient numbers to statistically test the hypotheses makes 
it difficult to draw robust conclusions but first impressions suggest uncertainty 
about the association between readiness to change and cannabis use outcomes. 
 
7.7 Discussion 
 This chapter described a naturalistic design that examined readiness to 
change at baseline and 3 months and cannabis use outcome at 12 months. Due to 
the low number of patients who completed the readiness to change measures 
and had been assessed on their cannabis use at 12 months, it was not feasible to 
perform a statistical analysis. To our knowledge, this is the first study to attempt 
an investigation of readiness to change as a measure of cannabis use outcome in 
patients with psychosis so the results can only be compared against the limited 
research on readiness to change substance use in co-morbid populations. 
 Individuals, and even patients admitted to drug or alcohol programs, vary 
widely in their readiness to change (DiClemente and Hughes, 1990). 
Nevertheless, low levels of motivation to change substance using behaviour have 
been observed in a variety of treatment settings. Ziedonis and Trudeau (1997) 
found that in 224 dually diagnosed outpatients with schizophrenia-spectrum and 
substance use disorders, 50% were in the pre-contemplation stage, 2% in 
contemplation, 8% in preparation and 4% in action. In contrary, present findings 
showed that the majority of users at baseline and 3 months were assigned to the 
action stage. Differences in sample size and diagnosis are very much likely to 
have contributed to this discrepancy. However, due to the paucity of research, it 
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is not possible to exclude the possibility that there is something particular about 
cannabis use or the way we measure readiness to change in patients with 
psychosis that has led to such inconsistencies. 
Contrary to evidence that higher readiness to change leads to lower rates 
of substance use (Zhang et al, 2006; Carey et al, 2002), present findings show 
that more patients in the pre-contemplation rather than the action stage were 
not using cannabis at 12 months. However, neither of the previous studies 
reported specific results for cannabis and focused on reduction in use rather than 
abstinence. Cannabis exposure was also not specified in this sample whereas 
previous studies had used rigorous methods of classifying patients according to 
frequency and/or abuse and dependence criteria. Sample recruitment has not 
been widely standardized with patients in dual diagnosis programs (Ries and 
Ellingson, 1990; Velasquez et al, 1999) to patients with primary schizophrenia-
spectrum disorders (Carey et al, 1999b) included in the analyses. Similarly, some 
studies included patients from treatment-seeking populations (Pantalon and 
Swanson, 2003). The aforementioned discrepancies are likely to also obscure any 
meaningful comparisons between studies that reported results similar to the 
present findings. Pantalon and Swanson (2003) and Ziedonis and Trudeau (1997) 
found that patients with high motivation were not enrolled in treatment and 
those with low motivation were more likely to adhere to their treatment 
programs respectively, but neither of these studies collected data on substance 
use outcomes.  
Measures of readiness to change have not been developed with dual-
diagnosis populations in mind and so far very few studies have evaluated 
motivational assessments in co-morbid populations. Evidence for the validity and 
reliability of staging algorithms, the most widely used measures in assessing 
motivation to change in primary substance users, cannot be generalized to 
support their use in dually diagnosed patients. A study of co-morbid substance 
users found that allocation to different stages was consistent with predictions 
from the Transtheoretical Model (Prochaska and DiClemente, 1983) but 
distinctions between the stages were not as clear (Belding et al, 1996). 
Convergence was also low between an algorithm and the URICA; only 31% of the 
cases were allocated to the same stage (Belding et al, 1996). Additionally, the 4-
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factor structure of the URICA was replicated and was shown to have good 
concurrent validity in one study with dually diagnosed patients (Velasquez et al, 
1999) but not in another (Pantalon and Swanson, 2003). In 2003, Carey and 
colleagues examined the reliability and validity of a self-report algorithm in a 
population with co-morbid diagnoses and reported that it can be extended to 
the assessment of patients with severe mental illness. However, several study 
limitations raise concerns over the algorithm’s applicability. It was the aim of this 
study to evaluate the effectiveness of the RR and the RCQ-TV in assessing 
readiness to change cannabis use in patients with psychosis. They are both 
recently developed measures that have only been validated for use with primary 
substance users as all previous instruments. It would have been of research and 
clinical value to compare two different instruments – a short, 4-point scale and a 
longer, more comprehensive questionnaire. Due to the high attrition rate their 
utility in assessing readiness to change cannabis use in psychotic populations was 
not validated and only general observations were drawn. 
 There was concern that the lack of the preparation stage in the RCTQ-TV 
would have made any comparisons between the two instruments impractical and 
initially it was aimed to group the stages into readiness (action) and non-
readiness (pre-contemplation, contemplation and preparation) to prevent 
inconsistency although this distinction is arbitrary as previous research has 
classified motivation differently; low motivation included pre-contemplation and 
contemplation and high motivation included preparation, action and 
maintenance (Ziedonis and Trudeau, 1997). Although low completion rates did 
not allow for any type of re-classification, it appears that the difference between 
the instruments has not interfered with assignment to stage of change with high 
convergence between the two, as 11 of the 14 patients were allocated to the 
same stage. The patient who was assigned to contemplation by the RR and 
action by the RCQ-TV was the only one not to be using cannabis at 12 months but 
it would be very hasty to conclude that the predictive validity of the RCQ-TV is 
higher than that of the RR based on this observation only.  
 Regardless of stage allocation, rates of cannabis use were high at 12 
months. The majority of baseline users (16/27) were using cannabis and 13 of the 
14 3-month users reported cannabis use at 12 months. Clinical and demographic 
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characteristics that could have independently contributed to persistent cannabis 
use and accounted for the high number of users at 12 months were not taken 
into consideration due the lack of statistical ability for this investigation. The 
cross-sectional study design also did not allow for longitudinal data to be 
collected. This could have affected the results in two ways: a) frequency and 
amount of cannabis use might have varied between the 3 time points influencing 
changes in motivation as well as cannabis use outcomes at 12 months and b) 
readiness to change is a dynamic and fluctuating process and assessment of 
cannabis use outcomes based on evaluation of readiness to change at one time-
point only might not be representative. Repeated measures of motivation as well 
as cannabis use might be more accurate when assessing the association, or lack 
thereof, between readiness to change and cannabis use outcomes. Finally, 
cognitive processes needed to accurately complete a self-report readiness to 
change measure as well as move through the stages and undertake activities to 
sustain behavioural change might not operate in a similar manner in patients 
with a primary substance use problem and patients with co-morbid conditions. 
Deficits in memory, attention and executive function observed in patients with 
schizophrenia might compromise the accuracy with which they can report 
motivational intentions (Buchanan et al, 2005) as well as interfere with 
developing and following a sustainable goal to reducing or quitting cannabis 
(DiClemente et al, 2008). However, neuropsychological studies have reported 
that patients with co-morbid psychosis and substance use perform better at 
cognitive tests than non-using psychotic patients (McCleery et al, 2006). If 
patients with psychosis who use cannabis were at a cognitive disadvantage, we 
would have expected to observe some discrepancies in the completion of the 
two questionnaires. A short 4-point scale would be less cognitively demanding 
than a 15-item questionnaire with complex motivational constructs, which would 
have led to inconsistencies of stage allocation but this was not observed. 
Similarly, motivation was not more closely associated with cannabis use outcome 
by either instrument. However, this could mean that even more simple 
motivational concepts as expressed in the RR prove challenging to patients with 
psychosis hence the consistent lack of association between readiness to change 
and cannabis use outcome across the questionnaires. 
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7.8 Summary 
 This chapter presented the results from a naturalistic assessment of 
readiness to change at baseline and 3 months and cannabis use outcomes at 12 
months. No clear pattern of association between readiness to change and 
cannabis use outcome was observed through either the RR or RCQ-TV. The low 
completion rates did not allow to statistically test the hypotheses. In the next 
and final chapter, the main findings and a summary of the chapters will be 
presented together with a general discussion on strengths and limitations and 
future directions. 
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Chapter 8 - General Discussion 
 
8.1 Synopsis 
 In this chapter the findings from each of the studies conducted to test the 
six main hypotheses are summarized together with the basic demographic and 
clinical characteristics of the sample at baseline. The main weaknesses of the 
PUMP study as well as the thesis are reviewed. The main finding was that 
cannabis use was not associated with total or positive PANSS scores at 12 
months, contributing to the evidence base that cannabis use does not affect 
prognosis in recent-onset psychosis. Cannabis use was associated with other 
drug use at baseline but this could not be investigated at 3 and 12 months. 
Cannabis users endorsed enhancement and social reasons as the main 
motivators for their use further supporting an ‘alleviation of dysphoria’ model 
and providing little evidence for the self-medication hypothesis in its original 
form. Statistical analysis of readiness to change as a measure of cannabis use 
outcome was not feasible but preliminary investigation showed that stage of 
change allocation at baseline and 3 months was not associated with cannabis use 
at 12 months. It was not possible to investigate the validity of the RR and the 
RCQ-TV in measuring readiness to change in patients with psychosis. The 
potential research and clinical implications of these findings are discussed.   
 
8.2 Summary of main findings 
General characteristics of the baseline sample and differences between 
participants and non-participants as well cannabis users and non-users were 
described in Chapter 4. No differences were noted between participants and 
non-participants. The majority of patients were in their late twenties, male, of 
white ethnicity, with vocational or professional qualifications and currently 
unemployed, single but living with others. Psychopathology was low with mean 
total PANSS scores in the lower end of the moderately ill category and no 
patients were in the severely ill group. Low rates of stressful events and high 
medication adherence were reported. High rates of lifetime and current tobacco 
and alcohol use were observed as well as high rates of other lifetime illicit drug 
use. Over half the patients reported current cannabis use. Cannabis users were 
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more likely to be younger, male and living alone. They also reported higher total 
and positive PANSS scores than non-users and more stressful events. Cannabis 
users were also more likely to report lifetime and current tobacco, alcohol and 
other drug use than non-users.  
The aim of the study in Chapter 5 was to investigate the association of 
cannabis use and mental health outcomes at 12 months and the association 
between cannabis use and other illicit drug use at baseline, 3 months and 12 
months. Using a series of cross-sectional assessments, it was firstly observed that 
cannabis use was not associated with total PANSS scores at 12 months. The only 
variable associated with 12-month total symptom severity was baseline total 
PANSS scores. The second finding was that although cannabis use was 
independently associated with positive PANSS scores at 12 months, in a 
multivariate analysis baseline PANSS scores remained the only variable 
significantly associated with 12-month positive PANSS scores. These results do 
not support the evidence base that cannabis use affects prognosis in patients 
with psychosis. The small sample size, low psychopathology rates and lack of 
cannabis exposure classification might have contributed to these negative 
findings. Thirdly, cannabis use at baseline was associated with other illicit drug 
use and this remained significant after adjusting for potential confounders. This 
was not possible to test at 3 and 12 months due small sample size.  The 
association between cannabis and other drug use in patients with psychosis has 
not been investigated before but these findings suggest there is a robust 
relationship that warrants further examination.  
 In the study in Chapter 6, the aim was to assess the reasons for cannabis 
use at baseline, 3 months and 12 months. In a cross-sectional design, patients 
endorsed enhancement as more important than any other reason at all 3 time 
points with social motives following closely. In a post-hoc mixed model analysis it 
was observed that patients felt much more strongly about their reasons for 
cannabis use at baseline than at 12 months but this difference was not found in 
comparisons between 3- and 12-month ratings.  The use of a validated measure to 
assess reasons for use and the large sample size and inclusion of in- and 
outpatients contribute reliable evidence to support enhancement and social 
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reasons for use rather than the traditional self-medication hypothesis adding to 
the existing evidence base of similar findings.   
The aim of the study in Chapter 7 was to investigate readiness to change 
at baseline and 3 months as a predictor of cannabis use outcomes at 12 months. 
The utility of two instruments in assessing readiness to change as a measure of 
cannabis use outcome was also examined. The lack of sufficient numbers did not 
allow for statistical testing in this series of naturalistic assessments but 
preliminary results showed that high readiness to change was not associated 
with cannabis non-use. The majority of cannabis users were assigned to the 
action stage at baseline but more than half were using cannabis at 12 months. At 
3-month assessments of readiness to change, all users in the action stage were 
using cannabis at 12 months. The Readiness Ruler and Readiness to Change 
Questionnaire- Treatment Version could not be validated for assessing readiness 
to change cannabis use in patients with psychosis.  
 
8.3 General limitations 
These studies, though both consistent with some previous research and 
delivering some novel findings, were not without limitations and the weaknesses 
of the PUMP study in general and a summary of the biases in the thesis methods 
will be addressed here. 
 
8.3.1 Limitations of the PUMP study  
Some issues with the present investigation stem from the fact that it was 
nested within a larger cohort study, the PUMP study. PUMP recruited 
participants from a number of inpatient and outpatient settings covering large 
catchment areas, included an intensive study battery and employed a high 
number of research workers that delivered the assessments. Within a limited 
time frame in the context of a smaller study, it would not have been otherwise 
feasible to reach such a wide range of patients or collect this amount of data 
without the enhanced resources available. However, the magnitude of the study 
produced some methodological weaknesses. 
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Length of assessments 
The length of assessments administered to patients (around 4 hours) 
meant that many were unable to complete the assessments at baseline or 
refused to return for follow-up investigations. Willingness to complete 
assessments or continue in the study may have been further compromised by the 
inclusion of biological assessments that some patients might have found 
intrusive (blood collection) that due to the fasting nature had to be conducted 
first.  Completion rates from one measure to another varied widely within each 
time point and attrition rates were very high. Consequently, statistical power was 
considerably reduced and analyses that were required to test the hypotheses 
were unavailable for Chapter 7. Every effort was made to complete measures as 
quickly and in as few sessions as possible but in some cases delays were 
necessary due the large study battery. Although it was more feasible to complete 
assessments quickly and efficiently in inpatient facilities, patients were 
sometimes discharged from hospital in the middle of the battery completion. 
Conducting assessments with outpatients was more challenging especially when 
circumstances such as work, study and child-care increased delays. Symptom 
severity measures could have been affected by these delays as psychopathology 
may change significantly throughout the course of assessments. Similarly, 
cannabis use could have been affected by availability due to changes in inpatient 
or outpatient status and symptom severity. It was not possible to guarantee that 
measures of symptom severity and cannabis exposure were collected at the 




Assessments were delivered and scored by multiple researchers, which 
may have affected ratings. Although steps were taken to ensure researchers 
were thoroughly trained in each measure with repeat training sessions available 
throughout the course of the study and relevant experts available for support 
and advice when needed, it is likely that differences between raters existed 
particularly for less structured instruments such as the PANSS or for cannabis 
exposure assessments. This might have caused a systematic effect and under- or 
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over-estimated symptom severity and cannabis exposure influencing the 
direction of the results. 
 
Selection bias 
The differences between completers and non-completers of measures 
have been examined where necessary throughout the thesis but it is important 
to note that a wider selection bias might have occurred in the PUMP study. It is 
not possible to ascertain how patients who agreed to take part in the study 
differed from those who refused. It is very likely, as also evident from the low 
psychopathology rates across the sample at baseline that patients who were 
severely ill were not able to consent and are underrepresented in the PUMP 
study and the thesis.  
 
Design 
Finally, a cohort design was chosen as it allows for multiple explanatory 
factors and multiple outcomes to be measured. It also provides a temporal 
sequence of exposure and outcome, which would not have been possible if a 
case-control design was chosen. Temporal causation would not have been 
determined through a one-time cross-sectional design. A randomised-controlled 
trial design wouldn’t have been feasible either, as it would be unethical to 
purposefully expose individuals to lifestyle habits (i.e. poor diet, substance use) 
that are known to have detrimental health effects. However, the cross-sectional 
pattern of data collection at the 3 time points did not allow for longitudinal, 
repeated assessments into changes in psychopathology, cannabis use, reasons 
for use and readiness to change to be conducted.  
 
8.3.2 Biases in thesis methodology 
The strengths and weaknesses of each investigation have been addressed 
in respective chapters and a summary of the main systematic and residual biases 
are discussed in this section.  
 One of the main sample characteristics that might have systematically 
affected the results of this study is the low psychopathology rate. This 
observation might have underestimated the effects of cannabis use on symptom 
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severity at 12 months especially because patients with more severe total and 
positive psychopathology at baseline were less likely to complete the PANSS 
scale at 12 months. It could also have affected the reasons patients endorsed for 
their cannabis use. With the inclusion of less severely ill patients, we avoided the 
potential bias from patients already having failed in self-medication attempts and 
being less likely to choose such reasons as important but might have created 
another confounder. If patients were relatively well, they might have endorsed 
other reasons as more important simply because their recovery has allowed 
them to enjoy cannabis in ways otherwise not possible had they been very 
psychotic. The consistency of our findings with previous research indicates that 
this systematic bias might not have influenced the results but is still essential to 
consider it. 
 The possibility of potential confounding that was not included in the 
analyses should be considered carefully. The high attrition rate prevented further 
classification of cannabis exposure based on quantity, frequency, duration of use 
before presentation to services or further categorization of use, abuse and 
dependence. Differences in psychopathology between cannabis groups might 
have been missed in this study, although research that has reported significant 
effects of cannabis use on psychotic symptoms as well as those studies that 
failed to observe a relationship have not always classified cannabis exposure 
based on the aforementioned criteria (Addington and Addington, 2007; Stirling 
et al, 2005).  The low rate of patients endorsing self-medication reasons as 
important might have been due to infrequent cannabis use that was not possible 
to consider. However, not all studies that examined different patterns of use 
reported a greater incentive to relief positive symptoms or medication side 
effects by patients using cannabis at higher frequency or greater amounts 
(Schaub et al, 2008).  
The effects of antipsychotic medication were not controlled for in this 
study and so it was not possible to test whether differences in 12-month follow-
up psychopathology ratings were related to the type or level of medication. This 
did not appear necessary in the present study as high medication compliance was 
observed and further confirmed by the low psychopathology rates and no 
differences were found on medication adherence between cannabis users and 
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non-users at baseline. Different antipsychotics might have influenced the 
endorsement of reasons for cannabis use. Previous research presented mixed 
findings with patients on typical antipsychotics reporting cannabis use to 
counteract the effect of ‘being slowed down’ more often than those on typical 
antipsychotics (Addington and Duchak, 1997). However, patients on atypical 
antipsychotics only chose to ‘reduce boredom’ as a reason for use more often 
than healthy controls (Schaub et al, 2008). The consistency of the present 
findings with previous research makes it unlikely that this residual bias had an 
effect on the results. 
 
8.3.3 Summary of strengths and limitations 
The strengths of this thesis included strict criteria for definition of first-
episode psychosis and cannabis use and the inclusion of inpatients and 
outpatients from all psychotic diagnoses. Another advantage has been the 
systematic adjustment for potential confounders identified from baseline 
comparisons between cannabis users and non-users. Urinalysis to corroborate 
self-reported cannabis use at the 3 time points has added validity to the 
investigations. Similarly, validated questionnaires were used for assessing effects 
of cannabis use on symptom severity and examining reasons for cannabis use in 
psychosis. The main limitations of the study were high attrition rates; low levels 
of psychopathology; lack of cannabis exposure classification and lack of 
longitudinal assessments through repeated measures.  
 
8.4  Research implications 
Effects of cannabis use on established psychotic disorders and its association with 
other drug use 
 No consensus has been reached as to whether cannabis independently 
affects the course of psychotic disorders. Some evidence exists that cannabis use 
exacerbates psychotic symptoms in patients and affects prognosis and recovery. 
However, some research, including the present, has not found an association 
between cannabis use and psychotic outcomes. No research has examined the 
association of cannabis use with other drug use in patients with psychosis. In this 
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section suggestions for future research aiming to examine these investigations 
are discussed. 
 Firstly, diagnostic criteria for psychosis and classification of first or recent-
onset need to be standardized. Studies vary in their definitions of inclusion 
criteria and some have excluded bipolar patients or those with substance-
induced psychosis from their analyses. The influence of cannabis use on these 
patients might differ from those with a schizophrenia-like presentation although 
Hinton et al (2007) did not observe such a distinction. Studies such as the 
present, which have included all psychotic diagnoses, provide valuable 
information to the evidence base but research on sub-groups of psychotic 
patients would contribute to the findings on the effects of cannabis use by 
highlighting issues that might otherwise be ignored. As Zammit et al (2008) 
observed, studies of patients with schizophrenia or related spectrum disorders 
consistently report worse outcomes in those who use cannabis. It would also be 
beneficial to avoiding observer bias if measures of symptom outcomes are 
masked to cannabis exposure (Grech et al, 2005; Linszen et al, 1994). In order to 
prevent overestimation of causal effects, adequate adjustment of confounders 
should be carried out both from baseline comparisons between using and non-
using groups as well as potential biases that have been identified in previous 
research. This has not been systematically adopted and might partly explain the 
inconsistent findings.  
 Another challenging issue for future research is the classification of 
cannabis and other drug use exposure. Some studies, including ours, failed to 
categorize patients based on frequency, intensity or duration of use and might 
have underestimated the true effect of cannabis and its association with other 
drug use, as this failed to be observed at 12 months. Similarly, a distinction 
between use, misuse and abuse should be applied wherever possible using 
validated methods. When distinction with respect to intensity was made, heavy 
cannabis users appeared to have poorer outcomes with more and earlier 
relapses (Linszen et al, 1994). Duration of use before presentation to services is 
also important, as Green et al (2004) observed that lifetime cannabis use was 
more strongly associated with worse outcomes although current cannabis use 
disorders were rare in their sample. Collecting this information from multiple 
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sources instead of solely relying on self-report might procure added validity and 
avoid recall bias. Urinary drug screens could assist in ascertaining cannabis and 
other drug use exposure but in order to establish the functional impact 
necessary to make a diagnosis, serum drug screens should also be analysed, 
whenever possible. Variations in potency of cannabis preparations and amounts 
metabolised can only be determined through these biochemical investigations.  
 Finally, the choice of study design and sample size will undeniably 
influence the validity and generalizability of results. Most research so far has 
inadvertently emphasized the problems with recruiting and retaining patients 
with co-morbid cannabis use and psychosis. Low completion and high attrition 
rates are common in research with this population. This unintentionally dictates 
the amount of information collected and the possibility of adjustments in 
analyses. Cross-sectional studies have the benefit of not requiring frequent 
assessments that patients might find time-consuming and intrusive but as 
demonstrated in the present study this does not necessarily prevent attrition. Of 
course longitudinal studies with repeated measures of psychopathology, 
exposure to cannabis and other substances and baseline comparisons on 
function, illness severity and other factors known to affect psychotic outcomes 
would be the ultimate paradigm. However, attaining such levels of 
methodological quality is not an easy task.  
 The ideal or gold standard study cannot be realistically achieved and I 
believe that future research should acknowledge these inherent limitations. 
What can be accomplished is consistency within these weaknesses. Whether 
studies are large or small, cross-sectional or longitudinal adhering to pre-defined 
standardized criteria will improve validity. Sometimes a study will settle for a 
smaller sample size in order to collect more data and other times a larger study 
will have to negotiate an intensive study battery in order to retain higher patient 
numbers at follow-up but the more of each that we have the more likely a certain 
pattern of the effects of cannabis use on psychotic outcomes will eventually 





Reasons for cannabis use in patients with psychosis 
 It has been widely shown that patients with psychosis use cannabis for its 
enhancing and social effects rather than to relieve illness-related symptoms thus 
providing little support for the self-medication hypothesis.  A few 
methodological problems that might question the validity of such findings as well 
as inherent issues in the assessment of motivations for cannabis use are 
discussed in this section together with recommendations for future research.  
 The major methodological inconsistency that has been observed is the 
lack of standardized instruments for the assessment of reasons for cannabis use 
in psychosis. The present study overcame this limitation by utilising an 
instrument that has been validated in patients with psychosis but most studies 
used predetermined lists. Besides the suggestibility bias that might arise through 
the use of such scales (Kot and Serper, 2002), it does not appear that any two 
studies used the same lists. In the future, an attempt should be made for 
research to utilize validated instruments in order to facilitate the generalizability 
of results.   
 Diagnostic and inclusion criteria for psychosis and cannabis exposure 
classification should also be utilized in a standardized manner. Previous studies 
have only included outpatients in an attempt to prevent bias from already failed 
self-medication attempts but the present study showed that reasons remain 
largely similar between inpatients and outpatients by including both groups. 
Studies comparing reasons in patients with varying degrees of psychopathology 
would be beneficial in establishing whether failed self-medication attempts in 
severely-ill groups or the relative remission of patients with fewer symptoms 
influence the endorsement of some reasons more than others. Inclusion of any 
psychotic diagnosis should also be employed. Most studies so far have examined 
reasons for use in patients with schizophrenia-spectrum disorders only but 
limited evidence from two studies as well as the present shows that populations 
with psychotic disorders endorse the same reasons and findings need to be 
replicated. Cannabis classification would highlight any effects that varying 
frequency or quantity of use might independently have on reasons for use as it 
has been shown that heavier use is sometimes associated with endorsement of 
medication-related reasons.  
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 Finally, pharmacological treatment should be taken into account when 
examining reasons for cannabis use in patients with psychosis. For evidence to 
support that relief from side effects is not an important reason for use, it would 
need to assume that all patients experience similar medication side effects at the 
same rate and extent. Since this is not clinically possible, future research should 
be conducted on investigating potential differences in the reasons for use 
between patients on typical and atypical antipsychotics as well as those on 
anxiolytic or antidepressant regimes. For instance, are patients treated with one 
type or a combination of neuroleptics more likely to report endorsement of 
particular reasons than other treated patients and do these differ from those 
who are medication-free? 
 Besides the aforementioned methodological issues that future research 
should aim to resolve, I would also like to present some thoughts and criticisms 
on the nature of assessing reasons for cannabis use and why it might already be 
problematic.  
 Self-reported reasons for cannabis use are subject to recall bias and might 
be further unreliable because they depend on the experiences that occur while 
under the influence of the substance. When these experiences do not live up to 
the expectations of actual use additional complications in assessments are 
inevitable. On the other hand, it would be impossible to assess reasons for use 
through third-party observations.  Relief of positive symptoms and medication 
side effects are invariably grouped and assessed as one reason but intuitively the 
attempt to cope with hallucinations or delusions is distinctly different from 
efforts to reduce medication side effects. Even in the case that these two groups 
of reasons can be reliably assessed as one category, how certain are we, as 
researchers and clinicians, that patients with psychosis can observe and deliver a 
clear report of what constitutes a medication side effect? Similarly, relieving 
anxiety or depression are recurrent themes in what motivates patients with 
psychosis to use cannabis but it is quite difficult to establish whether these 
symptoms are related to disease process or medication side effects. Inviting 
patients to make this distinction is even more challenging and unlikely to 
generate reliable responses. Investigation of reasons for use in the wider context 
of potential risk factors for cannabis use has also not been conducted. Most 
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studies on cannabis use and psychosis have been over-represented by young, 
male patients but differences based on gender and age have not been examined.  
 Findings in favour of the traditional self-medication hypothesis have not 
been observed but evidence for the ‘alleviation of dysphoria’ version of this 
hypothesis appears to be consistently reported. This presents further support for 
the secondary substance use disorder model, which postulates that substance 
use disorders are caused by severe mental illness (Mueser et al, 1998). Although 
patients endorse reasons that reflect symptom relief they are not related to 
positive symptoms but rather to alleviation of negative affective states. 
Regardless of methodological weaknesses that future research should attempt 
to settle, it is unlikely that this consistency in findings across studies has been 
fortuitous. Patients with psychosis are most likely to be using cannabis for the 
same hedonistic motives found in reasons for use by the general population. 
Nevertheless, there are some challenges with the nature of assessing reasons for 
use that could be revisited and resolved. 
 
Readiness to change cannabis use in patients with psychosis 
 Three main issues have arisen from the examination of readiness to 
change as a measure of cannabis use outcome: a) no research has been 
previously conducted in this area with most studies investigating readiness to 
change in primary substance users or co-morbid populations but without special 
focus on cannabis or psychosis, b) instruments developed to measure readiness 
to change substance use have not been validated for use in patients with 
psychosis and c) preliminary examination of the association between readiness 
to change and cannabis use in this study did not find that higher motivation is 
related to cannabis non-use. The future of research examining the validity of 
readiness to change to predict cannabis reduction or cessation needs to take into 
account all the aforementioned ‘gaps’.  
 Since there is a lack of studies reporting on this association in patients 
with psychosis that use cannabis, a starting point would be to determine basic 
methodological matters a priori. Results from the other two investigations in the 
present study have highlighted the importance of utilizing strict diagnostic 
criteria for psychosis and cannabis exposure. Longitudinal assessments would be 
 163 
more appropriate than a cross-sectional design as fluctuations in both cannabis 
use and readiness to change might influence cannabis use outcomes and 
assessment of either at one-time point only might not accurately reflect later 
behaviour change.  
 Before getting to the stage of conceptualising and realising a research 
study to measure any association between motivation and changes in cannabis 
use, a suitable instrument to assess this relationship needs to be developed. It’s 
likely that one of the numerous scales that have been developed for primary 
substance users is suitable for use in patients with psychosis but we were not 
able to reach such a conclusion. Cognitive processes that are required to 
complete such assessments might differ between substance users and patients 
with co-morbid conditions and this would need to be considered when 
developing the scale.  
 We did not observe any evidence that readiness to change explains 
cannabis use outcomes. This is likely due to the low numbers of completed 
assessments and lack of statistical analysis. However, a key question remains; if 
intention to change appears to be prominent in periods following first 
presentation but still fails to relate to later behaviour change, is this occurring 
because we have not categorized or evaluated motivation accurately or are other 
factors more likely to influence changes in cannabis use? Clinical and 
demographic characteristics that could independently contribute to cannabis use 
were not controlled for in this investigation and future research should ensure to 
at least consider age, gender, and psychopathology as possible explanatory 
variables of changes in cannabis use. Social and environmental circumstances 
could also separately influence changes in cannabis use.  
Observations by Spencer et al (2002) emphasize the likely association 
between reasons for use and readiness to change. They found that patients who 
used cannabis to cope with unpleasant affect had a higher readiness to change 
than those who endorsed other reasons. They also showed that increase in 
psychotic symptoms led to increase in motives for use, which in turn led to 
increased dependence. Reasons for use are the means by which psychotic 
symptoms affect problematic use of cannabis. Effects of psychotic symptoms on 
cannabis use are likely to be mediated by the motives that sustain the use and 
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influence readiness to change. Research should focus on investigating the 
reasons for cannabis use that patients are aware of and the patterns of use that 
are related to those reasons (Spencer et al, 2002). 
 
8.5 Clinical implications 
  So far we have reported on the effects of cannabis use on psychotic 
outcomes but this is only one aspect of illness trajectory and other elements of 
general functioning that might be affected by persistent use. Preceding 
psychotic symptoms seem to be much stronger and clinically important 
predictors of future psychotic symptoms but global functioning and mood are 
also important in sustaining remission from psychosis. Since cannabis use has 
been associated with smaller improvements in these areas (Hinton et al, 2007), it 
should be widely discouraged and efforts to reduce harmful effects from 
cannabis should remain a priority particularly if poly-drug use is present. 
Clinicians should provide information about the risks of cannabis and other drug 
use. Developing treatment strategies to prevent cannabis use is essential, as it 
appears to be at least a stressor for psychotic relapse.  
 Comprehensive early psychosis treatment should be paramount. There 
are optimistic observations that indicate a naturalistic reduction in substance use 
over time by patients who present to services for the first time (Addington and 
Addington, 2007; Hinton et al, 2007). It appears that there might a window of 
opportunity for encouragement and intervention but it will be a challenge for 
effective relapse prevention to develop and implement effective treatment 
strategies for co-morbid psychosis and cannabis use (Ley and Jeffery, 2003; 
Wade et al, 2006). 
 Despite the negative findings from the present study, a large body of 
evidence still suggests that cannabis use is likely to trigger relapse in this 
population and it is still important to develop strategies to reduce or eliminate 
motivators that sustain it. Since patients appear to largely use cannabis to relieve 
negative affective states such as depression and anxiety rather than positive 
psychotic symptoms, treatment should be modified to attempt alleviation of 
such states through psychological and pharmacological intervention. However, 
this cannot be adopted independently as treatment for the psychosis would have 
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to be applied concurrently. The purpose of examining the reasons for use should 
not be to reach a finite all-inclusive treatment strategy but to recognise individual 
preferences and target interventions accordingly. Awareness of patients’ 
reasons for cannabis use would give clinicians a theoretical basis for planning 
psychotherapeutic interventions as well as pharmacological treatments with a 
view to target positive symptoms and reduce side effects, which for some 
patients might still be strong motivators in sustaining their cannabis use. 
 Challenging the belief in each motivator and providing alternative means 
of achieving psychological effects from cannabis use should be an essential part 
of treatment. Patients who use cannabis for social reasons are likely to benefit 
from assertiveness training giving them the opportunity to explore the patterns 
of such social use, choosing social alternatives, identifying high risk situations 
and feeling socially comfortable in the absence of cannabis. Exploring perceived 
effects of cannabis use and challenging positive expectations might be 
advantageous to patients whose primary motive is psychological enhancement. 
Goal planning and lifestyle strategies should comprise the core treatment. For 
the minority of patients who use cannabis to relieve positive symptoms and 
medication side effects psycho-education would be a valuable starting point of 
intervention. There needs to be focus on raising awareness of mental health 
problems, recognising their presence and choosing appropriate techniques to 
overcome them. Exploring perceived expectations of cannabis use and actual 
benefits might help to break the cycle of dependence as would relapse 
prevention training. It would be of benefit to also consider alternative 
treatments to ease positive symptoms. As Gregg et al (2007) propose, patients 
who use drugs primarily for social and enhancement reasons should benefit from 
interventions such as Motivational Interviewing, whereas those who use drugs 
primarily for emotional reasons (e.g. negative states) might find Cognitive 
Behavioural Therapy more beneficial. It is likely that such patient-centred 
strategies would be helpful to patients with psychosis attempting to reduce or 
give up their cannabis use. 
 Knowledge of the reasons that encourage patients to use cannabis may 
offer clinicians an advantage in effecting change. This would be particularly 
helpful in cases where subjective experiences of cannabis use are opposite to the 
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actual motivations. Reflecting this discrepancy back to the patient may help with 
assisting them to move along the decision ladder and reaching a point of taking 
action to change.  
 Identifying the reasons that sustain cannabis use is a complex 
psychological process. Usually patients endorse more than one reason as 
pertinent for their cannabis use and so assessment of these motives should be a 
multidimensional and ongoing process. Reasons for use appear to vary with time 
and circumstances and so interventions will have to follow a similar pattern. In a 
case series examining reasons for cannabis use in patients with psychosis from 
the present study (Kolliakou et al, 2012), observations from clinical assessments 
appeared to be consistent with the subsequent choice of reasons for use. It is 
very promising that self-reported reasons for use appear to validate an existing 
clinical picture as in a clinical setting where standardised measures are not 
routinely used to assess reasons for use, ongoing observation and active 
listening can be employed in a non-confrontational manner to identify what 
sustains cannabis use and offer appropriate treatment. This can also be an 
effective strategy with patients who are reluctant to openly discuss cannabis use 
per se. 
  Co-morbid cannabis use and psychosis is likely to complicate behaviour 
change and demand multifaceted treatment planning, particularly when patients 
use other illicit drugs as well (DiClemente et al, 2008). Differential motivation 
with regards to each condition is likely to exist. Patients might be ready to make 
changes in their cannabis use but not other drug use and be reluctant to accept 
responsibility or adhere to treatment for their psychosis. Assisting these patients 
to contemplate and follow a behaviour change plan is difficult but essential. 
 Motivation to change cannabis and other drug use in the context of a 
psychotic disorder needs to be targeted separately as well as part of an 
integrated process. Clear aims about the specific behaviour change need to be 
set from the beginning. Is the patient more confident about gradual reduction of 
use or are they determined to quit altogether? Are they happy to consider a 
change plan with regards to cannabis or other drug use when they are refusing 
medication or involvement in psychological treatment for the psychosis? 
Motivation to change one behaviour does not imply motivation to change 
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another (DiClemente et al, 2008) and motivation to change is not identical to 
motivation for treatment (Freyer et al, 2005).  
 Self-reported readiness to change might not be judged at the same level 
as clinicians’ ratings and this can have important clinical implications. Research 
has shown that patients with schizophrenia rate themselves at a higher stage of 
change than they actually are according to clinicians’ ratings (Addington et al, 
1999) and this might complicate the choice of treatment interventions. Is the 
discrepancy in stage allocation due to report bias? If patients have difficulty in 
grasping the essence of motivation or expressing goal setting and following a 
behaviour change plan, then different ways of assessing readiness to change in 
clinical settings need to be utilised. Patients might also express higher motivation 
to change because they lack the ability to make practical evaluations of what a 
change plan actually involves. When clinicians consider patients’ motivation to be 
over-optimistic, they need to closely re-examine how realistic the goal setting has 
been and make sure that patients are aware of obstacles and difficulties they will 
undeniably encounter in the process of cannabis use change and how to best 
overcome them. A very delicate line exists between discouraging patients who 
seem unrealistically motivated to change their cannabis and other drug use and 
encouraging them to openly accept the challenges that come with a behaviour 
change plan and assisting in resolving them and reaching their goals.  
 Besides concerns about how accurately motivation can be assessed and 
how much it can be done to enhance it, clinicians need to acknowledge the 
existence of a multitude of problems that might affect it. Problems may exist in 
areas of beliefs and attitudes, interpersonal relationships, social systems and 
intra-personal conflicts and deficits (McLellan et al, 2000; Ziedonis et al, 2005). 
These contextual problems often complicate attempts to change behaviour and 
‘offering multiple resources simultaneously in treating individuals with multiple 
problems should be as much about motivation and completing the stage tasks 
for the target behaviours as it is about resolving additional problems’ 
(DiClemente et al, 2008; pp.31).  
 Finally, the structure of motivational and behavioural interventions 
depend on the level of readiness to change and stage allocation by the patient. 
Patients with lower motivation levels might benefit more from structured 
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programs that provide clear goals and reward participation and engagement, 
whereas patients at higher stages of change might gain more from 
reinforcement in assisting to promote the behaviour change that is already being 
adopted (DiClemente et al, 2008). Clinicians need to accept that motivation is 
largely about intrinsic processes of problem resolution, goal setting and 
achievement and what they consider to be a good plan might not reflect 
patients’ aspirations. Reduction of cannabis use with a view to minimize harm 
should be accepted as an intermediate goal while ensuring that mental stability is 
achieved before promoting more radical changes. Establishing what stimulates 
change is essential but it might not be consistent between patients and 
clinicians. 
 Although recommendations from this study cannot be made due to the 
negative findings, a main implication for clinical practice arises from previous 
research; the need for integration of cannabis-specific treatment in services 
primarily attended by patients with psychosis. Based on the findings from the 
current study, the development of personalised interventions, that suit individual 
needs by establishing the effect that cannabis use has on illness and wider 
functioning, motivations for cannabis use and readiness to change throughout 




 While it is plausible that cannabis interacts with a number of 
psychological, genetic and neurobiological factors to contribute to the onset of 
psychosis and worsen outcomes in patients with an established disorder, this 
study did not observe an effect of cannabis use on psychotic prognosis. Although 
patients use cannabis mostly because of its enhancing and social effects, some 
individuals still seek relief of positive symptoms and medication side effects 
through persistent use and the self-medication hypothesis cannot be invariably 
disproved. Motivation to change cannabis use in a population of young people 
already struggling with the effects of a potentially life-intrusive mental health 
illness would undoubtedly vary but might be amenable to patient-centred 
treatment. Developing suitable measures to help clinicians assess fluctuations in 
readiness to change will enable them to choose the appropriate intervention at 
the right time. Integrated treatment for patients with co-morbid cannabis use 
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Physical Health and Substance Use Measures in First Episode Psychosis (PUMP)  
 
                    PATIENT INFORMATION AND CONSENT FORM 
 
What is the purpose of this study? 
You are being invited to take part in the PUMP study. Please take time to read 
the information below and ask any questions if something is not clear. This 
study overlaps with Genetics and Psychosis (GAP) but there are also some 
differences. The similarities are that both studies are recruiting the same group 
of people and collecting similar information about mental health and lifestyles 
along with blood samples at baseline. The differences are that in PUMP we aim 
to explore how lifestyle factors (exercise, diet, substance use), genes and 
prescribed medication affects aspects of your physical health such as weight, 
cholesterol and sugar levels, and also your mental health over a 12 month 
period. By combining our resources with the GAP study we aim to reduce 
duplication of assessments and sampling.  
 
Why have I been invited? 
You have been invited to take part in this study because of the nature of the 
symptoms that you appear to have been experiencing. We are aiming to recruit 
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Do I have to take part?  
Participation in the study is voluntary. Your decision to participate (or not) will 
not affect your health care in any way. 
 
Are there any benefits involved in taking part? 
Through our testing and by maintaining contact with you at various points over 
a 12 month period you will be able to assess your level of physical health. Your 
care coordinator will also be involved in some of the assessments and will also 
learn about your physical health status. You will also be helping us to better 
understand the physical health problems faced by people from the time of their 
presentation to services with a diagnosis of psychosis. This will enable health 
care services to provide better care for patients with psychosis and develop 
better ways of screening for diabetes and risk factors for heart disease such as 
offering advice about ways to change diet, increase exercise and reducing use 
of illicit substances.   
We will reimburse any travel expense related to your participation into the 
study. 
 
What will happen to me if I take part?  
If you decide to help us with our study, we will ask you to complete a number of 
measures at the following time points: 
1. We will ask you various questions about your symptoms; any side effects 
from medication; diet; levels of physical activity; use of NHS services, and your 
views on your health risks. We will then give you a pedometer to wear for up to 
one week at both baseline and then again at 12 months to tell us how often you 
are active and the amount of calories you burn in a day. 
2. At baseline and 12 months a trained researcher will take a small sample 
of fasting blood (10mls which is 2 teaspoons) from you using disposable sterile 
equipment, to check your blood sugar, cholesterol and fat levels and assess 
your risk for diabetes, heart disease and other related health problems. This will 
only take a few minutes. You should not eat or drink anything from midnight 
and we take the blood sample first thing in the morning, ideally at 8am before 
you eat. 
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3. To monitor your physical health we ask you for your permission for us 
and/or your medical team to measure your weight, blood pressure and waist 
and hip measurements at 2 timepoints (baseline and 12 months), along with 
finger-pick tests for blood sugar levels when blood tests aren’t already 
scheduled. This will take approximately 15 minutes each time. At 12 months we 
will repeat the initial assessments to investigate changes over time. We will 
liaise with you, your care coordinator and your GP to plan the best way of 
collecting this information and share the sugar and fat level results with your 
clinical team so that you don’t need to do the tests twice. You will also be able 
to request a copy of the test results. 
4. We will also ask you to provide a urine or saliva sample to allow us to 
screen your drug use. We will not relay any information about the drug screen 
to the police. This information will be kept strictly confidential within the 
research team. 
 
The table below summarises points 1-4: 
 
 WHEN WE FIRST 
 SEE YOU (BASELINE) 















 WHO BY Your Researcher Your researcher 
 
The study will require approximately 1 hour at baseline and a further 3 hours 
over the 12 months. Each time you complete the measures required at each visit 
(baseline and 12 months) you will receive £20 for your time and any travel 
expenses will be reimbursed. 
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If you have already taken part in other research at the Institute of Psychiatry, 
London involving some of the above measures, we will not ask you to repeat 
them but request your permission to use the existing data.  
We will ask your consent for longer-term follow up to contact you or your GP 
and to view your medical records. This is so that we can see whether your 
physical health status changes over time, such as your risk for diabetes, or heart 
disease. We are also requesting your permission to contact you in the future to 
take part in other studies that you may be eligible for.  
 
Are there any risks involved in taking part? 
The risks involved are those of ordinary blood tests such as slight scratch and 
occasionally a small bruise from where the sample is taken. There is no risk in 
the collection of urine or saliva. 
 
Will my data be confidential? 
All personal information about you will be strictly confidential, unless you agree 
for some of this information to be shared with your clinical team. Only 
researchers belonging to the study team, and not external collaborators, will 
know which sample belongs to whom. All information about you will be kept 
anonymous so you cannot be identified in any research outcome. 
The blood samples will be stored in a secured laboratory for 5 years. Samples 
will be coded using identifiers, which will be entered on a secure computerized 
database. The identifiers will not refer to your name or date of birth. All clinical 
information collected on your sample will be securely held in the Institute of 
Psychiatry building. Access to the samples and the related information will be 
restricted to the researchers involved in the study. In case of commercial 
collaborations only the coded data will be shared. If there is a new study aim 
that requires further data collection not already covered by this study, this will 
be subject to review by a research ethics committee. 
 
You are free to withdraw from this study at any point without giving a reason by 
contacting the researcher whose details are at bottom of the consent form. 
Withdrawal will not affect your health care. 
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What will happen to the results of the study? 
We will send you a newsletter during the study to outline the project. Then 
when the project is completed we will send you a general summary of our 
research through a newsletter and a website under the Division of Psychological 
Medicine, Institute of Psychiatry (www.iop.kcl.ac.uk). 
 
Who is funding this project? 
This study is funded by the National Institute for Health Research (grant number 
1049) in the Department of Health. 
 
Who has reviewed the study? 
The study has been reviewed by the Mental Health Research Ethics Committee. 
 
Who can I contact for more information? 
If you have any questions, please contact Dr Stefania Bonaccorso on 0207 848 





If you have come to the decision of entering the study after carefully weighting 
the information provided please read and sign this form. 
 
Title of project: Physical Health and Substance Use Measures in First Episode 
Psychosis (PUMP) 
 




1.  I have read the information sheet and I have been given a copy. I was given 
the  opportunity to ask questions. I understand why the research is being done 
and risks involved. 
 
 
2. I agree to give blood samples for research in the above project and give 
consent for the results of my previous blood samples to be examined by the 
research team and to be included in the analysis of this study. I understand how 
the sample will be collected, that giving the sample is voluntary and that 
I am free to withdraw at any time without giving a reason, and without my 
medical treatment or legal rights being affected. I understand that I will be 
contacted in the future to repeat parts of the assessment. 
 
 
3.   I request a copy of my blood test results  
 
 





4.  I agree to give a urine/saliva sample for drug screening. I understand that 
giving the sample is voluntary and that I am free to withdraw at any time 




5.  I give permission for the results of my urine/saliva drug screen to be shared 
with my medical team and GP.   
 
 
6.  I give permission for some of my research data to be shared with the medical 
team. I understand that sharing this data with the medical team will reduce the 
amount of time and repeat assessments that I undergo.  
 
 
 7. I agree to wear a physical activity monitor.  
 
 




9. I give permission for my previous research and medical records to be looked 
at. This information will be analysed in strict confidence by the research team. 
Researchers external to the study team and collaborating in this project 




10. I give permission for blood results and the detection of any other serious 

















11.  I give permission for researchers to contact me or my GP in the future to 
enquire after my physical health and check the status of long term medical 
conditions such as diabetes, heart disease or cancer.  
 
 
12.  I agree that the samples I have given and the information gathered about 
me can be stored and statistically analysed as coded data put into a computer at 
the Institute of Psychiatry. To guarantee confidentiality, I agree that researchers 
external to the study team, including those from commercial collaborators, will 
only have access to coded data and not to my personal details. I understand I 
have the right to request, via the study co-ordinator, to review data concerning 
me, and to have such data modified if inaccurate, or deleted. 
 
 
13.  I understand I will not benefit financially if this research leads to the 




14. I request a copy of a newsletter detailing developments in the study and a 






















......................................              ........................         ........................................... 
 Name of subject   Date   Signature 
  
......................................              ........................         ........................................... 
 Name of parent/guardian  Date   Signature 
 
 
......................................              ........................         ........................................... 









Contact details for research team: Dr Stefania Bonaccorco, Institute of 






CANNABIS EXPERIENCE QUESTIONNAIRE – MODIFIED VERSION (CEQmv) 
 
1. Have you ever smoked/used cannabis? Yes   No   
2. How old were you when you first tried cannabis?  ______years 
3. Why did you first try cannabis? (You can tick more than one box) 
(a) My friends were using it   Yes  No           
(b) My family members were using it  Yes  No     
(c) To feel better     Yes  No     
     (to get relief from either physical  
     or psychological discomfort)  
 
(d) Other (please explain)   Yes  No          
     (not for data entry) 
________________________________________________________________ 
 
4. Do you currently use cannabis? 
Instructions to researcher: Please consider as current smokers all participants who 
report usually/customarily smoking cannabis in the last year (incl. patients who have not 
smoked while inpatient/in prison and patients who report occasional use i.e. once a 
year). 
 
a. Yes    (please answer b)     No    (please answer c and d)    
b. If yes, why did you continue to use cannabis? (You can tick more than one 
box) 
 
(i) I like the effect, it gives me a buzz   Yes  No     
(ii) It makes me feel relaxed   Yes  No     
(iii) It makes me feel less nervous  
and anxious     Yes  No     
(iv) It makes me feel more sociable  Yes  No     
(v) Other (please explain)   Yes  No     
________________________________________________________________ 
c. If no, at what age did you stop?  ____  ____  
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d. Please state why you stopped (not for data entry):  
________________________________________________________________ 
 
5. Would you like to stop using cannabis one day? 
a. Yes   No     
b. If yes, please explain: 
________________________________________________________________ 
 
6. Does/did cannabis affect your health in any way? 
a. Yes   No     
If yes, please explain (not for data entry): 
________________________________________________________________ 
 
7. Does/did cannabis facilitate social situations? 
a. Yes    No   
   
8. How do/did you mostly use cannabis? 
(a) I smoke it in a joint with tobacco    
(b) I smoke it in a joint without tobacco   
(c) I smoke it using a bong     
(d) I eat or drink it      
(e) Other (please explain)     
________________________________________________________________ 
 
9. How often do/did you use cannabis?   
(a) Every day      
(b) More than once a week                  
(c) A few times each month                    
(d) A few times each year       
(e) Only once or twice    
 
10. When do/did you mostly use cannabis? 
(a) At weekends     
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(b) During the day    
(c) During the evening    
(d) During the day and evening   
(e) Other (please explain)    
________________________________________________________________ 
 
11. Do you/did you mostly use cannabis: 
(a) Socially (with friends)    
(b) On my own   
  
12. On average how much money per week do/did you usually spend on 
cannabis? 
(a) Less than £2.50     
(b) £2.50 - £5     
(c) £6 - £10     
(d) £11 - £15     
(e) £16 - £20     
(f) Above £20     
 
13. What type of cannabis do/did you mostly use?   
(a) Hash (cannabis resin/solid)   
(b) Imported herbal cannabis    
(c) Home-grown skunk/ Sensimilla   
(d) Super skunk      
(e) Other (please state)     
 
14. How often have you had these experiences while smoking cannabis? Please 
rate whether it was a good, bad or neutral experience. If rarely or never, ignore 
rating (good, bad, neutral) and go to next item. 
 
Fearful 
(i)    rarely or never    
from time to time   
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sometimes   
more often than not    
  almost always    
      (ii)  Good              Bad       Neutral         
      
Feel like going crazy/mad 
(i)    rarely or never    
from time to time   
sometimes   
more often than not    
  almost always    
      (ii)  Good              Bad       Neutral         
 
Nervy 
(i)    rarely or never    
from time to time   
sometimes   
more often than not    
  almost always    
      (ii)  Good              Bad       Neutral         
 
Suspicious 
(i)    rarely or never    
from time to time   
sometimes   
more often than not    
  almost always    
      (ii)  Good              Bad       Neutral         
 
Feeling happy 
(i)    rarely or never    
from time to time   
sometimes   
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more often than not    
  almost always    
      (ii)  Good              Bad       Neutral         
 
Full of plans/ideas 
(i)    rarely or never    
from time to time   
sometimes   
more often than not    
  almost always    
      (ii) Good              Bad       Neutral         
 
Hearing voices 
(i)    rarely or never    
from time to time   
sometimes   
more often than not    
  almost always    
      (ii)  Good              Bad       Neutral         
 
Able to understand the world better 
(i)    rarely or never    
from time to time   
sometimes   
more often than not    
  almost always    
      (ii) Good              Bad       Neutral         
 
Seeing visions 
(i)    rarely or never    
from time to time   
sometimes   
more often than not    
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  almost always    
      (ii)  Good              Bad       Neutral         
 
 
15. How often have you had these experiences after the initial effects of 
cannabis have worn off? Please rate whether it was a good, bad or neutral 
experience. If rarely or never, ignore rating (good, bad, neutral) and go to next 
item. 
 
Not wanting to do anything 
 (i)   rarely or never    
from time to time   
sometimes   
more often than not    
  almost always    
      (ii)  Good              Bad       Neutral         
 
Being suspicious without reason 
(i)   rarely or never    
from time to time   
sometimes   
more often than not    
  almost always    




Slowed down thinking 
(i)   rarely or never    
from time to time   
sometimes   
more often than not    
  almost always    
      (ii)  Good              Bad       Neutral         
 
Difficulty in concentrating 
(i)   rarely or never    
from time to time   
sometimes   
more often than not    
  almost always    
      (ii)  Good              Bad       Neutral         
 
Not able to think clearly 
(i)   rarely or never    
from time to time   
sometimes   
more often than not    
  almost always    
      (ii)  Good              Bad       Neutral         
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16. Life-Time Cannabis History questionnaire. 
Instructions to researcher: Please hand this section over to participant for 
completion. Explain to participant how to complete this part by using (a) as an 
example: If you were smoking cannabis when you were 15, were smoking 2-3 
joints per day on average, you usually smoked hash and you only smoked by 
yourself. 
 




Every day                            
More than once a 
week 
 
About once a week          
  
About once/twice a 
month 
 
A few times each year       
About once a year        
      
I have only used 
cannabis once or twice                     
 
(ii) QUANTITY  
(i) (avg. per 
day) 
1 joint     
             
2 or 3 joints  
       
















herbal cannabis  
 
Skunk/ 
Sensimilla   
             
Super skunk        
               
Other                               
  






On my own  
                 
















Every day                            
More than once a 
week 
 
About once a week          
  
About once/twice a 
month 
 
A few times each year       
About once a year        
      
I have only used 
cannabis once or twice                     
 
(ii) QUANTITY  
(i) (avg. per 
day) 
1 joint     
             
2 or 3 joints  
       
















herbal cannabis  
 
Skunk/ 
Sensimilla   
             
Super skunk        
               
Other                               
  






On my own  
                 






















Every day                            
More than once a 
week 
 
About once a week          
  
About once/twice a 
month 
 
A few times each year       
About once a year        
      
I have only used 
cannabis once or twice                     
 
(ii) QUANTITY  
(i) (avg. per 
day) 
1 joint     
             
2 or 3 joints  
       
















herbal cannabis  
 
Skunk/ 
Sensimilla   
             
Super skunk        
               
Other                               
  






On my own  
                 










17. Instructions to researcher: Please give participant prompt sheet and then 
read out following instruction: ‘Please have a look at the list I handed to you 
and indicate which drugs you use/have used recreationally in the past. Also 
please state how often you use/have used it, the age at which you first tried the 
drug(s) and whether you are a past or current user’.  
Use a new box for each additional drug and please include tobacco and alcohol 
where applicable. 
 
a. DRUG: _____________________________________ 
(i)  FREQUENCY 
    Every day                            
      
    More than once a week     
        
    A few times each month      
      
    A few times each year        
       
    Only once or twice  
(ii) AGE  
 
   __ __  
(iii) USE 
Current    
  
Past                
(iv) WHEN 
Day      
            
Night       
                   




b. DRUG: _____________________________________ 
(i)  FREQUENCY 
    Every day                            
      
    More than once a week     
        
    A few times each month      
      
    A few times each year        
       
    Only once or twice  
(ii) AGE  
 
   __ __  
(iii) USE 
Current    
  
Past                
(iv) WHEN 
Day      
            
Night       
                   






c. DRUG: _____________________________________ 
(i)  FREQUENCY 
    Every day                            
      
    More than once a week     
        
    A few times each month      
      
    A few times each year        
       
    Only once or twice    
(ii) AGE  
 
   __ __  
(iii) USE 
Current    
  
Past                
(iv) WHEN 
Day      
            
Night       
                   




d. DRUG: _____________________________________ 
(i)  FREQUENCY 
    Every day                            
      
    More than once a week     
        
    A few times each month      
      
    A few times each year        
       
    Only once or twice    
(ii) AGE  
 
   __ __  
(iii) USE 
Current    
  
Past                
(iv) WHEN 
Day      
            
Night       
                   














e. DRUG: _____________________________________ 
(i)  FREQUENCY 
    Every day                            
      
    More than once a week     
        
    A few times each month      
      
    A few times each year        
       
    Only once or twice    
(ii) AGE  
 
   __ __  
(iii) USE 
Current    
  
Past                
(iv) WHEN 
Day      
            
Night       
                   





f. DRUG: _____________________________________ 
(i)  FREQUENCY 
    Every day                            
      
    More than once a week     
        
    A few times each month      
      
    A few times each year        
       
    Only once or twice    
(ii) AGE  
 
   __ __  
(iii) USE 
Current    
  
Past                
(iv) WHEN 
Day      
            
Night       
                   













g. DRUG: _____________________________________ 
(i)  FREQUENCY 
    Every day                            
      
    More than once a week     
        
    A few times each month      
      
    A few times each year        
       
    Only once or twice    
(ii) AGE  
 
   __ __  
(iii) USE 
Current    
  
Past                
(iv) WHEN 
Day      
            
Night       
                   




h. DRUG: _____________________________________ 
(i)  FREQUENCY 
    Every day                            
      
    More than once a week     
        
    A few times each month      
      
    A few times each year        
       
    Only once or twice    
(ii) AGE  
 
   __ __  
(iii) USE 
Current    
  
Past                
(iv) WHEN 
Day      
            
Night       
                   














i. DRUG: _____________________________________ 
(i)  FREQUENCY 
    Every day                            
      
    More than once a week     
        
    A few times each month      
      
    A few times each year        
       
    Only once or twice    
(ii) AGE  
 
   __ __  
(iii) USE 
Current    
  
Past                
(iv) WHEN 
Day      
            
Night       
                   




j. DRUG: _____________________________________ 
(i)  FREQUENCY 
    Every day                            
      
    More than once a week     
        
    A few times each month      
      
    A few times each year        
       
    Only once or twice    
(ii) AGE  
 
   __ __  
(iii) USE 
Current    
  
Past                
(iv) WHEN 
Day      
            
Night       
                   














k. DRUG: _____________________________________ 
(i)  FREQUENCY 
    Every day                            
      
    More than once a week     
        
    A few times each month      
      
    A few times each year        
       
    Only once or twice    
(ii) AGE  
 
   __ __  
(iii) USE 
Current    
  
Past                
(iv) WHEN 
Day      
            
Night       
                   

























REASONS FOR USE SCALE (RFUS) 
The following questionnaire asks about your reasons for smoking cannabis. 
Please read each of the reasons on the left. Then, tick only one of the five boxes 
on each line to show how often you smoke cannabis because of each reason. 
 














1 To relieve boredom 
 
1 2 3 4 5 
2 To make it easier to 
sleep 
 
1 2 3 4 5 
3 To slow down racing 
thoughts 
 
1 2 3 4 5 
4 To be sociable 
 
1 2 3 4 5 
5 To relax 
 
1 2 3 4 5 
6 To be part of a group 
 
1 2 3 4 5 
7 To get high 
 
1 2 3 4 5 




1 2 3 4 5 
9 To forget your 
worries 
 
1 2 3 4 5 
10 Because its fun 
 
1 2 3 4 5 




1 2 3 4 5 







1 2 3 4 5 
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1 2 3 4 5 
14 To get away from 
the voices 
1 2 3 4 5 
15 Because you feel 
more self confident 
and sure of yourself 
 
1 2 3 4 5 
16 Because it helps 
when you feel 
nervous 
 
1 2 3 4 5 
17 Because its what 
most of your friends 
do when you get 
together 
 
1 2 3 4 5 
18 As a way to 
celebrate 
 
1 2 3 4 5 
19 To decrease 
restlessness 
 
1 2 3 4 5 
20 Help me concentrate 
 
1 2 3 4 5 
21 Because your  friends 
pressure you to do it 
 
1 2 3 4 5 
22 To be liked 
 
1 2 3 4 5 
23 So you won’t  feel 
left out 
 
1 2 3 4 5 
24 It helps when  you 
feel depressed 
 
1 2 3 4 5 
25 To feel more 
motivated 
 
1 2 3 4 5 
26 Because it makes 
you feel good 




READINESS RULER (RR) 
Please tick one of the four boxes below to indicate how you feel about your 
cannabis smoking right now, even if you are not currently smoking. 
 
I never think 
about  
smoking less  
 
        □ 









     □ 
I am already trying to 
cut back on my 
smoking 
 








































READINESS TO CHANGE QUESTIONNAIRE – TREATMENT VERSION (RCQ-TV) 
The following questionnaire is designed to identify how you personally feel about 
your cannabis smoking. Please think about your situation and smoking habits, 
even if you are not smoking at the moment. Please read each of the statements 
on the left carefully and then decide whether you agree or disagree with the 
statement and to what extent. Please tick only one box for each statement that 
best represents your answer. 
 
  Strongly 
disagree 
 
Disagree Unsure Agree Strongly 
agree 
1 It’s a waste of time 
thinking about my 
cannabis smoking 
because I do not have a 
problem 
 
-2 1 0 1 +2 
2 I enjoy my cannabis                     
smoking but 
sometimes I smoke too 
much  
 
-2 1 0 1 +2 
3 I am trying to stop or 
cut down on my 
cannabis smoking 
 
-2 1 0 1 +2 
4 There is nothing 
seriously wrong with 
my cannabis smoking 
 
-2 1 0 1 +2 
5 Sometimes I think I 
should quit or cut 
down on my cannabis 
smoking  
 
-2 1 0 1 +2 
6 Anyone can talk about 
wanting to do 
something about 
smoking cannabis but I 
am actually doing 
something about it  
 
 
-2 1 0 1 +2 
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  Strongly 
disagree 
 
Disagree Unsure Agree Strongly 
agree 
7 My cannabis smoking is 
fairly normal 
 
-2 1 0 1 +2 
8 My cannabis smoking is 
a problem sometimes 
 
-2 1 0 1 +2 
9 I am actually changing 
my cannabis smoking 
right now (either 
cutting down or 
quitting) 
 
-2 1 0 1 +2 
10 Giving up or smoking 
less cannabis would be 
pointless for me 
 
-2 1 0 1 +2 
11 I am weighing up the                   
advantages and 




-2 1 0 1 +2 
12 I have started to carry 
out a plan to cut down 
or quit smoking 
cannabis 
 
-2 1 0 1 +2 
13 There is nothing I really 
need to change about 
my cannabis smoking 
 
-2 1 0 1 +2 
14 Sometimes I wonder if 
my cannabis smoking is 
out of control 
 
-2 1 0 1 +2 
15 I am actively working 
on my cannabis 
smoking 
-2 1 0 1 +2 
 
 
 
  
 
